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      Urinary tract infections (UTIs) represent one of the most common infections in humans. 
Prevalence is especially high in women, with 50% having at least one symptomatic episode in their 
lifetime and 25% of primary infections followed by a recurrent episode. Although UTIs are 
generally self-limiting and perceived to be therapeutically manageable with hospitalisations being 
rare, they still exert a significant burden on public healthcare systems. Moreover, due to frequent 
sometimes ineffectual antibiotic usage, the emergence of drug resistance is a serious concern. 
Uropathogenic Escherichia coli (UPEC) are the primary causative agents of UTIs accounting for 
about 80% of community acquired as well as nosocomial infections. Investigation of UPEC has 
revealed details about this pathogen’s complex life cycle, which includes both intracellular and 
extracellular stages within diverse host niches. To grow, survive and efficiently colonise the harsh 
nutrient starved environment of the human urinary tract, these pathogens have acquired an arsenal 
of diverse virulence factors. Since UPEC do not encode a universal set of virulence factors, 
regulation of virulence factor expression mediated by DNA methylation could play an important 
role in pathogenesis.  
      DNA methylation refers to the covalent attachment of methyl groups to adenine or cytosine 
nucleotides in the context of specific sequences. This sequence specific methylation of DNA is 
mediated by methyltransferases, which are either solitary enzymes or part of restriction 
modification systems (RMSs). Solitary or orphan methyltransferases have been studied extensively 
in several bacterial species and are known to play a role in regulating DNA replication, mismatch 
repair, chromatin stability and gene expression. On the other hand, the primary function of RMS 
mediated methylation is host defence, by differentially tagging self and non-self DNA, so as to 
allow the selective degradation of non-self DNA. The precise molecular mechanisms via which 
DNA methylation regulates gene expression are known only for a few epigenetically regulated 
genomic loci. Also, any additional roles possessed by RMS associated methyltransferases by virtue 




      Our analysis of the methylome of cystitis causing UPEC isolate UTI89 identified methylation 
motifs corresponding with two previously known orphan methyltransferases and a novel bipartite 
methylation sequence 5’-CCA(N7)CTTC-3’ characteristic of a Type I RMS. We assigned this novel 
methylation to the Type I gene cluster hsdSMR and proceeded to investigate the role of this 
methylation in UTI89 biology besides host defence. The UTI89 Type I gene cluster was 
functionally validated, confirming that both the restriction and modification functions of this 
putative RMS are intact. To mimic the diversification of RMS repertoires, we replaced the native 
Type I methylation of UTI89 with that of lab strain K12 and pyelonephritis causing UPEC isolate 
CFT073. Swapping of either a single hsdS gene or the entire hsdSMR locus successfully resulted in 
completely changing all the Type I methylation marks, while retaining functional RMSs. To check 
if replacing or abolishing about 700 genomic methylation marks affects virulence, we utilised 
UPEC specific in vitro assays as well as the transurethral murine model of ascending UTI. 
Observing no differences at all in vitro or in vivo, we hypothesised that Type I RMS mediated 
methylation may have evolved not to interfere with bacterial physiology. To systematically test this 
hypothesis, we used RNA-seq to analyse gene expression patterns in different growth stages and 
phenotype microarray to screen a range of about 2000 diverse phenotypes, to shed light on any 
Type I methylation mediated effects. Confirming our hypothesis, UTI89 mutants with altered Type 
I methylation display no changes to gene expression patterns or phenotypic traits. To further 
strengthen our argument, we extended our broad high throughput transcriptomic and phenotypic 
screen to K12 and CFT073 Type I RMS deletion mutants. Similar to UTI89, in both these cases no 
global alterations were observed, with only exponential phase cultures showing a few genes (2-4) 
belonging to a single prophage being affected in K12. Overall, our study suggests that Type I RMS 
mediated methylation does not alter global E. coli gene expression. And in the case of UPEC isolate 
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1.1       Urinary Tract Infections (UTIs) 
       Urinary Tract Infections (UTIs) refer to infections of the urinary tract and encompass 
infections with diverse aetiologies, clinical manifestations, sites of infection and patient 
outcomes.  UTIs are one of the most common infections in humans afflicting more than 150 
million people annually worldwide [1]. UTIs can be clinically classified as either complicated or 
uncomplicated. Uncomplicated UTIs refer to infections in otherwise healthy individuals with no 
anatomical or immunological abnormalities. Factors which increase the risk of uncomplicated 
UTIs are female gender, a prior UTI, vaginal infection, sexual activity, diabetes, obesity and host 
genetics. Complicated UTIs on the other hand refer to infections associated with a compromised 
urinary tract; due to factors such as urinary obstruction, urinary retention, immune suppression, 
surgery of the urinary tract and presence of a foreign medical device such as an indwelling 
catheter [2]. UTIs can be further classified as lower and upper UTIs. Lower UTIs or cystitis refers 
to an infection of the bladder commonly associated with symptoms such as dysuria (painful 
urination), increased urinary frequency and urgency, suprapubic pain and in severe cases 
haematuria (blood in urine). Upper UTIs or pyelonephritis is an infection of the kidneys, which 
includes symptoms of cystitis as well as fever, flank pain, vomiting and nausea. In 30% of cases, 
bacteria might eventually spread from the kidneys to the bloodstream causing a life-threatening 
systemic infection [3]. 
       About 50% of women and 12% of men will experience a symptomatic UTI in the course of 
their life time [4]. This strikingly high prevalence of UTIs especially in women is believed to be 
due to the shorter length of the female urethra and the close proximity of the vaginal as well as 
gastrointestinal flora in the peri urethral area. Both these anatomical features come together to 
facilitate colonization of the urinary tract in women. Furthermore, 25% of these women will 




positive UTI in the last 6 months or 3 episodes in the last 12 months [5]. rUTI can either be due 
to recurrent ascending infections from an external source such as the gastrointestinal flora or 
chronic persistent infection of the bladder. There is evidence that strains of Uropathogenic 
Escherichia coli (UPEC) causing rUTI bear close resemblance to the colonic flora of the same 
individual [6] and in 77% of cases,  UPEC causing rUTI are identical to the primary infection 
strain [7]. Although episodes of symptomatic UTI are usually self-limiting and amenable to 
antibiotic treatment, it does result in 6.1 symptomatic days and 2.4 days of restricted activity [4]. 
Taken together with the high rate of prevalence and recurrence, UTIs constitute a significant 
burden on global public healthcare systems and a serious cause of reduction of quality of life for 
women.   
 
1.2       Uropathogenic Escherichia coli (UPEC) 
       Uropathogenic Escherichia coli (UPEC) is the primary causative agent for both 
uncomplicated (75%) and complicated (65%) UTIs. Although UTIs can be caused by a plethora 
of other bacterial and fungal pathogens, UPEC are by far the primary aetiological agents. 
Uncomplicated UTIs are also caused by other pathogens such as Klebsiella pneumoniae (6%), 
Staphylococcus saprophyticus (6%), Enterococcus faecalis (5%), group B Streptococcus (3%) 
and others. For complicated UTIs, common causes after UPEC include Enterococcus faecalis 
(11%), Klebsiella pneumoniae (8%), Candida spp. (7%), Staphylococcus aureus (3%) and others 
[1]. Owing to its pre-eminence as an uropathogen; the pathogenesis, genomics and potential 
therapeutics against UPEC have been subjects of immense interest. 
1.2.1       Pathogenesis of UPEC 
       Escherichia coli is a bacterium capable of successful colonization of a diverse range of 
environmental as well as host niches, in the form of both commensals and pathogens. The 
pathogenic cycle of UPEC in uncomplicated UTI involves several distinct intracellular and 




tract. After migration to the bladder via the urethra, the first step involves adhesion and invasion 
of terminally differentiated superficial bladder epithelial cells lining the bladder lumen. This 
attachment and invasion is mediated by filamentous adhesive appendages present on the bacterial 
surface called pili. One of the main pili involved in attachment to the urothelium is the UPEC 
Type I pilus [8]. These Type I pili mediate intimate contact with the urothelium by binding to 
mannosylated glycoprotein receptors such as uroplakin 1a and α3β1 integrins present on the host 
cells. UPEC invasion is Type I pilus dependent and involves localized actin and microtubule 
rearrangements, which aids in a zipper-like internalization of bacteria [9, 10]. UPEC enters 
urothelial cells in a clathrin dependent manner and initially reside in Ca2+ and cAMP regulated 
exocytic vesicles [11, 12]. At these initial stages of infection, the host response consists of 
antimicrobial peptides, neutrophil infiltration, shear force exerted by urine, exfoliation of 
superficial urothelial cells and expulsion of vesicles containing bacteria [12, 13].         
        Upon invasion, UPEC are capable of giving rise to complex biofilm like Intracellular 
Bacterial Communities (IBCs) within the host cell cytoplasm. Fast replicating, rod shaped motile 
bacterial cells initially form loose colonies in the cytoplasm, gradually giving way to compact 
slow growing, non-motile coccoid cells which fill up the entire cytoplasm [14]. These form pod 
like bulges with bacteria enmeshed in polysaccharide rich matrix within the cell cytoplasm, 
which protrude from the urothelial surface with approximately 104 bacteria each [15, 16]. These 
bacteria containing IBCs are an acute transient state in the infection, whose main purpose is 
subversion of host immune response in the form of neutrophil attack, secreted pro-inflammatory 
cytokines and removal by urine flow. Moreover bacteria present in IBCs are phenotypically 
resistant to antibiotics [15]. Finally, bacteria present in mature IBCs acquire a filamentous form 
and begin fluxing from the host cell, with the potential to initiate a second round of IBC 
formation. Exfoliation of the terminally differentiated superficial layer of cells, exposes the 
underlying layer of undifferentiated cells which are also susceptible to UPEC. However UPEC 
in these transitional bladder epithelial cells exist in a barely replicating quiescent state enmeshed 




cells due to epithelial turnover are directed to acidic compartments, where cytoskeletal alterations 
trigger growth and expulsion [18]. QIR formation depends on the integrity of the urothelium 
during the initial infection and offers an excellent means of subverting host response to UTI, 
while maintaining a potential source for a rUTI. Supporting this model, QIRs within transitional 
cells are capable of seeding reinfection if epithelial exfoliation is chemically induced [19]. 
       Acute stages of UPEC mediated UTI trigger an inflammatory response in the host, which 
sets the stage for the long term outcome of the infection [13]. A severe initial inflammatory 
response sensitizes the bladder and remodels the tissue to a chronic cystitis state, wherein the 
hyperplastic state of the urothelium restricts UPEC to an extracellular state incapable of IBC 
formation. A mild inflammatory response can result in resolution of the infection, with a small 
possibility of QIR formation and rUTI. A deficient response usually leads to persistent 
asymptomatic bacteriuria [20]. Biofilm formation in the extracellular niche, either urothelium or 
catheter associated is yet another important step in bladder colonization. From the bladder, UPEC 
can ascend to and proliferate in the kidneys and ultimately result in bacteraemia if the host 
barriers are sufficiently compromised [21]. IBC formation, which represents an unique and 
important stage in the UPEC infection cycle is not an artefact of the murine model, as clinical 
UPEC isolates can form IBCs in 4 different mice strains [22]. Also, urine samples from patients 
with UPEC contained IBCs (22% of subjects) and filamentous bacteria (45% of subjects), 
hallmarks of the murine in vivo infection model [23].    
1.2.2       UPEC virulence factors and genomics 
       UPEC virulence factors can be broadly categorised as adhesins, iron acquisition systems, 
toxins and others. Adhesins consist of filamentous surface structures called pili or fimbriae, which 
mediate attachment to specific host surface receptors. These include Type I pili, P pili, S pili, F1C 
pili and Dr adhesins [1, 24]. Type I and P pili represent two of the most important and consequently 
well studied pili recognising mannosylated glycoprotein receptors and globotriasylceramide 




corresponding receptors varies, accordingly Type I pili primarily mediate attachment in the bladder 
and P pili in the kidneys. However, Type I pilus is the most exciting UPEC virulence factor because 
it is required for attachment, invasion as well as biofilm and IBC formation, with Type I pilus 
deficient strains being significantly attenuated in vivo both in mice [24] and patients [25]. Iron is 
an essential nutrient for bacterial growth and owing to the incredibly iron deficient nature of the 
urinary tract, UPEC encode several seemingly redundant iron acquisition systems. These iron 
acquisition systems primarily consist of siderophores such as Aerobactin, Enterobactin, 
Salmochelin and Yersiniabactin, which bind to iron with high affinity and scavenge it from the 
environment [26, 27]. Secreted UPEC toxins such as α-hemolysin, cytotoxic necrotising factor 1 
(cnf1), vacuolating autotransporter protein (vat) and secreted autotransporter protein (sat) play 
diverse roles in UTI progression. Pore forming toxin α-hemolysin can lead to host cell lysis and the 
release of nutrients, however physiologically relevant levels of the toxin are sub-lytic. α-hemolysin 
is also capable of altering host serine/threonine kinase (Akt) signalling, disrupting cellular 
processes such as cell cycle progression, metabolism, vesicular trafficking, inflammation and 
survival [28]. Cnf1 similarly via constitutive activation of Rho family of GTPases can alter host 
cytoskeletal arrangement and inflammatory response. Cnf1 can stimulate urothelial apoptosis and 
exfoliation, exposing underlying transitional cells to UPEC [1, 21]. Other virulence factors include 
Antigen 43 (Agn43) an adhesive autotransporter protein involved in host cell adhesion and biofilm 
formation, and flagella, which are supramolecular mediators of bacterial motility, which play 
important roles in host cell adhesion, biofilm formation and ascension through the urinary tract [29-
31].   
       Pathogenic E. coli are simplistically classified as either diarrheagenic E. coli or Extraintestinal 
Pathogenic E. coli (ExPEC). Uropathogenic E. coli come under the broad group of ExPEC. The 
purpose of such general pathotypes is to cluster bacteria on the basis of similarities in clinical 
outcomes, pathogenesis and virulence factors [27]. Comparative genomic analysis of multiple 
pathovars including enterotoxigenic, enteropathogenic, enteroaggregative and commensal E. coli 




few pathovar specific genes could be identified and no unique genomic signatures emerged. Taken 
together, the 17 genomes analysed did reveal an astonishingly diverse pangenome of about 13,000 
genes [32]. Comparing the genomes of enterohemorrhagic, uropathogenic and commensal E. coli; 
a few trends begin to emerge. Genomic content differs not only between pathogenic and commensal 
E. coli (8-22% more open reading frames in pathogens) and between pathotypes as expected, but 
also between sequenced UPEC isolates [33, 34]. UPEC isolates are enriched in virulence factors 
such as iron acquisition systems, adhesins and autotransporters compared to other pathogenic E 
coli. However, the sequenced UPEC genomes differ in the types and numbers of virulence factors 
encoded, primarily associated with pathogenicity islands [27].  Based on genomic analysis there 
exists a substantial amount of similarity between UPEC and Avian Pathogenic E. coli (APEC), with 
regards to serogroups, phylogenetic groups and virulence genes. These genomic overlaps include 
pathogenicity islands and plasmid encoded virulence genes [27, 35]. Thus, APEC might represent 
a direct zoonotic risk or at least a reservoir of potential virulence phenotypes. It is evident that the 
classification uropathogenic E. coli (UPEC) encompasses a diverse set of pathogenic bacteria 
having evolved to retain a high degree of genome plasticity and with access to an impressive arsenal 
of virulence factors, enabling successful adaptation to and colonization of the human urinary tract. 
1.2.3       Treatment of UPEC Induced UTI 
       Treatment strategies for both UTI and rUTI involves antibiotic usage, which can alleviate 
symptoms and reduce bacterial colonization. Commonly prescribed antibiotics include 
trimethoprim-sulfamethoxazole, Ciprofloxacin, Nitrofurantoin and Ampicillin [36]. Analysis of a 
panel of 17 different antibiotics revealed that though planktonic bacteria grown in liquid media are 
susceptible to killing, when tested against biofilms and IBCs in vitro efficacy drops drastically, 
with IBCs susceptible only to Nitrofurantoin, Ciprofloxacin and Sparfloxacin. This in vitro efficacy 
was entirely absent when extended and tested in vivo [37]. Further studies in mice have revealed 




trimethoprim-sulfamethoxazole treatment reduces recurrences and eliminates faecal colonization, 
it is unable to eliminate the bladder reservoir [38].  
          Our understanding of the complex UPEC life cycle and virulence mechanisms sheds light on 
the persistence of this pathogen even in the face of long term antibiotic therapy and permits the 
rational design of novel prophylactic small molecule inhibitors. Pilicides which are inhibitors of 
crucial steps in the assembly of adhesive pili are one such inhibitor. Pilicides with broad spectrum 
activity, such as ec240 which is active against Type I, P and S pili exist. ec240 functions by 
inhibiting the phase variable expression of type I pili and effectively shutting down transcription 
[39]. Mannosides are orally bioavailable, fast acting, high affinity Type I pili receptor antagonists 
which prevent binding of Type I pili to their mannosylated glycoprotein receptors. Effective against 
both uncomplicated UTI and catheter associated UTIs [40], mannosides have even shown efficacy 
against acute as well as chronic bladder colonization by multidrug resistant lineage of UPEC [41]. 
Combination therapies of new classes of antibiotics with β-lactamase inhibitors, chemical inducers 
of urothelium exfoliation [19, 42], pilicides and mannosides holds great promise. Vaccines 
targeting UPEC are primarily directed against the type I pilus adhesion subunit protein FimH, iron 
acquisition system components and secreted toxins. Vaccination against type I adhesin has been 
shown to mount an effective urinary tract specific antibody response capable of blocking host 
pathogen interaction and thus bacterial colonization, in both mice [43, 44] and monkeys [44]. 
Vaccines against different siderophore components are effective in specific host niches only and 
vaccination against toxin like α-hemolysin does not prevent colonization, only mitigates severity 
of clinical outcome [1]. Two commercially available vaccines exist, which either contain membrane 
components from 18 E. coli or 10 heat killed UPEC. However, these are not universally approved 
or effective [45]. 
      Owing to high prevalence and morbidity combined with a significant rate of recurrence and 
the immense financial and human burden of UPEC induced UTIs, the shortcomings of current 




repeated prolonged use in UTI treatment runs the risk of altering host microbiota and more 
importantly drug resistance in UPEC. Indeed, multidrug resistant UPEC are now beginning to 
emerge which encode an impressive array of resistance mechanisms such as extended spectrum β-
lactamases (ESBLs) such as cefotaximases (CTX-Ms) and oxacillinases (OXAs). Most 
disturbingly, carbapenemases active against a broad spectrum of β-lactam antibiotics including the 
last line carbapenems, such as the New Delhi Metallo-β-lactamase (NDM1) have begun to rapidly 
emerge. Drug resistance amongst clinical UPEC isolates can vary from 8.6% to 48.7% depending 
on the antibiotic [2] and globally disseminated lineages of drug resistant UPEC such as Sequence 
Type or ST131, ST69, ST73 and ST95 now exist [46].  
       Knowledge of Uropathogenic E. coli infectious life cycle, virulence factors and genomics has 
helped clinical management of this pervasive infectious disease and further research into these 
fundamental bacterial processes will definitely aid in designing better therapeutic strategies. 
 
1.3       Epigenetic DNA Methylation 
       Epigenetics refers to functionally relevant, heritable information encoded by the genome of 
living organisms, which does not include the underlying nucleotide sequence. This definition can 
cover several distinct mechanisms such as regulatory RNAs, chromatin remodelling and covalent 
modification of DNA. Arguably one of the most common and well-studied epigenetic mechanisms 
in all kingdoms of life is DNA methylation. Methylation of DNA is mediated by enzymes called 
DNA methyltransferases and involves covalent attachment of a methyl group either to the carbon 
ring of cytosine (producing 5-methyltcytosine, 5mC) or the exocyclic amino groups of cytosine or 
adenine (producing N4-methylcytosine, 4mC or N6-methyladenine, 6mA respectively) [47]. The 
functional role of DNA methylation in eukaryotes has been studied primarily in the context of 5mC 
methylation of CpG nucleotides. More than half of vertebrate genomes possess CpG nucleotide 
rich stretches called CpG islands or (CGI) in their genomes. 5mC methylation of CGIs present at 




occur at CGIs present at other sites and also other genomic contexts such as gene bodies, regulatory 
elements and repeat sequences, we are still learning about their mechanisms and functions [48]. 
6mA which was believed to be an exclusively prokaryotic epigenetic mark is now being discovered 
in regulated sequence and tissue specific contexts in higher eukaryotes such as Chlamydomonas 
reinhardtii, Caenorhabditis elegans, and Drosophila melanogaster [49]. DNA methylation in 
humans for example, plays an important role in differentiation and development such as X-
chromosome inactivation, genetic imprinting, controlling transposition, development and tissue 
specific gene expression [50]. DNA methylation also plays an important role in cancer by altering 
gene expression and mutation rates of genes [48]. This brief overview does not do justice to the 
fascinating role of DNA methylation in eukaryotes, however the focus of this study is to elucidate 
the role of this important epigenetic mechanism in bacteria, specifically UPEC.  
1.3.1       Types of DNA Methyltransferases 
       The first evidence for DNA methylation was found in Escherichia coli K12 by Joe Bertani 
and Jean Weigle in 1953, when they reported a barrier to λ phage transduction. Briefly, when λ 
phage from a heterologous E. coli strain was used to infect E. coli K12, it failed. But, λ phage 
propagated in E. coli K12 could effortlessly reinfect the homologous strain. This lead to 2 pivotal 
and elegant conclusions: 1. Bacteria are capable of imparting upon their DNA an identification 
“tag” and 2. Bacteria are capable of recognising and restricting a foreign identification tag. Years 
of research would show that this barrier was mediated by a Restriction Modification System (RMS) 
and the identification tag imparted to DNA was DNA methylation. The study of RMSs discovered 
over half a century ago has led to several major steps in our understanding of DNA methylation, 
cleavage, translocation, bacterial defence mechanisms and phage evasion strategies, but most 
importantly allowed us to develop molecular biology tools essential in genome manipulation [51].  
DNA methyltransferases in bacteria are of two types: Components of Restriction Modification 





1.3.1.1       Restriction Modification Systems 
       Restriction Modification Systems (RMSs) as the name suggests perform two contrasting 
enzymatic functions, DNA methylation or modification and DNA cleavage or restriction. RMSs 
perform these contrasting activities in the context of a specific DNA recognition sequence. RMSs 
ensure methylation of host genomic or self DNA at the specific recognition sequence, however, 
upon encountering the unmethylated recognition sequence in exogenous or non-self DNA, trigger 
cleavage. Thus allowing differentiation between self and non-self DNA and selectively degrading 
potentially harmful foreign DNA such as phages, plasmids, etc. Based on this primary function, 
RMSs could be considered a prokaryotic innate immune system [52]. RMSs display exceptional 
diversity and prevalence in both bacterial and archaeal genomes. About 90% of all sequenced 
prokaryotic genome possess at least one RMS, with 80% containing multiple systems. The 
distribution of the number of RMSs positively correlates with the size of the host genome. Obligate 
intracellular pathogens like Buchnera, Borrelia and Rickettsia are devoid of RMSs and naturally 
competent bacterial species such as Helicobacter, Neisseria, Haemophilus and Streptococcus 
encode a disproportionally large number of RMSs, more than 20 in Helicobacter pylori [53]. 
Arguably, this correlates with the exposure of these different bacterial species to exogenous DNA 
such as phages. Although primarily involved in host defence, DNA methyltransferases associated 
with RMSs by virtue of their ability to methylate DNA have the potential to perform additional 
epigenetic functions. Based on recognition sequence, co-factor requirement, sub-unit composition 
and cleavage position RMSs can be classified into 4 types, I to IV, summarised in Figure 1. 
      Type I Restriction Modification Systems consist of three genes, hsdS, hsdM and hsdR. HsdS 
is the sequence recognition protein, HsdM the methyltransferase and HsdR the endonuclease of 
these RMSs. Type I RMSs are complex multi subunit systems, with the functional restriction 
holoenzyme, R2M2S1 consisting of two endonuclease (R), two methyltransferase (M) and one 
specificity (S) subunit. The functional methyltransferase consists of a M2S1 heterotrimeric complex. 




a degenerate central sequence of fixed length, for example, AAC(N6)GTGC. Methylation occurs at 
specific nucleotides on both strands of the recognition sequence and requires S-Adenosyl 
methionine (SAM) as a methyl donor and cofactor [54]. Restriction of DNA occurs by recognition 
of two unmethylated sites and ATP/Mg2+ dependent bi-directional translocation of DNA until two 
Type I heteropentameric complexes collide, triggering cleavage. Cleavage thus occurs at a random 
site each time which is located hundreds to thousands of bp away from the recognition site [55]. 
RMS recognition sites have been classically identified based on their plasmid cleavage patterns, 
since both methylation and restriction functions are mediated by the same recognition sequence. 
The variable position of the Type I RMS cut site explains the difficulty in identifying and hence 





Figure 1: Characteristics of Type I-III Restriction Modification Systems. A) Genetic 
organisation of RMS genes. hsdM, M and mod – DNA methyltransferases. hsdR, R and res – 
endonucleases. hsdS – Type I RMS specificity determining DNA binding sub-unit. B) DNA 
methylation – holoenzyme components, cofactor requirements and recognition site characteristics. 
C) DNA cleavage – holoenzyme components, cofactor requirements, cleavage site and mechanism. 
M = Methyltransferase, R = Endonuclease and S = Specificity subunit. 
 
  The Type I HsdS sub-unit consists of two highly variable target recognition domains 
(TRDs) separated by conserved regions between and flanking the TRDs. It is these TRDs, each 
biding to one half of the bipartite recognition sequence, which determines the Type I recognition 
sequence. The central conserved region present between the TRDs can vary in length and this 
correlates with the length of the degenerate sequence present in the recognition site [56, 57]. In 
addition to the flanking conserved regions, hsdS TRDs sometimes contain flanking invertible 
repeats [58]. The presence of these elements permits Type I RMSs to exchange not just the hsdS 
gene, but also individual TRDs and even vary the central degenerate sequence length to generate a 
phenomenally diverse repertoire of recognition sequences. Evidence for such Type I RMS diversity 
comes from the existence of systems with combinations of TRDs which match precisely the 
combinations of bipartite recognition sequences [51, 54, 56]. Type I RMS genes hsdSMR usually 
occur at the same locus, however the number of sub-units and genomic location can vary. Multiple 
HsdS each with a different recognition sequence, located at different loci can be recruited by the 
same HsdMR to form a functional RMS. This genetic complementation occurs naturally in diverse 
bacteria such as Mycoplasma pulmonis [59, 60], Bacteroides fragilis [61] and Streptococcus 
pneumoniae [62, 63] as well as experimentally in the lab, provided the genes belong to the same 
family of Type I RMSs. Overall Type I RMSs represent extremely flexible molecular machines 




       Type II Restriction Modification Systems consist of two genes, encoding a 
methyltransferase (M) and an endonuclease (R). Both genes contain DNA recognition domains and 
are capable of enzymatic activity independent of each other. The recognition site for these systems 
consists of short (4-8bp) usually palindromic but occasionally asymmetric sequences, for example 
GAATTC. Cofactors required by these systems include SAM for methylation and Mg2+ for 
restriction. The site of endonuclease digestion is at a fixed position at or near the recognition site, 
with no need for DNA translocation. The precise nature of DNA digestion mediated by these 
systems has allowed for their easy biochemical characterization. Also, the independent recognition 
and enzymatic activities has allowed cloning and commercial production of these endonucleases as 
precise tools in molecular biology. The classification of Type II systems is based more on 
enzymatic behaviour than phylogeny, resulting in a rather heterogeneous group of systems [64]. 
Since the two activities of these systems can act independently of each other, loss or inefficient 
methyltransferase activity risks endonucleolytic attack on the host genome. Thus, Type II RMSs 
can be considered as selfish genetic elements [65]. This has also resulted in the evolution of 
temporal regulatory mechanisms for the methyltransferase and endonuclease, so as to ensure 
adequate genomic methylation and mitigate toxicity to the host [66].  
       Type III Restriction Modification Systems are also encoded by two genes, a 
methyltransferase (mod) and an endonuclease (res) gene. Only the methyltransferse has the ability 
to recognise the Type III recognition site. Thus the functional methyltransferase consists of a 
homodimeric (mod2) holoenzyme, while the functional endonuclease consists of either 
heterotrimeric (mod2 res1) or heterotetrameirc (mod2 res2) holoenzyme. The recognition site for 
Type III RMSs consists of short (4-6bp) non-palindromic sequences, for example CGAAT, with 
methylation characteristically occurring only on one of the two strands. DNA cleavage requires 
binding of Type III enzyme complex to two inversely oriented (head to head oriented) unmethylated 
recognition sites, followed by DNA translocation, stalling due to collision between the two systems 
and cleavage at a fixed position approximately 25 to 27 bp from one of the recognition sites. Type 




translocation and cleavage of DNA [67]. Similar to other RMSs methylation can occur in the 
absence of the restriction component, as the methyltransferase encodes the DNA recognition 
domain [68]. However, unlike Type II RMSs where the recognition domain is present on both M 
and R, alteration in DNA recognition domain does not risk endonucleolytic cleavage of the host 
genome. Thus, similar to Type I RMSs we observe a mod gene organization where numerous alleles 
differing only in a central DNA target recognition domain exist with conserved flanking sequences 
and the potential to easily acquire novel specificities via horizontal gene transfer [69].    
       Type IV Restriction Modifications Systems are not considered as classical RMSs, since 
they do not possess a methyltransferase component. Unlike other RMSs, they recognise and cleave 
modified DNA [68]. The recognition site for these systems has very low specificity, such as RC 
(where R = A or G) separated by about 40 to 3000 bp. Also, the type of methylation detected by 
these systems are highly variable, such as 5-methyltcytosine (5-mC), 5-hydroxymethyltcytosine (5-
hmC), N4-methyltcytosine (4-mC), N6-methyltadenine (6-mA) or even 5-
glucosylhydroxymethyltcytosine. These systems utilise GTP for translocation and cleavage of 
DNA [70]. Since the recognition sequence is relatively promiscuous and the type of methylation 
detected is rare but often found in some phage genomes, Type IV RMSs still behave as host defence 
mechanisms, capable of killing an infected host as well [71]. However, since these systems do not 
encode a methyltransferse component, they are relatively less interesting from the epigenetic 
perspective. 
1.3.1.2       Orphan Methyltransferases 
       Orphan or solitary methyltransferases as the name implies are stand-alone enzymes lacking 
any partner endonuclease. Like Type II RMS methyltransferases, orphan methyltransferases 
predominantly utilize SAM to methylate either cytosine or adenine in short (4–6 bp) palindromic 
sequences, for example GATC, CCWGG (W = A or T) and RCCGGY (R = A or G and Y = C or 
T) [72-74]. Orphan methyltransferases are believed to be evolutionary degradation products of 




methyltransferase dam and Type II RMS DpnI both recognise the same palindrome, GATC. A 
study of over 1000 genomes revealed that orphan methyltransferases far outnumber 
methyltransferases encoded by RMSs, based on sequence analysis [75]. A far more comprehensive 
and broad analysis of actual DNA methylation patterns in 230 (217 bacterial and 13 archaeal 
species) prokaryotic genomes revealed that over 48% of methylated Type II motifs are due to 
orphan systems. This number is probably higher, since the presence of the endonuclease gene does 
not necessarily mean that its enzymatic activity is functional, which is not experimentally verified 
in these studies. Type I and III orphan methyltransferases in contrast constitute only 2.8% and 6.7% 
respectively of the identified methyltransferases [76]. Also, while RMSs show a high degree of 
variability, orphan methyltransferases are phylogenetically well-conserved across a particular 
genus/family and even essential in some bacteria [75, 76]. Thus, although orphan 
methyltransferases may have lost their ability to function as classical RMSs, the conserved nature 
of these enzymes and their ability to methylate DNA at specific sequences is indicative of 
alternative epigenetic functions.  
1.3.2       Detection of DNA Methylation 
      Direct detection of methylated bases in DNA has been classically achieved by using either 
radiolabelled substrates or mass spectroscopic analysis. But depending on the method, they have 
severe drawbacks such as lack of genome wide analysis and inability to determine the specific 
sequence context of methylation [49, 51]. The first truly genome wide, strand and context specific 
detection of DNA methylation was achieved with the advent of bisulfite sequencing. This method 
involves the conversion of cytosine to uracil via bisulfite treatment followed by conventional next 
generation sequencing, resulting in C to T conversion of unmethylated cytosines only. This method 
has been the gold standard for detection of methylated DNA and a major aid in our understanding 
of the function of DNA methylation. However, Bisulfite sequencing can specifically detect 5-mC 
and 5-hmC only, and is also sensitive to differences in efficiency of bisulfite conversion of DNA 




sequencing platforms, especially Single Molecule Real Time (SMRT) Sequencing by Pacific 
Biosciences [77].  
      SMRT sequencing is unique because the incorporation of fluorescently labelled nucleotides in 
the sequencing reaction is detected in real-time, allowing an in-depth analysis of sequencing 
polymerase kinetics. This real-time detection is possible since each polymerase enzyme molecule 
is immobilized in individual reaction wells called zero mode waveguides [78]. Incorporation of a 
nucleotide complementary to a modified nucleotide such as N6-methyladenine, N4-methylcytosine 
and 5-methylcytosine amongst others, causes a characteristic and significant change in polymerase 
kinetics [79]. When compared to an in silico control for polymerase kinetics of unmodified DNA 
it is possible to reliably detect, genome wide, strand and context specific methylation patterns in 
bacterial as well as eukaryotic DNA [80]. Combined with the long read length (>10kbp), lack of 
sequencing bias, high consensus accuracy and use of native DNA, SMRT sequencing allows de 
novo assembly of bacterial genomes and the reliable analysis of the epigenome [81, 82].  
       Since SMRT sequencing allows the detection of methylation independent of the presence or 
type of RMS restriction activity, researchers can now easily identify Type I and III RMSs, vastly 
increasing the numbers of such systems [76, 83, 84]. SMRT allows the detection of Type II and III 
RMSs with degenerate specificity, such as those observed in Bacillus cereus [85]. Detection of 
methylation systems in diverse bacterial and archaeal species, which differ in important genomic 
characteristics such as size, G+C and repeat content, is possible [76, 84]. SMRT has also allowed 
the identification of unique sub-types of RMSs such as Type IIG, IIS and IIT whose identification 
by conventional methods such as studying DNA cleavage patterns would have been difficult. This 
is because of several reasons such as presence of a single fused M/R protein for Type IIG, presence 
of cleavage sites outside the recognition site either on one or both sides, diversity of recognition 
sites (symmetric, asymmetric or even bipartite) and in some cases, a tendency towards incomplete 
cleavage of DNA [85, 86]. Finally, SMRT sequencing has allowed the analysis and characterisation 




express 17 to 20 functional methyltransferases [87]. Thus, it is now possible to temporally detect 
specific methylated, hemimethylated or unmethylated sites at a genome wide level [76, 88-90]. 
With tools such as SMRT sequencing our ability to characterize DNA methyltransferases has 
greatly improved, revealing a vast diversity of such systems and possible roles in epigenetic 
regulation.         
 
1.4       Role of DNA Methylation in altering virulence 
       The virulence phenotype of a pathogenic bacterium is a direct consequence of specific spatial 
and temporal gene expression patterns. Methylation of DNA irrespective of the enzyme 
responsible, has the potential to alter expression of genes required not only for essential 
physiological processes, but also virulence. The aim of this section is to summarise the effect of 
DNA methylation mediated by orphan as well as Restriction Modification System 
methyltransferases on a diverse set of bacterial pathogens. 
1.4.1       Orphan Methyltransferases 
         Arguably the majority of methyltransferases studied to date capable of altering virulence are 
orphans. The most well characterised being DNA Adenine Methyltransferase (dam), DNA 
Cytosine Methyltransferase (dcm), and Cell Cycle Regulated DNA Methyltransferase (ccrM). For 
dam and ccrM the molecular mechanisms used in order to execute specific functions is also known 
[91]. It is important to note that methylation of DNA can alter the thermodynamics and curvature 
of DNA, and also the ability of important regulatory proteins such as RNA polymerase and 
transcription factors to bind to their target sites [92]. Besides the locus specific effects of these two 
orphan methyltransferases the mechanistic cause for global gene expression changes for orphan as 






1.4.1.1       DNA Adenine Methyltransferase (dam)  
       Dam is a highly conserved methyltransferase found in Gammaproteobacteria which includes 
many important Gram negative pathogens such as Escherichia coli, Salmonella spp, Vibrio cholera, 
Yersinia spp, Haemophilus influenzae and Neisseria meningitidis. The target sequence for Dam is 
5’-GATC-3’ with the adenine on both strands undergoing N6-methylation [91]. Unlike RMS 
associated methyltransferases with the same sequence specificity, Dam is a highly processive 
enzyme. Although Dam shows equal binding affinity for both hemi and unmethylated sites 
irrespective of the local sequence context, the kinetics of methylation are affected up to 12 fold by 
the local sequence context of individual GATC sites, especially poly-adenine tracts [93]. These 
features of Dam mediated methylation play an important role and known Dam regulatory 
mechanisms involve arrays of GATC sites present in the promoters of regulated genes whose 
methylation status can affect protein binding and gene expression. Dam has been primarily studied 
in Escherichia coli and Salmonella spp. 
       E. coli Dam plays an important role in regulating DNA replication and mismatch repair. 
Methylation of three GATC sites in the promoter of the dnaA gene, located at the origin of 
replication causes expression of DnaA which is responsible for initiation of replication. 
Immediately thereafter, protein SeqA binds to these specific hemimethylated GATC sites to prevent 
further DnaA synthesis till the completion of one round of replication. Thus, Dam methylation is 
required for co-ordination of replication and cell division [94]. As replication proceeds GATC sites 
immediately after the replication fork are transiently hemimethylated. The mismatch repair system 
mutHLS scans DNA looking for mismatches (replication errors) and utilises the methylation status 
of GATC to differentiate the template strand from the newly synthesized strand to correct errors 
[92]. Antibiotic stress stimulates error prone DNA polymerase IV which, in the absence of dam 
directed mismatch repair, reduces the survival of pathogenic E. coli like UPEC and even drug 
resistant strains [95]. Although dam is not an essential gene in E. coli, deletion mutants are severely 




vaccines in vivo [96]. A Dam methylation site present at the -10 RNA polymerase binding site of 
insertion element IS10 transposase gene tnp regulates its transcription. Only during replication, the 
expression of tnp is possible due to transient hemimethylation and thus Dam methylation is capable 
of regulating transposition [94]. Deletion of dam in E.coli resulted in the differential expression of 
several hundred genes, confirmed by transcriptomics and proteomics in multiple conditions as well 
as growth phases. Genes upregulated in the dam deficient strain include those involved in 
respiration, DNA and amino acid metabolism, and SOS response, while downregulated genes were 
found to be involved in anaerobic respiration, chemotaxis and motility. Computational analysis 
revealed a biased distribution of GATC sites in the regulatory regions of the E. coli chromosome, 
with an enrichment in regulatory regions flanking genes identified as differentially expressed [97, 
98].  
       Dam methylation has also been studied in the context of specific E. coli pathotypes such as 
Enterohaemorrhagic E. coli (EHEC). EHEC adhesion and actin pedestal formation upon contact 
with intestinal epithelial cells is dramatically increased in dam deletion strains. Virulence factors 
such as intimin and Type 3 secretion system effectors show increased expression via an unknown 
mechanism independent of transcription. This Dam mediated effect is unique both in its potential 
mechanism and in the fact that it increases virulence [73]. Pyelonephritis associated adhesive P- 
pili and autotransporter adhesin Agn43 are important Uropathogenic E. coli (UPEC) virulence 
factors as discussed earlier and are subject to Dam methylation regulated phase variation. Phase 
variation refers to the rapid reversible on/off switching of gene expression, which allows the host 
to quickly respond and adapt to environmental cues. Upstream of P- pili genes papAB, there are six 
binding sites for the regulatory protein leucine-responsive protein (Lrp) of which two have 
overlapping Dam GATC sites. Lrp cannot bind to its binding site when it is methylated and 
depending on this methylation status, Lrp can either bind and repress P-pilus or vice versa [99]. 
Similarly, the upstream region of agn43 has three binding sites for LysR-like factor OxyR and these 
OxyR binding sites each have an overlapping GATC site. Methylated GATC sites do not allow 




and agn43 repression [100]. Both these dam methylation regulated epigenetic switches of UPEC 
are complex multi-step epigenetic mechanisms which aid in virulence. 
        Salmonella spp. also encode a dam homologue which has been the subject of great interest. 
Salmonella enterica serovar typhimurium lacking dam is attenuated, with significantly reduced 
murine LD50 values and even considered as a potential live vaccine [101, 102]. Salmonella lacking 
dam methylation was incapable of colonising deep tissue sites such as the liver and spleen [101], 
and showed reduced cytotoxicity, invasion and intracellular survival in phagocytic cells in vitro 
[102]. Salmonella typhimurium lacking dam methylation shows up to 139 genes upregulated and 
37 genes downregulated when compared to wild type. These gene expression changes resulted in 
altered levels of secretory proteins, reduced motility and chemotaxis, reduced bile resistance and 
attenuated SOS response [103, 104]. Deletion of dam resulted in gene expression changes only in 
pathogenic and not lab adapted Salmonella typhimurium strains [104]. A locus specific mechanism 
for dysregulation has been elucidated for the Salmonella Std fimbrium. Std fimbrial expression is 
activated by the LysR-like protein HdfR and repressed by hemimethylated GATC binding protein 
SeqA. In the absence of dam methylation wherein SeqA no longer binds to GATC sites or a deletion 
of SeqA itself, HdfR mediated upregulation of Std fimbrial transcription occurs; which contributes 
to in vivo attenuation [105]. Another phase variable locus reminiscent of the agn43 locus of E. coli 
is the opvAB locus of Salmonella enterica. In the OpvABON state a shorter O-chain length LPS is 
formed, while OpvABOFF state results in normal longer LPS O-chain length. The opvAB operon 
contains four dam GATC methylation sites and four LysR-like protein OxyR binding sites. 
Depending on the combinations of GATC sites methylated, OxyR binds at the remaining 
unmethylated sites and this rapid switching of methylation and OxyR binding can switch expression 
of OpvAB on or off [106]. The normal LPS O-chain serves as a receptor for several Salmonella 
phages and hence the OpvABON sub-population although less virulent can survive phage attack. 
After the phage pressure is relieved this epigenetic phasevariable element can switch again and 




        Other Gammaproteobacteria also possess dam homologues. In Yersinia pseudotuberculosis 
and Vibrio cholerae, dam is essential and it is believed that dam methylation could be involved in 
co-ordinating replication and maintenance of the two chromosomes harboured by these bacterial 
species [91]. Y. pseudotuberculosis and V. cholera strains overexpressing dam are attenuated and 
completely protective in the murine gastric infection model [108]. Moreover, Y. pseudotuberculosis 
dam methylation is involved in mismatch repair, resistance to detergents and overexpression 
mutants ectopically secrete virulence factors [108, 109]. Similarly, dam is also essential in Yersinia 
enterolytica with overexpression mutants showing increased rate of spontaneous mutations, 
increased motility, increased proportion of rough O-side chain containing LPS and reduced 
resistance to detergents [110, 111]. Similarly, lack or overexpression of dam methylation results in 
altered virulence factor expression which results in attenuation of Aeromonas hydrophila [112], 
Actinobacillus actinomycetemcomitans [113] and Klebsiella pneumoniae [114].   
1.4.1.2       DNA Cytosine Methyltransferase (dcm)  
        Dcm is an orphan methyltransferase which performs 5-methylcytosine methylation of the 
second cytosine in the sequence 5’-CCWGG-3’ (W = A or T). Although conserved in all sequenced 
E. coli, the exact biological role of this methyltransferase has remained elusive [115]. Cells lacking 
dcm show numerous gene expression changes, but only during stationary phase. Most notably, lack 
of dcm results in reduced expression of ribosomal genes and increased expression of stress induced 
sigma factor RpoS as well as its downstream targets [74]. Other dcm regulated genes such as cold 
shock protein b (cspb) could be required for optimal stationary phase growth at 20°C [116]. Lack 
of dcm also results in increased expression of antibiotic efflux transporter SugE, resulting in 
increased resistance to EtBr [117]. Although not involved in virulence, there is evidence for E. coli 







1.4.1.3       Cell Cycle Regulated DNA Methyltransferase (ccrM) 
        CcrM is a N6-methyladenine methyltransferase targeting adenine in the sequence 5’-
GANTC-3’ (where N = A, T, G or C). This methyltransferase is conserved amongst most 
Alphaproteobacteria including Agrobacterium tumefaciens, Rhizobium meliloti and Brucella 
abortus [91]. However, CcrM has been studied mainly in the context of the Gram negative 
bacterium Caulobacter crescentus, known for its dimorphic life cycle consisting of a swarmer and 
stalked cell type. ccrM plays an important role in regulating the C. crescentus cell replication cycle. 
Unlike dam, ccrM is not constitutively expressed and does not perform mismatch repair [118]. 
Instead it is one of four hierarchical cell cycle master regulators, namely DnaA, GcrA, CtrA and 
CcrM in that order. DNA replication is initiated by DnaA and results in hemimethylated GANTC 
sites starting from the origin, progressing through the chromosome as replication proceeds. Each 
regulator sequentially activates the next until finally CcrM is expressed, which then rapidly 
methylates all the hemimethylated GANTC sites in the genome followed by cell division [90, 118]. 
This gradual transition of the C. crescentus epigenome from methylated to hemimethylated and 
back to fully methylated has been tracked in exquisite single base resolution at every step in the 
replication cycle by SMRT sequencing [90]. Computational analysis indicates that GANTC sites 
are overrepresented in the intergenic regions. Comparing the time of activation of genes, the 
position of GANTC sites in their promoters and the methylation state of these GANTC sites at the 
time of their regulation, we can list 59 genes regulated by ccrM. Not surprisingly these genes are 
mainly involved in cell cycle progression, cell division and DNA metabolism [90, 118]. Epigenetic 
DNA methylation thus plays an important role in the complex cell cycle progression of C. 
crescentus and potentially other Alphaproteobacteria.   
1.4.1.4      Other Orphan Methyltransferases 
       Additional orphan methyltransferases from diverse bacteria have been recently discovered 
and their role in epigenetically altering gene regulation analysed. Vibrio cholerae Methyltransferase 




RCCGGY-3’ (where R = A or G and Y = C or T). V. cholerae mutant lacking vchM shows both in 
vitro growth defect as well as attenuation in the murine gastric infection model. The methylation 
mediated by vchM is not dynamic, rather it is stably maintained on both chromosomes throughout 
the cell cycle. Deletion of vchM does result in global gene expression changes, with 134 genes 
upregulated and 63 downregulated. Analysis of its genetic interactions revealed that envelope stress 
responsive sigma factor RpoE (σE) is not essential in a vchM deletion mutant. Genes regulated by 
vchM include several cell envelope maintenance proteins including those involved in LPS 
biosynthesis and those localised at the cell envelope. This implies that vchM mediated epigenetics 
results in altered expression which induces envelope stress, making the RpoE gene essential in wild 
type. No satisfactory molecular mechanism exists, except for one gene whose expression is 
regulated by a single RCCGGY site within its coding sequence [72].  
       Mycobacterium tuberculosis encodes the Mycobacterial adenine methyltransferase mamA 
gene, which methylates adenine in the sequence 5’-CTCCAG-3’. Deletion of this methyltransferase 
resulted in only modest gene expression changes (11 genes). However, in several of the 
dysregulated genes, the methylation site CTCCAG occurs at the same position relative to the 
transcription start site and overlaps with a putative σ factor -10 binding site. The lack of mamA 
methylation does not result in in vivo or in vitro defects. However, under hypoxic growth conditions 
mimicking M. tuberculosis granulomas, the mamA mutant is attenuated [119]. Further analysis of 
12 different M. tuberculosis strains revealed a functional orphan Type I RMS methyltransferase 
(hsdSM, hsdR is missing) in addition to mamA. For both mamA and hsdSM the number of 
constitutively unmethylated sites is higher than expected, possibly due to masking by DNA binding 
regulatory proteins. Intriguingly, the relatively rare (600 to 700 sites / genome) Type I recognition 
sites of hsdSM are significantly enriched in intergenic regions [89]. This provides interesting hints 
towards additional regulatory roles for these orphan methyltransferases. 
       Helicobacter pylori encodes an orphan 5-methylcytosine methyltransferase called hpyAVIBM 




strains tested. Deletion of this methyltransferase results in altered gene expression, specifically 
outer membrane proteins, LPS biosynthesis genes, motility associated genes, virulence factors 
including adhesins and other RMSs. Phenotypically H. pylori strains lacking hpyAVIBM exhibit 
altered motility, LPS profile and elicit a heightened IL8 response. This orphan methyltransferase 
also possesses polymeric AG repeat tracts, which due to slipped-strand mispairing can result in 
phasevariable (reversible ON/OFF) expression of hpyAVIBM [120]. 
       Mycoplasma hyorhinis encodes two 5-methylcytosine methyltransferases (mhy1 and mhy2), 
both methylating cytosine in the dinucleotide 5’-CG-3’. M. hyorhinis in planktonic growth displays 
two subpopulations, displaying high and low levels of CG methylation. However, upon infection 
only the low CG methylation population survives, escapes endosomal degradation, undergoes 
exocytosis and re-infects new cells. Thus low CG methylation pattern in the M. hyorhinis genome 
predisposes it to intracellular survival and replication. Although Mhy1 and Mhy2 
methyltransferases escape and enter the mammalian host nucleus, their effect on host CpG 
methylation and its functional consequences are unknown. Thus, epigenetic regulation by this 
orphan methyltransferase potentially alters gene expression to aid in intracellular survival [121]. 
 
1.4.2      Restriction Modification System Methyltransferases 
        There is a paucity of information regarding the role of methyltransferases associated with 
RMSs in regulation of bacterial virulence. This probably stems from the fact that RMSs are believed 
to be first and foremost bacterial defence systems against exogenous DNA. There are however a 
few exceptions, where the functions of this diverse and prevalent set of epigenetic information have 
been investigated. It should be noted that not all studies test for the activity of the restriction 
endonuclease component of a RMS. This is important because any inactivating mutation such as a 
truncation, single nucleotide polymorphism or frame shift mutation in the endonuclease of a RMS 





1.4.2.1      Phasevarions  
          Phasevarions are the most well characterised set of RMS associated methyltransferases. 
Phasevariation refers to the high-frequency, rapid and reversible ON/OFF switching of gene 
expression patterns or regulons. Phasevariable Type III RMSs have been discovered in several 
important host adapted pathogens such as Helicobacter pylori, Neisseria meningitidis, Neisseria 
gonorrhoeae and Haemophilus influenzae. They can regulate the expression of a diverse set of 
genes, depending on the presence or absence of DNA methylation [122, 123]. These phasevariable 
regulons or Phasevarions possess characteristic homopolymeric dinucleotide, tetranucleotide or 
pentanucleotide repeat tracts of varying lengths either in the gene body or promoter of the 
methyltransferase (mod) gene [69, 123]. Phasevariation occurs by a mechanism called slipped 
strand mispairing, wherein owing to DNA polymerase errors at these repeat tracts, the number of 
repeats changes resulting in reversible ON/OFF expression of the mod gene [123]. This 
phasevariable methylation by Type III systems resulting in altered gene expression is a unique 
mechanism for increasing phenotypic diversity and fitness within the host.  
        The mod gene encoding the methyltransferase of Type III RMSs contains a DNA target 
recognition domain (TRD) which determines the recognition site specificity [67]. Computational 
analysis of different mod alleles methylating different sequences demonstrated significant identity 
between these genes from distinct bacterial species, hinting at horizontal gene transfer. 
Furthermore, the TRD of mod alleles shows mosaicism with regions of inter- and intra-allelic 
similarity indicative of recombination driven diversification of mod. In certain cases mod alleles 
such as the modA12 allele of N. meningitidis demonstrates not only an en bloc transfer of the entire 
TRD to other mod genes, but also an enrichment in clinical isolates, indicative of selection for this 
particular allele [69]. Importantly, in 70% of sequenced N. meningitidis and 20% of sequenced H. 
influenzae phasevarions, the restriction endonuclease (res) has an inactivating mutation. This 
inactivation of res genes is also observed in N. gonorrhoeae phasevarions associated with two 




phasevarions in Mycoplasma spp. and Helicobacter pylori [69, 123, 124]. The frequent 
identification of Phasevariable Type III RMSs with an inactive restriction (res) component 
demonstrates a selective advantage conferred by the phasevariable gene regulation mediated by the 
methyltransferase and not the restriction phenotype.  
        Phasevariable Type III RMSs capable of coordinated switching of gene expression patterns 
have also been found in H. influenzae [124]. Screening of clinical isolates of non-typeable H. 
influenzae responsible for otitis media demonstrated an overrepresentation of five modA 
methyltransferase alleles in more than two thirds of all cases. The effect of phasevariable 
methylation was studied on both the transcriptome and the proteome, in the context of different 
mod alleles. Differentially expressed genes included outer membrane proteins which include 
vaccine candidates. Phenotypically phasevariation of mod resulted in altered antibiotic sensitivity, 
evasion of phagocytic killing, biofilm formation and in a chinchilla model of middle ear infection, 
the predominant modA2 allele was preferentially isolated in the ON state [125]. Neisseria 
gonorrhoeae contains multiple phasevarions even within the same strain, FA1090. Phasevariation 
of modA13 (recognition site: 5’-AGAAA-3’) resulted in global gene expression changes which 
included antibiotic efflux systems, ABC transporters, genes involved in DNA metabolism and 
others. Moreover, phase variation of modA13 methylation resulted in altered antibiotic resistance, 
biofilm formation and adhesion-invasion of in vitro cell line model [126]. Similarly phasevariation 
of the other system ngoAXmod (recognition site: 5’-CCACC-3’) resulted in differential expression 
of over 121 genes. Once again there were phenotypic consequences which included altered growth 
rates, attachment-invasion of cell lines and biofilm formation [127]. Neisseria meningitidis strains 
such as MC58 also encode multiple phasevariable methyltransferases such as modA11 (recognition 
site: 5’-CGYAG-3’) and modA12 (recognition site: 5’-ACACC-3’), both of which regulate the 
expression of multiple genes including surface expressed vaccine candidates Lactoferrin-binding 
proteins A and B, amongst others [126]. Testing the antibiotic sensitivity of different N. 
meningitidis phasevariable systems against a panel of 13 antibiotics, revealed altered sensitivity to 




methylation sites of phasevarions in the intergenic regions of genes regulated by them [129]. 
Helicobacter pylori has one of the largest repertoires of phasevarions, up to 17 different mod alleles. 
One of the most common phasevarions, containing allele modH, is responsible for altered 
expression of only 6 genes but this includes important virulence factors like flaA (motility 
associated) and hopG (outer membrane protein associated with colonisation and gastric cancer) 
[130]. Moraxella catarrhalis also has a phasevariable Type III RMS with three different alleles 
(modM1-3). Screening of clinical isolates revealed that modM2 is the most common allele, while 
symptomatic stratification revealed that the allele modM3 shows a significant association with otitis 
media. Possibly due to the gene expression switching mediated by this phasevarion conferring a 
fitness advantage in this host niche. modM2 is also involved in the regulation of up to 34 genes, 
many of them virulence factors involved in evasion of host immune responses and colonisation 
[131]. 
        Although phasevarions have been primarily studied in the context of Type III RMSs, the 
homopolymeric repeat tracts responsible for phasevariation are also found within Type I and II 
RMSs [126, 132]. Campylobacter jejuni encodes a phasevariable Type IIG RMS, wherein both 
methyltransferase and endonuclease are fused into a single polypeptide. The stochastic ON/OFF 
switching of methylation mediated by this system results in altered biofilm formation as well as 
attachment and invasion of colorectal epithelial cell line. Phasevariation of this system caused 
differential expression of over 200 genes, with over 23% showing the presence of more than four 
methylation sites in their coding sequence. This Type IIG RMS is fully functional, with both 
methylation and restriction functions experimentally confirmed [86].  Potentially phasevariable 
RMSs have also been identified in a more diverse set of bacteria, including Mycoplasma spp, 
Pasteurella haemolytica and Streptococcus thermophilus [123].   
1.4.2.2      Complex Phasevariable Type I Restriction Modification Systems 
        Streptococcus pneumoniae clonal populations have been previously shown to have two 




associated with invasive disease and a transparent variant associated with nasopharyngeal carriage. 
S. pneumoniae possesses a unique Type I RMS, which encodes for two distinct hsdS genes, one 
partial hsdS, one methyltransferase component hsdM, one endonuclease component hsdR and one 
tyrosine recombinase (psrA or creX) at the same genomic locus [62, 63]. The Type I RMS 
specificity determining HsdS subunit contains two target recognition domains (TRDs), each 
recognising one half of a bipartite recognition sequence. The two and a half hsdS genes of these 
Streptococcal Type I RMSs essentially contain five TRDs, each with flanking inverted repeats. It 
is observed that the five hsdS TRDs can undergo random, high frequency recombination to give six 
different viable hsdS combinations with two TRDs each. Thus, a single Type I RMS can recombine 
to yield six distinct specificities, with both methylation and restriction functions verified 
experimentally [62, 63]. One of the recombinations responsible for TRD rearrangements is 
performed by the tyrosine recombinase present at the same locus [62]. The numbers for each of the 
six recognition sites for strain D39 Type I RMS in its genome ranged drastically from 424 up to 
1029. The distribution of these sites did not show any bias for promoters, small RNA, genes or 
operons; but were enriched on the lagging strand of the genome, a unique feature amongst Type I 
RMSs [63]. 
        Phenotypically, the phasevariable opaque and transparent colony types are due to changes in 
methylation patterns mediated by this Type I RMS [62, 63]. Of the six possible phasevariable 
methylation patterns one correlated with a predominantly opaque colony type (SpnIIIA in strain 
D39 and hsdSA1 in strain 556). A non-phasevariable mutant with the SpnIIIA methylation pattern 
for D39 also strongly correlated with bacteraemia in a murine model of invasive disease, while the 
other variants did not [63]. Similarly, the other variants resulted in a transparent colony type to 
different extents (for example SpnIIIB in strain D39 and hsdSA2 or hsdSA3 in strain 556). A non-
phasevariable mutant with the transparent colony type and methylation pattern correlated with 
excellent nasopharyngeal colonisation in a murine carriage model [62, 63]. Differentially 
methylated variants of S. pneumoniae not only accounted for variable colony type, but also variable 




patterns most importantly for capsular genes. Also, when the invasive murine model is inoculated 
with a wild type phase variable D39 strain, it contains a heterogeneous population of all six hsdS 
variants (SpnIIIA to F). However, within 4 hours this population predominantly shifts to the 
SpnIIIA opaque invasive variant, indicative of selection [63].  
        These unique, complex phasevariable Type I RMSs enable S. pneumoniae to rapidly and 
reversibly switch between methylation specificities. Each methylation specificity differentially 
regulates gene expression resulting in distinct phenotypic patterns, each with a distinct advantage 
in different host niches. These unique RMSs have also been found in other bacteria such as 
Mycoplasma pulmonis [59], Bacteroides fragilis [61], Treponema medium, Campylobacter 
upsaliensis, Enterococcus faecalis and Streptococcus agalactiae [62] but not functionally analysed. 
It is reasonable to assume that these Type I RMSs can rapidly switch methylation specificities and 
in the process epigenetically alter phenotypic traits of their host organisms. 
1.4.2.3       Classical Restriction Modification Systems  
        As noted earlier, cases of classical RMS mediated bacterial gene regulation are rare. One 
such system was discovered in Hemolytic uremic syndrome (HUS)-linked E. coli O104:H4. This 
diarrhoeal E. coli strain was responsible for the serious 2011 HUS outbreak in Germany, primarily 
due to the acquisition of genes stxAB encoding the Shiga toxin from a new prophage (ϕStx104).  
Further analysis revealed that the phage ϕStx104 also encoded a fully functional Type II RMS 
targeting the sequence 5’-CTGCAG-3’, with over 2486 sites in the genome. Methylation mediated 
by this Type II RMS resulted in differential expression of 1951 genes representing 38% of E. coli 
coding sequences. Upregulated genes include those involved in ion transport, while motility 
associated genes were downregulated. Interestingly, an increased abundance of methylation sites 
was observed within 500bp of motility associated genes, possibly hinting at a direct mechanism of 
methylation mediated regulation of gene expression. Comparison of strain C227-11 bearing the 
phage encode Type II RMS with another closely related E. coli O104 strain without the prophage, 




to C227-11 mutant lacking the Type II RMS [88]. This classical RMS although recently acquired 
via transduction had significant effects on the gene expression of this pathogenic E. coli. 
        Helicobacter pylori is a host adapted pathogen with an immensely complex methylome with 
even closely related strains showing highly variable sets of methyltransferases. In fact, 10% of H. 
pylori strain specific genes are RMSs [132]. An analysis of five different H. pylori strains revealed 
evidence of Inter and Intragenic target recognition domain rearrangements for Type I RMSs. This 
results in the evolution of diverse RMS specificities, with minimal risk of endonucleolytic attack 
of host DNA due to the modular nature, low numbers of recognition sites and genetic 
complementation of these systems. Computational analysis revealed regions of hyper and 
hypomethylation in the H. pylori genomes. Hypermethylated regions repeatedly consisted of RNA 
polymerase beta subunit gene (rpoB) and chaperonin (groEL) genes. Deletion of one classical Type 
I RMS of H. pylori strain P12 resulted in downregulation of only four genes encoding ATP/GTP-
binding proteins and belonging to the same operon. These genes also had three copies of the Type 
I RMS methylation site within their coding sequence, with one site overlapping a long 22 bp 
palindromic sequence possibly a DNA binding protein recognition site [58]. Thus a single classical 
Type I RMS of H. pylori did not result in massive global gene expression changes, but did affect 
expression at a single locus via an unknown mechanism.   
 
1.5       Role of DNA Methylation in Bacterial Evolution 
        Bacterial evolution is driven not only by spontaneous mutations, but also by the acquisition 
of horizontally transferred genes. Genetic exchange between closely related bacterial species can 
result in successful integration due to higher sequence homology. Such frequently transferred 
genetic material often encodes advantageous alleles whose frequency in a population increases due 
to selection. However, genetic material can also be transferred between completely unrelated clades 
due to illegitimate recombination. Although this occurs at a lower frequency, successful gene 




[133]. However, maintenance of species identity requires controlled uptake of exogenous genetic 
material. The genetic uniqueness of bacterial species often enables the efficient colonisation of a 
specific environmental or host niche, which can be lost if a certain degree of genetic isolation is not 
maintained [134]. A systematic study of bacterial evolutionary mechanisms, using over 600 
Streptococcus pneumoniae genomes revealed the presence of multiple co-circulating lineages. 
Stable genomic islands are infrequently transferred between lineages, mainly via transformation, 
and by integrative and conjugative elements. On the other hand, the prophage content is highly 
diverse even within lineages, indicative of horizontal transfer which represents a more frequent 
short term means of genetic exchange [135].  
       Restriction Modification Systems (RMSs) exert their primary function of host defence by 
blocking potentially harmful foreign DNA, such as phages and plasmids. However, RMSs never 
provide full protection against incoming DNA, which is also inherently transient [54, 68]. 
Moreover, other complementary systems for host defence against phages exist such as CRISPR 
[136] and BREX [137]. Thus, the selection pressure exerted by phage infection does not fully 
explain the exceptional diversity and wide distribution of bacterial RMSs [138]. Recognition site 
avoidance is a mechanism by which phages can subvert RMSs by underrepresenting the recognition 
sites of RMSs in their genomes; for example palindrome avoidance to subvert Type II RMSs. A 
systematic study of all available genomes and RMS recognition sites revealed that palindrome 
avoidance i.e. Type II RMS recognition site avoidance in the corresponding host genome is not 
universal and occurs only in about 50% of cases [139, 140]. However, recognition sites for other 
RMSs such as Type I, IIG, IIM, III and IV are not avoided in the vast majority of cases [140]. This 
implies that for the vast majority of functional RMSs site avoidance also does not explain need for 
RMS diversity and prevalence. Other slightly indirect functions besides host defence might exist 
for bacterial RMSs. Their ability to provide a barrier against the majority of foreign DNA, enables 




        The role of DNA methylation and RMSs in bacterial evolution can be illustrated with the 
bacterium Staphylococcus aureus. The majority of human S. aureus infections are caused by one 
of ten distinct lineages, characterised by their surface architecture. Methicillin-resistant 
Staphylococcus aureus represents six of these lineages and depending on the situation is responsible 
for 50% of infections [141]. S. aureus possesses a functional Type I RMS locus (Sau1) which 
encodes lineage specific hsdS alleles. The presence of this RMS is not only a hindrance to cloning, 
but also inhibits the transfer of resistance genes and mobile genetic elements from other bacterial 
species as well as different S. aureus lineages to one another [142, 143]. Type I RMS sites are 
distributed evenly in the genome and each lineage appears to be evolving independently [143]. A 
less conserved but fully functional Type III RMS is also found in some clinical S. aureus strains 
[144]. The restriction barrier presented by these RMSs is capable of blocking horizontal gene 
transfer between different MRSA lineages. In fact, the hsdS allele of S. aureus is used for rapid 
molecular typing of hospital MRSA isolates to track outbreaks, since its distribution is lineage-
specific [141]. This trend of bacterial clades with distinct core and accessory genomes 
superimposed with clade specific repertoires of functional RMSs is also observed in Burkholderia 
pseudomallei, indicative of a barrier to uncontrolled horizontal gene transfer between B. 
pseudomallei clades [145]. The globally disseminated drug resistant ST131 lineage of 
Uropathogenic E. coli (UPEC) also shows a distinct lineage specific RMS repertoire [146].  
        Thus, in several diverse bacterial species, there exist lineage specific repertoires of RMSs, 
which control DNA uptake. By virtue of their defensive function in regulating the uptake of 
exogenous DNA, RMSs act as regulators of bacterial evolution. Thus, methylation mediated by 
RMSs has the ability over time to drive bacterial evolution and possibly select for traits or gene 
expression patterns advantageous to the host. One of the most relevant and obvious examples is the 
transfer and spread of antibiotic resistance genes within specific bacterial lineages. This represents 





1.6      Hypothesis and Aims 
        Bacterial DNA methylation is an important epigenetic mechanism with the ability to regulate 
gene expression. The majority of information regarding diverse methylation mediated functions is 
restricted to orphan methyltransferases.  There is a paucity of information regarding the full extent 
and importance of RMS mediated methylation in bacterial virulence as well as basic physiological 
processes. Also, for most methylation mediated gene expression changes both local and global, we 
still don’t know how this epigenetic modification exerts its effect. Uropathogenic E. coli (UPEC) 
is the primary causative agent for urinary tract infections (UTIs) and has been studied in great detail 
with respect to its life cycle, niche specific gene expression patterns, immune evasion strategies 
and diverse repertoire of virulence factors. But the role of epigenetic DNA modification in this 
important human pathogen is relatively unclear. Based on the pervasiveness of DNA 
methyltransferases and their ability to regulate bacterial gene expression, we hypothesise that DNA 
methylation could potentially play an important role in regulating UPEC virulence or other cellular 
processes.  The following are the major aims of my PhD thesis: 
Aim 1: Characterise the methylome of UPEC strain UTI89 and assign the identified methylated 
motifs to their corresponding methyltransferases.  
Aim 2: Analyse whether a loss or modification of UTI89 methylation has any effect on virulence 
and gene expression patterns, using both in vivo models and high throughput strategies. 




2. MATERIALS AND METHODS 
 
2.1  Media and Culture conditions 
        All strains were routinely propagated in Lysogeny Broth (LB) [10g/L Tryptone, 5g/L Yeast 
extract, 10g/L Sodium chloride] at 37°C unless specifically noted otherwise. Other media used 
include M9 minimal medium [1X M9 salts, 2mM Magnesium sulphate, 0.1mM Calcium chloride, 
0.2% glucose] and Yeast extract-Casamino acids (YESCA) medium [10g/L Casamino acids, 1g/L 
Yeast extract], for specific purposes. Liquid media and agar plates were supplemented where 
appropriate with ampicillin (100 µg/ml), kanamycin (50 µg/ml) and chloramphenicol (20 µg/ml), 
purchased from SIGMA, Singapore. 
 
2.2  Strain Generation 
         All strains and plasmids used in this study are listed in Tables 11 and 12. Primers used for 
this study are listed in Table 13 and were ordered from SIGMA, Singapore. Deletion mutants were 
generated in E. coli using the lambda Red recombinase based homologous recombination protocol 
described previously with minor modifications [147]. Red recombinase was expressed from helper 
plasmid pKM208 in the target strain. Cells were made electrocompetent by diluting an overnight 
culture 1:100 and growing to OD600 = 0.2 – 0.25, followed by induction with 1mM IPTG for 30-
45mins in LB-ampicillin at 30°C. The induced cells were heat shocked at 42°C for 15 mins and 
placed on ice for 15 mins, with gentle swirling every 5 mins. Cells were then washed with sterile 
water twice and sterile 10% glycerol once at 5000 rpm for 10 mins at 4°C, careful to maintain cold 
conditions throughout. Cells were resuspended in 1/100 of initial culture volume of 10% glycerol 
and stored at -80°C. Primers were designed to amplify a positive selection cassette (from pKD3 for 
cat or pKD4 for neo) using universal priming sites and 50 bp flanking homology to the targeted 




competent cells using 1mm electroporation cuvettes in a GenePulser XCELL system set at 400 Ω 
resistance, 25µF capacitance and 1500V output voltage (Bio-Rad, Singapore). Cells were recovered 
in LB at 37°C for 2 hours with shaking, 2 hours statically and finally plated on appropriate selection 
plates. Double crossover homologous recombination allowed replacement of the genomic target 
with the amplified selection cassette and correct clones were isolated by purifying to single colonies 
by restreaking on new plates, validation by PCR using test primers flanking the site of 
recombination and finally sequencing the targeted genomic locus by Sanger sequencing (1st Base, 
Singapore).  
             For generating strains with seamless start to stop codon replacement of a target gene with 
a different allele, a negative selection strategy was used [148]. As described in Figure 2.A, UTI89 
strains bearing different Type I RMS alleles were generated via two successive rounds of 
homologous recombination. A dual positive-negative selection cassette (from pSLC-217) was used 
to knockout the native allele, rendering the strain kanamycin resistant and sensitive to growth on 
rhamnose due to inducible toxin RelE, both present on the same selection cassette. A second round 
of homologous recombination was used to replace the selection cassette with the desired allele. 
Desired clones were identified after each round of recombination by purifying to singles by 
streaking on selective plates (LB with kanamycin and M9 with 0.2% Rhamnose), PCR validation 
using primers flanking the site of recombination and finally Sanger sequencing the genomic target 
(1st Base, Singapore). 
                For replacing an essential gene such as nrdA with a mutant allele, a slightly altered 
negative selection strategy was utilised, Figure 2.B. Rather than replacing the target gene which is 
not possible, the dual selection cassette was inserted at an upstream locus which was not lethal to 
the host, in this case gene yfaL. Next, a PCR product bearing the desired mutant allele was used to 
replace a large piece of DNA including the essential gene, using homologous recombination with 
screening performed as described above. The resulting mutants do not carry over any selection 









Figure 2: Generating seamless allelic replacements. A) Replacing a non-essential gene such as 
hsdS. Wild type hsdS gene is first replaced with a dual positive-negative selection cassette via 
homologous recombination. Next, using PCR products with flanking homology to the target locus 






replaces the selection cassette to generate the desired strain. B) Replacing an essential gene such as 
nrdA with a mutant allele nrdA K584N. First, the dual positive-negative selection cassette is 
inserted at a permissive locus further upstream, depicted by a vertical black line. Followed by a 
second recombination with a PCR product not only flanking the selection cassette but also the wild 
type nrdA gene so as to replace both and generate the desired mutant. Selection is performed at 
each step in both A) and B) using positive selection marker; for example, kanamycin and the 
rhamnose inducible negative selection marker; for example, toxin RelE. Blue arrows represent 
homologous recombination steps.   
 
2.3  Plasmid Generation 
        Plasmids bearing one or two copies of the predicted Type I RMS recognition motifs for 
UTI89 (5’ GAAG (N7) TGG -3’), K12 MG1655 (5’ AAC (N6) GTGC -3’) and CFT073 (5’ GAG 
(N7) GTCA -3’) were generated by PCR mediated insertion. Briefly, low copy number plasmid 
pACYC184 which does not have any of the three Type I recognition motifs was selected and 
primers designed to insert the desired recognition motif, followed by plasmid amplification. 
Amplified linear plasmid was then recircularized by restriction digestion to obtain compatible ends, 
followed by ligation. The two copies of each recognition site were inserted in the same location 
exactly 1500 bp apart. Primers used for plasmid generation are listed in Table 12.  
 
2.4  Restriction Modification Assay 
         Plasmids bearing 1 and 2 copies of the bipartite Type I RMS motif in question were extracted 
from host strains possessing or lacking the corresponding functional RMS to obtain methylated and 
unmethylated plasmids, respectively. Plasmids were extracted using the GeneAll Hybrid-Q plasmid 
miniprep kit (South Korea) according to the manufacturer’s instructions.  Competent cells were 




phase ( OD600 = 0.45 – 0.55) at 37°C, followed by two washes with sterile water and one wash with 
sterile 10% glycerol, maintaining chilled conditions. Cells were resuspended in 1/100 original 
volume in 10% glycerol and stored in 50 µl aliquots. 100 ng of each plasmid was transformed into 
electrocompetent cells using 1mm electroporation cuvettes in a GenePulser XCELL system set at 
400 Ω resistance, 25µF capacitance and 1700V output voltage (Bio-Rad, Singapore). Cells were 
recovered in 1 ml LB at 37°C for 1 hour with shaking and plated on selective (LB-chloramphenicol) 
and non-selective (LB) plates to calculate colony forming units per ml (cfu/ml). Efficiency of 
Transformation (EoT) was calculated by dividing the cfu/ml obtained on selective vs non selective 
plates per unit amount of plasmid DNA. 
 
2.5  Mouse Infections 
         Infections were performed using a well-established murine transurethral model of urinary 
tract infection [149]. Bacterial strains were cultured in Type I pili inducing conditions by growing 
in LB statically at 37°C for two 24 hour passages and normalized to OD600 = 1 with sterile cold 
PBS. Type I piliation for each strain was evaluated by Hemagglutination assay and Type I phase 
assay as described previously [150]. Seven to eight week old female C3H/HeN mice (InVivos, 
Singapore) were anaesthetized using isofluorane and 50 µl of inoculum (2 x 107 cfu) was 
transurethrally instilled into the bladder with a catheter. Post infection, bladders and kidneys were 
harvested aseptically and homogenized in 1 ml and 0.8 ml sterile PBS respectively. Ten fold serial 
dilutions were plated on appropriate selective plates and cfu/ml calculated. 
        For co-infections, the inoculum consisted of a 1:1 mixture of two differentially marked 
antibiotic resistant strains; otherwise, the procedure was identical to that described for single 
infections above. For example, wild type UTI89 with KanR was co-inoculated with Mutant UTI89 
with ChlorR and plated on respective selective plates for enumeration. To reduce any bias, selection 
markers were reversed and UTI89 with ChlorR was co-inoculated with Mutant UTI89 with KanR 




with both combinations of marked strains. Bacterial titres from each organ and starting inoculum 
were calculated and used to calculate the Competitive Index (CI) as follows: CI = (Output wild 
type / Output mutant) / (Input wild type / Input mutant). CI value was log transformed and plotted. 
 
2.6  RNAseq 
Bacterial strains were propagated statically for two serial 24 hour passages at 37°C to mimic 
the stationary phase inoculum used for murine infections. Log phase cells were obtained by 
diluting an overnight culture 1:100 in LB and growing to early log phase (OD600 = 0.4 – 0.5)  at 
37°C with shaking. RNA was extracted from three biological replicates for both log and stationary 
phase samples using 7 x 108 cells with the RNeasy Mini kit (Qiagen, Singapore). RNA quality 
was assessed using the Agilent RNA 6000 pico kit on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, USA) and only samples with a RNA integrity number (RIN) above 7  were used 
for library preparation. Ribosomal RNA (rRNA) depletion was performed using the Ribo-Zero 
rRNA removal kit (Epicenter, USA) according to the manufacturer’s recommended protocol and 
the quality of purified mRNA was checked using the Agilent RNA 6000 pico kit. Libraries were 
generated using the ScriptSeq v2 RNA-Seq library preparation kit (Epicenter, USA) according to 
the manufacturer’s recommended protocol. Each uniquely indexed strand specific library was 
assessed for library size and amount using the Agilent DNA 1000 kit (Agilent Technologies, 
USA). After normalization and pooling, samples were sequenced on either Illumina HiSeq or 
NextSeq series sequencers with paired end reads, either 2 x 151 bp or 2 x 76 bp (Illumina, USA).  
    Raw sequencing reads were mapped to their respective reference genomes, for E. coli 
UTI89 (NCBI accession number NC_007946), E. coli K12 substr. MG1655 (NCBI accession 
number NC_000913.3) and E. coli CFT073 (NCBI accession number AE014075.1) using BWA-
MEM (version 0.7.10) with default parameters [151]. HTseq was used to quantify sequencing 
reads mapping to predicted open reading frames (ORFs) [152]. Ribosomal RNA (rRNA) and 




set. R (version 2.15.1) was used for differential expression analysis, using the Bioconductor 
package, edgeR [153]. Briefly, samples were normalized by TMM (trimmed median of means), 
common and tagwise dispersion factors were estimated using a negative binomial model, and 
then fold change values were calculated on these normalized counts as a proxy for expression. A 
cutoff of False Discovery Rate (FDR) <0.05 and log fold change >1.5 was used to identify the 
final set of differentially expressed genes.  
 
2.7  Whole Genome Sequencing (WGS) 
         Genomic DNA was extracted from log phase bacterial cultures (OD600 = 0.4 – 0.5) using the 
QIAamp DNA mini kit (Qiagen, Singapore) and sheared to 350 bp sized fragments using a Covaris 
S220 focused-ultrasonicator (Covaris, USA) according to manufacturer’s instructions. Sheared 
DNA was used to generate libraries for whole genome sequencing using the TruSeq Nano DNA 
LT library preparation kit (Illumina, USA). Library size and quantity was checked using the Agilent 
DNA 1000 kit (Agilent Technologies, USA). Individual libraries were pooled and sequencing was 
performed as described in Section 2.6 for RNA sequencing. Sequencing reads were mapped to their 
respective genomes (E. coli UTI89 (NCBI accession number NC_007946), E. coli K12 substr. 
MG1655 (NCBI accession number NC_000913.3) and E. coli CFT073 (NCBI accession number 
AE014075.1)) using BWA-MEM (version 0.7.10) with default parameters [151]. Lofreq was used 
to do local realignment, insertion of indel qualities, and insertion of alignment qualities prior to 
variant calling of Single Nucleotide Polymorphisms (SNPs) and indels using default parameters 
[154]. Sanger sequencing was performed to validate variants identified by Lofreq. 
 
2.8  Single Molecule Real Time (SMRT) Sequencing 
        Genomic DNA was extracted from log phase bacterial cultures and quantified using a Qubit 




manufacturer’s protocol. 5 µg of DNA was sheared to 10 kbp size using a g-Tube (Covaris, USA) 
and a SMRTbell library was generated according to manufacturer’s instructions using the 
SMRTbell template prep kit 1.0 (Pacific Biosciences, USA). Library quality and quantity was 
assessed using the Agilent DNA 12000 kit (Agilent Technologies, USA) and, after loading the 
library using Mag-Bead bound protocol for large insert libraries, sequenced on the PacBio RS II 
sequencer (Pacific Biosciences, USA). Sequencing was performed using a single SMRTCell and 
the P4-C2 enzyme chemistry with 180 mins of data acquisition. Reads were mapped back to the 
corresponding reference genome and methylated motifs identified using the 
‘RS_Modification_and_motif_analysis’ algorithm in SMRT Analysis suite v2.3 using default 
parameters. Bases with a coverage of at least 25x and a kinetic score of at least 60 were identified 
as being methylated by SMRT sequencing. 
 
2.9  Quantitative RT-PCR 
        Total RNA was extracted from relevant samples using the RNeasy Mini kit (Qiagen, 
Singapore). 1 µg of RNA was treated with DNase I, RNase-free (Thermo Scientific, USA) at 37°C 
for 1 hour to remove any residual genomic DNA, followed by RNA purification using RNeasy 
Mini kit according to the manufacturer’s recommended protocol. Next, 500 ng of RNA was used 
for cDNA synthesis with SuperScript II Reverse Transcriptase and Random hexamers (Invitrogen, 
USA) according the manufacturer’s recommended protocol. Amplified cDNA was diluted 1:4 for 
all target genes and 1:400 for the rrsA internal control. Real-time PCR was performed with the 
KAPA SYBR FAST qPCR kit (KAPA Biosystems, USA) on a LightCycler 480 instrument (Roche, 
Singapore) with the following cycle: 95°C for 5 mins for enzyme activation, followed by 40 cycles 
of 95°C for 30 seconds and 60°C for 30 seconds. Target specific primers for qRT-PCR were 
designed using the IDT PrimerQuest tool (IDT, Singapore) and are listed in Table 13. Relative fold 




as the internal control. No reverse transcriptase controls and negative controls were included in 
each run. 
 
2.10    Motility Assay 
        Motility assays were performed as described previously with slight modifications [29]. 
Strains were grown up to log phase (OD600 = 0.4 – 0.5) by sub-culturing overnight bacterial culture 
1:100 in LB at 37°C and normalized to OD600 = 0.4 across all strains with sterile PBS. 0.25% LB 
agar plates were prepared and stabbed with each strain using sterile toothpicks. The soft agar plate 
was then incubated at 37°C for 7 – 8 hours depending on the strain. Motility was calculated by 
measuring the diameter of bacterial motility, normalizing the diameter measured for each test strain 
to its corresponding wild type and expressing motility as a percentage of wildtype motility. 
 
2.11      Biofilm Assay 
        A 96-well Crystal Violet staining protocol for biofilm quantification was performed [155]. 
Briefly, an inoculum was prepared by growing bacterial strains up to log phase and normalizing to 
OD600 = 0.4. 96 well clear flat bottom poly vinyl chloride (PVC) plates (Costar, Singapore) were 
seeded with 200 µl of sterile media (LB or YESCA) and 5 µl of normalized inoculum. PVC plates 
were incubated for the desired duration at 26°C or 37°C in a moistened chamber.  Plates were 
washed once with water and stained with Crystal Violet for 30 mins. Excess stain was removed by 
washing thrice with water and finally the stain was dissolved with 50% ethanol, with care taken to 
avoid disturbing the biofilm. The amount of biofilm was quantified by measuring OD at 590nm 
using a Sunrise 96 well microplate absorbance reader (Tecan, Switzerland). The biofilm produced 
by each test strain was normalized to that of its corresponding wild type strain and expressed as a 





2.12      Growth Curves 
        Growth curves for bacterial strains were determined using the Bioscreen C instrument 
(Bioscreen, Finland). Briefly, bacterial strains were inoculated from single colonies into LB media 
and allowed to grow overnight at 37°C. Cultures were then diluted 1:100 in fresh LB and allowed 
to grow till mid-log phase (OD600 = 0.5). All strains were then normalised to OD600 = 0.4 using 
sterile PBS, 5 µl of this normalised culture was inoculated into 145 µl of the desired growth media 
in triplicates. LB (rich) medium and M9 (minimal) medium were used at 37°C and measurements 
were taken every 15 mins for 24 hours.  
 
2.13       Phenotype Microarray 
        Phenotype microarrays are a high throughput screen utilizing specialized 96 well plates 
containing different sets of conditions (including various carbon, nitrogen and phosphorous 
sources, pH, osmolytes and chemical inhibitors) to rapidly test for gene function amongst other 
applications [156]. Phenotype Microarray (PM) assays were performed using PM plates 1 to 20 by 
the PM services group at Biolog, USA using their standard protocol for E. coli. Briefly, PM plates 
contain: PM1-2 Carbon sources, PM3 Nitrogen sources, PM4 Phosphorous and Sulphur sources, 
PM5 Nutrient supplements, PM6-8 Peptide nitrogen sources, PM9 Osmolytes, PM10 pH and 
PM11-20 Inhibitors for different metabolic pathways. Each strain is normalized and inoculated into 
all 20 PM plates with supplementation of Niacin, since UTI89 is auxotrophic for niacin. Cellular 
respiration causes reduction of a tetrazolium dye which results in a colour change measured 
colorimetrically by the OmniLog instrument. Plates are incubated at 37°C for 24 hours and the 
entire panel repeated twice. Output consists of growth curves for both wild type and test strains in 
each well of the twenty 96 well PM plates. These are analysed according to the recommendations 
of Biolog. Briefly, under each condition the two curves are superimposed, effectively normalising 
the test strain versus the wild type so as to identify any gained/lost phenotypes. The area under the 




height difference in wells which show a difference in both replicates was calculated. The average 
height difference is an arbitrary quality score that is positive for an acquired phenotype or negative 
for a lost phenotype in the test strain. A static threshold (recommended by Biolog) was set at 150 
above which phenotypic differences are considered significant; further emphasis is laid on 
phenotypes which show the largest magnitude, show a dose dependent response, or belong to 
similar metabolic pathways. Identified putative phenotypic differences are subsequently validated 












Elucidating the role of Type I restriction modification system mediated 













3.1  Single Molecule Real Time (SMRT) sequencing identifies a novel methylated motif   
                in UTI89 
       To gain insight into the role of epigenetic DNA modification in Uropathogenic Escherichia 
coli (UPEC) virulence, we sequenced the cystitis UPEC isolate UTI89 using SMRT sequencing 
[Performed by Dr. Jacqueline Chee]. SMRT sequencing of unamplified log phase UTI89 genomic 
DNA allowed detection of 46,407 modified bases in the genome and 3 sequence motifs to which 
they belong (Table 1). The methylated palindromic motifs 5’-GATC-3’ and 5’-CCWGG-3’ belong 
to the previously identified orphan methyltransferases DNA adenine methyltransferse (dam) and 
DNA cytosine methyltransferse (dcm), respectively [138]. The third methylated motif, 5’-
CCA(N7)CTTC-3’, is bipartite with a 7 bp degenerate sequence between the two specific DNA 
targets and a methylated adenine on both strands. This recognition sequence is characteristic of 
methyltransferases belonging to Type I RMSs and represents a novel Type I methylation motif.  
Motif Methylation Total # of 
motifs in 
genome 
# of motifs 
detected 







6mA 41190 39916 96.9% 84.8X 
CCWGG 
GGWCC 












Table 1: UTI89 methylated motifs. SMRT sequencing identified 3 methylated motifs in the 
UTI89 genome. dam (5’-GATC-3), dcm (5’-CCWGG-3’) and a novel Type I RMS motif  (5’-
CCA(N7)CTTC-3’). Methylated positions on each strand are underlined and in bold 
  
        The UTI89 genome contains only one putative Type I RMS, encoded by the host specificity 
determinant (hsd) locus, consisting of 3 genes. hsdS encodes a specificity determinant DNA binding 




recognition sites for this Type I RMS appear to be methylated, typical of functional RMSs. The 
low percentage of methylated dcm motifs (1.8%), can be attributed to the weak and dispersed 
kinetic signal emanating from 5-methylcytosine (5mC) in SMRT sequencing [79], the better 
detection of which requires conversion of 5mC to 5-hydroxymethylcytosine (5hmC) before 
sequencing [157]. However, since dam [91] and dcm [74, 116, 117] represent previously well 
characterized orphan methyltransferases, we decided to focus our study on characterizing the novel 
Type I RMS found in UTI89 and exhaustively identifying the functional consequences of this 
methylation on bacterial physiology and virulence.   
 
3.2  Characterization of Type I Restriction Modification Systems 
3.2.1  Novel UTI89 Type I methylation is mediated by a functional Restriction  
               Modification System (RMS) 
        To assign the novel Type I methylation motif (5’-CCA(N7)CTTC-3’) to the UTI89 hsdSMR 
Type I RMS and identify if both methylation and restriction functions are intact, we optimised a 
plasmid transformation based Restriction Modification (RM) assay. As depicted in Figure 3, the 
RM assay employs plasmids with either 0 (p0), 1 (p1) or 2 (p2) copies of the Type I RMS 
recognition site in question. These plasmids are extracted from a methylation capable or isogenic 
methylation incapable strain to obtain methylated or unmethylated versions, respectively, of the 
same plasmid. These plasmids are then transformed into the test strain bearing the putative Type I 
RMS (Figure 3.A and 3.B). The test strain transformed with plasmids bearing 0, 1 or 2 copies of 
the methylated recognition sites should show no difference in the efficiency of transformation 
(EOT) (Figure 3.A). However, if the same test strain bears a functional Type I RMS and is 
transformed with unmethylated preparations of the same plasmids, we expect to observe a decline 
in EOT with an increasing number of recognition sites (Figure 3.B). Finally, an otherwise isogenic 
test strain carrying a deletion of the Type I RMS transformed with the same set of methylated and 




cannot be recognized irrespective of methylation status (Figure 3.C).  Greater the number of 
unmethylated recognition sites, lower is the expected EOT, since Type I RMSs translocate DNA 
between two adjacent recognition sites and cleave at a random position between them when 
translocation is blocked [55].  
 
  
Figure 3: Principle of the Restriction Modification Assay. Plasmids bearing 0, 1 or 2 copies of 
the Type I RMS recognition site were transformed into a recipient strain with the corresponding 
Type I RMS and the number of transformants obtained was used to calculate the Efficiency of 
Transformation. Experiment was performed in a restriction-modification competent strain 
(hsdSMR) with methylated A) and unmethylated plasmids B). And repeated again with a restriction-
modification incapable isogenic deletion strain (ΔhsdSMR) C). p=plasmid. EOT=Efficiency of 
Transformation. hsdSMR= host specificity determinant genes of Type I RMSs. 
 
        In order to test whether the RM assay works as designed, it was first tested using the K12 Type 




the workhorse of researchers studying RMSs in general and Type I systems in particular [54]. 
UTI89, K12 and K12 ΔhsdSMR (KSM2-102-7) were transformed with unmethylated and 
methylated variants of the plasmids p0 (pACYC184), p1 (pKSM3-42-1) and p2 (pKSM3-45-1), 
bearing the known K12 recognition sequence (Figure 4.A). Methylated and unmethylated versions 
of the plasmids were obtained by propagation in K12 and UTI89 respectively. Plasmids p1 and p2 
show a 2 log drop in EOT only when unmethylated and transformed into K12, as shown in Figure 
4.A (middle red and green bars). When the same plasmids are transformed into K12 ΔhsdSMR 
(right bars) or UTI89 (left bars), both lacking a Type I RMS capable of recognising the 
unmethylated plasmid recognition sites, the EOT is the same as the control (orange in right and left 
sets of bars). Based on the inverse correlation between the EOT and the number of unmethylated 
sites, we conclude that our RM assay performs as expected to properly detect both functions. The 
efficiency of transformation for unmethylated plasmids p1 and p2 transformed into K12 as shown 
in Figure 4.A (middle purple and blue bars) is higher than the EOT for p0 (middle orange bar). This 
is due to the fact that plasmid p0 was extracted from UTI89, while unmethylated p1 and p2 were 
extracted from K12 ΔhsdSMR. This observed difference in EOT is independent of the RMS, but 
rather due to the difference in plasmid quality when extracted from a cloning strain such as K12 or 
its mutants versus from a clinical isolate such as UTI89. 
        We then applied the RM assay to test the putative UTI89 Type I RMS (Figure 4.B). 
Methylated and unmethylated variants of plasmids p0 (pACYC184), p1 (pKSM3-16-1) and p2 
(pKSM3-17-1), bearing the novel UTI89 recognition sequence were obtained by propagation in 
UTI89 and K12 respectively. Each plasmid was transformed into K12, UTI89 and UTI89 ΔhsdSMR 
(KSM2-102-4). EOT shows a progressive 2 log decrease from p0 to p2, as the number of 
unmethylated UTI89 Type I motifs increases from 0 to 2 (Figure 4.B, middle red and green bars). 
The EOT for the same transformations with methylated plasmids remains unchanged (middle 
purple and blue bars). Finally, when transformed into K12 and UTI89 ΔhsdSMR, the methylation 
status of the UTI89 Type I motif bearing plasmids has no effect on the EOT (Figure 4.B, left and 




the hsdSMR genes, encoding a fully functional Type I RMS capable of methylating self DNA and 
restricting unmethylated non-self DNA. Again, the EOT for unmethylated plasmids p0, p1 and p2 
extracted from K12 show a higher baseline EOT compared to methylated versions of the same 
plasmids extracted from UTI89 (Figure 4.B, left set of bars). It is important to note this repeated 
and inherent difference in baseline EOT when isolating identical plasmids from different strains, 


























Figure 4: Restriction Modification assay for Type I Restriction Modification Systems. 
Restriction Modification assay for A) K12, B) UTI89 and C) CFT073 Type I RMSs. The Type I 
motif present on the test plasmids is indicated above each figure. Log efficiency of transformation 
(EOT) for plasmids bearing 0, 1 or 2 copies of the recognition site when transformed into different 
test strains is plotted. EOT is the number of colonies obtained on selective vs. non-selective plates, 
per unit amount of DNA. Data represents mean and standard deviation from 3 independent 
biological replicates. *p<0.05 by Student’s T-test. 
  
        UPEC isolate CFT073 was isolated from the blood of a patient suffering from pyelonephritis 
[34] and represents another widely used UPEC model strain. CFT073 also possesses a Type I RMS 
gene cluster like K12 and UTI89, with yet another distinct methylation motif, 5’-GAG (N7) GTCA 
-3’ [138]. However, this motif is a prediction based on homology and the functionality of this 
system has not been experimentally verified. Plasmids p0 (pACYC184), p1 (pKSM4-95-4) and p2 
(pKSM4-99-1) bearing the methylated and unmethylated CFT073 motifs were obtained by 
extracting them from CFT073 and CFT073 ΔhsdSMR (KSM7-15-1) respectively. Each plasmid 





Transformation of unmethylated plasmids p1 and p2 results in a 2 log decrease in EOT with respect 
to p0 (Figure 4.C, middle red and green bars). No change in EOT between p0, p1, and p2 is seen, 
regardless of methylation status, when transformed into K12 and CFT073 ΔhsdSMR. Thus, CFT073 
also has a functionally intact Type I RMS with the recognition sequence 5’-GAG (N7) GTCA -3’. 
To control for the host strain dependent differences in the baseline EOT observed in Figures 4.A 
and 4.B, all plasmids used in Figure 4.C were extracted from clinical strain CFT073 or its isogenic 
methylation deletion mutant CFT073 ΔhsdSMR. As expected, Figure 4.C does not show any 
differences in the baseline EOT for any recipient strain. 
3.2.2       Generating UTI89 strains bearing diverse E. coli Type I methylation motifs. 
 Type I RMSs have been classified into five families, designated A-E, based on genetic 
complementation of sub-units, DNA hybridization, serology using HsdM and HsdR, and most 
recently based on sequence homology [51, 158]. Systems belonging to the same family have >80% 
HsdM and HsdR amino acid identity and should be able to retain function after swapping individual 
subunits. Different Type I families have only approximately 20 – 30 % identity and cannot recruit 
sub-units belonging to another family [158]. Sequence comparisons between the K12 and UTI89 
HsdM/R sequences reveal 99% amino acid identity for both proteins, thus both systems can be 
classified as Type IA RMSs. The UTI89 and CFT073 Type I systems, however, possess only 22.3% 
(HsdM) and 13.85% (HsdR) identity, indicating that they are from different families. Therefore, to 
introduce K12 methylation into UTI89, we exchanged the UTI89 hsdS with the K12 allele. To 
introduce CFT073 methylation into UTI89 we exchanged the entire hsdSMR operon with the 
CFT073 hsdSMR genes. 
              UTI89 hsdSK12 (KSM6-26-1), UTI89 hsdSMRCFT073 (KSM6-80-15) and UTI89 hsdSUTI89 
(KSM3-95-4) were generated to introduce K12, CFT073 and UTI89 Type I methylation, 
respectively, in UTI89. UTI89 hsdSK12, UTI89 hsdSMRCFT073 and UTI89 hsdSUTI89 shall 
henceforth be referred to as UTI89 SWAP K12, UTI89 SWAP CFT073 and UTI89 SWAP 




allele or entire hsdSMR Type I RMS for another. UTI89 SWAP UTI89 functions as a control as it 
has been subjected to the same recombineering as the other swap mutants, but the final result is a 
revertant strain with the native hsdS allele in the original wild type genomic context. Whole 
Genome Sequencing (WGS) was performed on all of these engineered mutant strains to confirm 
the expected genetic manipulations at the hsd locus and to verify that no off target mutations were 
inadvertently introduced during cloning.  
 
Figure 5: Restriction Modification Assay for UTI89 SWAP strains. Restriction Modification 
assay for UTI89 SWAP K12, UTI89 SWAP CFT073 and UTI89 SWAP UTI89 strains. Type I 
motif present on test plasmids is indicated above bars. Efficiency of transformation is number of 
colonies obtained on selective vs. non-selective plates, per unit amount of DNA.  Data represents 
mean and standard deviation from 3 independent biological replicates. *p<0.05 by Student’s T-test. 
 
        When transformed with unmethylated and methylated plasmids bearing the UTI89 Type I 
motif, the UTI89 SWAP K12 strain no longer displays a restriction mediated drop in EOT (Figure 
5, first set of bars). However, if transformed with unmethylated K12 Type I motif bearing plasmids, 




(Figure 5, second set of bars). Similarly, the UTI89 SWAP CFT073 strain shows a drop in the EOT 
when transformed with plasmids bearing unmethylated CFT073 Type I motif and the UTI89 SWAP 
UTI89 revertant shows a decrease in the EOT for plasmids with unmethylated UTI89 Type I sites 
(Figure 5, third and fourth set of bars, respectively). Methylated K12, CFT073 and UTI89 site 
bearing plasmids were obtained by passaging the plasmids in the respective SWAP strain. The EOT 
for these methylated plasmids does not change (Figure 5, purple and blue in each set of bars), 
suggesting that both methylation and restriction functions of these Type I RMSs are intact, but the 
methylome is different from wild type UTI89. Thus, UTI89 strains were successfully generated to 
express fully functional K12, CFT073 and a UTI89 revertant Type I RMS, with both methylation 
and restriction functions still intact. 
 
3.3      Effect of Type I methylation on UTI89 virulence in vitro 
        Before proceeding to the established in vivo transurethral murine model for ascending UTI, 
we decided to first utilise in vitro phenotypic assays for known UPEC virulence factors. Although 
these in vitro assays are by no means exhaustive and one could envision additional assays from 
the perspective of UTIs caused by UPEC, these assays represent powerful in vitro proxies for in 
vivo virulence. Growth kinetics, Type I pili mediated hemagglutination, motility and biofilm 
formation are some of the assays used here to gauge UPEC virulence regulated by Type I RMS 
methylation prior to in vivo tests.  
3.3.1    Type I methylation does not affect UTI89 motility 
        Motility and chemotaxis are important bacterial processes required for immune evasion as 
well as nutrient acquisition and colonisation both in vivo and in vitro [159]. UPEC flagellar 
expression occurs only transiently in vivo and non-motile strains are primarily defective in kidney 
colonisation at specific late time points [29, 30]. UPEC motility and chemotaxis do contribute to 
fitness in vivo, but this contribution is only transient and is not absolutely required for virulence 




methylation resulted in any alterations to UTI89 swimming motility (Figure 6). UTI89 ΔhsdS is 
the parental strain to UTI89 SWAP K12, SWAP CFT073 and SWAP UTI89 revertant strains and 
is therefore included as a control. UTI89 ΔfliC lacks flagellin and is completely non-motile, as 
expected. 
 
 Figure 6: Motility of UTI89 mutants. Motility of UTI89 Type I methylation mutants relative 
to wild type using the soft agar motility assay. Data represents mean and standard deviation from 
biological triplicates. UTI89 ΔfliC is a non-motile control. 
 
3.3.2      Type I methylation does not affect biofilm formation in UTI89 
       Biofilms represent complex, differentiated multicellular bacterial communities consisting 
of bacteria along with their extracellular products. Biofilm formation in UPEC confers significant 
advantages such as immune evasion and phenotypic resistance to antibiotics. Biofilm like 
intracellular bacterial communities (IBCs) are an important step in acute UTI, and catheter 
associated biofilms are an important source of inpatient nosocomial UTIs [2, 160]. In vitro defects 




[155]. Therefore, we tested for an effect of Type I methylation on biofilm formation by UTI89 
using a 96 well Crystal Violet biofilm assay.  
        Biofilms formed in LB media are multifactorial, but primarily believed to be Type I pili 
dependent; while biofilms in YESCA media are curli and cellulose dependent. However, 
depending on the attachment substrate, temperature and media conditions UPEC mediated 
biofilms are multifactorial phenotypes. To check biofilm formation mediated by UTI89 and its 
mutants, we tested LB and YESCA media at 26°C (ambient temperature) and 37°C (body 
temperature) over 48 hours (Figure 7). No significant difference was observed when comparing 
wild type UTI89 (dark blue bar) biofilms to the different mutants in LB or YESCA at 26°C 
(Figure 7.A). Biofilm formation at 37°C also did not vary significantly from wild type (Figure 
7.B). Significant difference in biofilm formation was observed for the revertant strain in LB at 
37°C (Figure 7.B, orange bars), and ΔhsdSMR and SWAP K12 strains in YESCA at 37°C after 
48 hours (Figure 7.B, green and purple bars). UTI89 ΔhsdS serves as a control as it is the parental 
strain to all of the SWAP strains, and as expected phenotypically behaves similar to UTI89 
ΔhsdSMR.      






Figure 7: Biofilm formation by UTI89 mutants. Biofilm formation by UTI89 mutants relative 
to wild type both in LB and YESCA media at A) 26°C and B) 37°C. Biofilms formed in 96 well 
PVC plates, stained using Crystal Violet and quantified by measuring absorbance at 590nm. Data 
represents mean and standard deviation from three biological replicates. Significance measured 
compared to wild type UTI89 under matching conditions by student’s T-test *p<0.05  
 
           Thus, two important in vitro surrogates for fitness, motility and biofilm formation, reveal 
that removal or replacement of Type I methylation in UTI89 has no phenotypic consequences under 
the diverse set of conditions checked. 
3.3.3    Type I RMS mediated methylation does not affect UTI89 growth  
      To test for a general effect of Type I methylation on growth, we tested growth in both rich 
(LB) and minimal (M9) media (Figure 8). UTI89 lacking native Type I methylation or expressing 
foreign Type I methylation from other E. coli strains does not show any significant alterations in 





UTI89. Although the final OD achieved by Type I methylation mutants is different in M9, these 













Figure 8: Growth curves for UTI89 methylation mutants. Growth curves were generated for 
UTI89 and its Type I methylation mutants in A) LB and B) M9 media. Experiment was performed 
at 37°C and curves represent the mean values from three biological replicates. Negative control 
(NC) contains media only. Significance measured by Student’s T-test, with p<0.05 considered 
significant. 
        
      Next, we tested the effect of native Type I methylation in other E. coli, namely K12 and 






and purple curves) remains unaffected. However, K12 ΔhsdSMR shows a significant growth defect 
compared to wild type K12 in LB, from 2 hours to 18 hours (Figure 9.A, blue and red curves). K12 









Figure 9: Growth curves for K12 and CFT073 methylation mutants. Growth curves for K12 
and CFT073 along with their corresponding Type I RMS deletion mutants in A) LB and B) M9. 
Negative control (NC) contains media only. Means from three biological replicates are plotted and 
significance calculated using student’s T-test p<0.05. For K12 and K12 ΔhsdSMR in A) LB, error 






3.4      Effect of Type I methylation on UTI89 virulence in vivo 
3.4.1        Loss of native UTI89 methylation does not affect virulence in vivo 
         In order to perform co-infections with UTI89 and its methylation mutants, we generated 
differentially marked strains for UTI89 wild type, UTI89 ΔhsdSMR and UTI89 SWAP K12 
carrying both neo (KanR) and cat (ChlorR) resistance genes. Kanamycin and Chloramphenicol 
resistance cassettes were added at the phage HK022 attachment site [161], a position known to 
maintain selection cassettes stably without selection pressure and with no measurable effect on 
virulence [162]. Type I pili, encoded by the fim operon, are filamentous surface structures expressed 
in UTI89 that mediate both attachment and invasion of bladder epithelial cells and, formation of 
intracellular bacterial communities [163]. To check if Type I methylation has any consequences on 
the expression of this important virulence factor before murine infection, we performed a 
Hemagglutination assay using guinea pig RBCs. As shown in Table 2, neither insertion of an 
antibiotic cassette at attHK022 or alteration of Type I methylation altered hemagglutination titres. 
 
Table 2: HA titres for UTI89 strains. HA titres were performed on 3 independent occasions and 
prior to each murine infection. 
        
           After verifying that there were no differences in growth or HA titres, we proceeded to in 
vivo infection tests. Female C3H/HeN mice were inoculated transurethrally with 2 x 107 cfu of 
either UTI89 or UTI89 ΔhsdSMR according to the well-established ascending urinary tract 
Strain Genotype Hemagglutination 
titre 
UTI89 UTI89 wild type 7 
KSM2-102-4 UTI89 hsdSMR::neo 7 
KSM3-39-2 UTI89 attHK022::neo 7 
KSM3-39-1 UTI89 attHK022::cat 7 
KSM3-39-6 UTI89 hsdSMR::FRT attHK022::neo 7 
KSM3-39-3 UTI89 hsdSMR::FRT attHK022::cat 7 
KSM6-29-3 UTI89 hsdSK12 attHK022::neo 7 




infection (UTI) model [149]. After 24 hours, the bacterial load in both bladders and kidneys were 
determined. There were no statistically significant differences in the median bladder and kidney 











Figure 10: Deletion of the UTI89 Type I RMS has no effect on in vivo urinary tract infection. 
A) Single infections with wild type UTI89 and UTI89 ΔhsdSMR. Female C3H/HeN mice (n=5 
mice/strain) were transurethrally inoculated with the strains indicated on the x-axis. The log10 of 






on the y-axis. Medians for each group are indicated by a black horizontal line. Mann-Whitney U 
test with p <0.05, is considered significant. B) Competitive infection with wild type UTI89 and 
UTI89 ΔhsdSMR strains. Female C3H/HeN mice (n=20 mice/time point) were inoculated with 
equal mixtures of UTI89 and UTI89 ΔhsdSMR and sacrificed at the time point indicated on the 
x-axis. The log10 of the competitive index between the two bacterial strains in bladders (blue 
dots) and kidneys (red dots) are plotted on the y-axis. Medians for each group are indicated by a 
black horizontal line. Wilcoxon signed rank test with p <0.05, is considered significant. 
  
       Co-infection was performed with differentially marked strains, Figure 10.B i.e. UTI89 
attHK022::neo with UTI89 hsdSMR::FRT attHK022::cat and UTI89 attHK022::cat with UTI89 
hsdSMR::FRT attHK022::neo, to eliminate any bias due to selection markers and insertion at HK022 
phage attachment site. Since single infection did not reveal any phenotype, infecting 
simultaneously with wild type and deletion mutant allows greater sensitivity in identifying any 
subtle phenotype. Moreover, infections were performed for 1 day and 7 days to represent the 
acute and chronic stages of infection respectively. Log Competitive Indices (CI) did not reveal 
any significant fitness advantage for either strain in the bladder or kidney, at 1 day or 7 days post 
infection, Figure 10.B. Thus, irrespective of the duration and site of infection, loss of native Type 
I methylation does not seem to alter UTI89 virulence in vivo at all. 
3.4.2       Switching Type I methylation in UTI89 does not affect in vivo virulence. 
       The UTI89 SWAP K12 strain differs from UTI89 in the loss of UTI89 Type I methylation 
at 754 predicted sites and the gain of K12 Type I methylation at 668 predicted sites in the UTI89 
genome. Even though the K12 Type I RMS belongs to the same family as the UTI89 Type I 
RMS, it is taken from a gut derived lab adapted non-pathogenic strain. Since methylation has the 
potential to alter gene expression, we hypothesised that this change in Type I methylation 




specificity with higher UTI virulence would suggest a novel potential epigenetic influence on 
UPEC evolution. 
                To test this hypothesis for K12 methylation, competitive infections between UTI89 and 
UTI89 SWAP K12 were performed with differentially marked strains as described in Section 
3.4.1 (i.e. UTI89 attHK022::neo with UTI89 hsdSK12 attHK022::cat and UTI89 attHK022::cat with 
UTI89 hsdSK12 attHK022::neo; Figure 11). Infections were allowed to proceed for 1 day (acute) and 
7 days (chronic). Interestingly the log CI was not significantly different from zero at either 1 day 
or 7 days post infection in either bladders or kidneys, indicating no significant difference between 
wild type UTI89 and UTI89 SWAP K12 (Figure 11). Therefore, switching the Type I methylation 
specificity in UTI89 had no detectable effect on in vivo virulence. 
 
Figure 11. Co-infection with UTI89 SWAP K12 strain. Co-infections with wild type and 
UTI89 SWAP K12 strains at 1 (n=25 mice) and 7 (n=20 mice) days post infection. Log 
competitive indices for UTI89 vs. UTI89 SWAP K12 are plotted and median value marked with 
a horizontal line. Wilcoxon signed rank test used to evaluate if median value is significantly 





3.5       Effect of Type I methylation on Escherichia coli gene expression 
3.5.1    RNA-seq reveals no consequence of altered Type I DNA methylation on UTI89  
            transcriptome 
       Loss of UTI89 Type I methylation or replacement with foreign K12 methylation did not 
affect virulence in vivo. Since DNA methylation mediated by orphan methyltransferases [91, 92] 
and certain phase variable RMSs [122] are capable of altering gene expression in other bacterial 
pathogens, we questioned whether the loss of native UTI89 Type I methylation or replacement 
with foreign K12 or CFT073 methylation has any influence on gene expression in UTI89. RNA 
was extracted from log phase cultures and cultures grown statically for two successive 24 hour 
incubations, mimicking the stationary phase cells used for murine infections (n=3 independent 
biological replicates for each). Strand specific RNA-seq was performed and compared to wild 








Table 3: Differentially expressed genes in UTI89 Type I methylation mutants. A) Log and 
B) Stationary phase cultures of UTI89 methylation mutants were compared to wild type. Genes 
knocked out or replaced are marked in red and serves as controls. Data is from three biological 
replicates. Significance is calculated by exact test assuming negative binomial distribution. False 
Discovery Rate (FDR) <0.05 and log Fold change >1.5 is considered significant.   
 
       As expected, the hsdSMR genes were all found to be significantly downregulated in the 
ΔhsdSMR mutant compared with the wild type. Two genes, yjiW and UTI89_C1127, were 
differentially expressed (both upregulated) in both log (Table 3.A) and stationary (Table 3.B) 
phase in UTI89 ΔhsdSMR. One gene, mrr, was upregulated in stationary phase only. mrr (Gene 
ID UTI89_C5049) and yjiW (Gene ID UTI89_C5054) are located on either side of the hsd locus; 
the ΔhsdSMR mutation results in the introduction of a kanamycin cassette into the hsdSMR locus, 
which may lead to altered transcription of the adjacent genes. Therefore, the putative transposase 





assays in independent cultures did not validate the upregulation of this gene (Table 3). Therefore, 
I concluded that deletion of the hsdSMR locus in UTI89 had no effect on the transcription of 
other genes. 
       The UTI89 SWAP K12 and UTI89 SWAP CFT073 strains also show the expected 
downregulation of the UTI89 hsdS and hsdSMR genes, respectively. Transcription of a single 
hypothetical protein appears altered for either strain under either condition (Table 3). Finally, as 
expected, the UTI89 SWAP UTI89 revertant shows no significant changes in gene expression 
compared with the wild type. Therefore, removal of methylation from 754 predicted UTI89 
methylation sites in UTI89 ΔhsdSMR and, replacement with methylation of either 668 predicted 
K12 methylation sites in UTI89 SWAP K12 or 784 predicted CFT073 methylation sites in UTI89 
SWAP CFT073 appears to have no effect on UTI89 gene expression. This is in stark contrast to 
published reports of global gene expression changes due to mutation of some other bacterial DNA 
methyltransferases [91, 123]. 
3.5.2     RNA-seq reveals minimal Type I methylation mediated gene expression changes in  
            K12 and CFT073 
           To confirm the surprising observation that Type I methylation does not affect UTI89 gene 
expression in vitro nor virulence in vivo, we extended our RNA-seq analysis to another UPEC 
strain, CFT073, and the K12 lab strain MG1655. I performed RNA-seq on CFT073 and the 
CFT073 ΔhsdSMR strain in log and stationary phase as described above for UTI89 (Section 
3.5.1). Loss of CFT073 Type I methylation had no effect on stationary phase transcription, 
however three genes were dysregulated in log phase (Table 4). yjiW (Gene ID CFT073_c5422), 
which is adjacent to the hsd locus, was upregulated as in UTI89. I again attributed this to the 
insertion of the antibiotic cassette into the hsdSMR locus. malK and lamB were both 
downregulated in log phase. Subsequent qRT-PCR assays also failed to validate that these genes 
were downregulated in CFT073 ΔhsdSMR mutant (Table 4). Therefore, similar to UTI89, 




           
Table 4: Differentially expressed genes in CFT073 ΔhsdSMR. CFT073 ΔhsdSMR genes 
differentially expressed from triplicate log and stationary phase cultures are listed. Genes marked 
in red are knocked out and serve as controls. FDR <0.05 and log Fold change >1.5 was considered 
significant. 
  
          E. coli K12 substrain MG1655 is a commonly used lab cloning strain. Type I RMS genes 
are often deleted to eliminate the restriction barrier to exogenous DNA and allow more efficient 
cloning in several cloning strains such as DH10β, DH5α, TOP10 and BL21 (New England 
Biolabs). To further test whether Type I methylation affected gene expression, I also performed 
RNA-seq analysis on triplicate log and stationary phase samples for K12 and K12 ΔhsdSMR. 
Removal of Type I methylation resulted in 6 genes significantly upregulated in log phase (Table 
5). Once again, the genes flanking the selection cassette were upregulated, mrr (Gene ID 
K12_b4351) and symE (Gene ID K12_b4347). I again attributed these to insertion of the 
kanamycin resistance cassette into the hsdSMR locus as before for UTI89 and CFT073. 




also has 4 Intragenic (IG) K12 methylation sites (Table 5). I used qRT-PCR to validate that two 
of these genes, flu and yeeS, were indeed upregulated in the K12 ΔhsdSMR mutant (Table 5). 
This increased CP4-44 phage transcription could either be due to alleviation of restriction 
pressure owing to the presence of multiple K12 methylation sites or due to direct methylation 
mediated regulatory suppression of CP4-44 transcription. Stationary phase transcriptional 
differences between K12 and K12 ΔhsdSMR consists of a single gene, uhpA differentially 
regulated (excluding polar effect mrr) (Table 5). uhpA is part of a two component regulatory 
system responsible for hexose phosphate utilization. Coincidently uhpA also possesses an 




Table 5. Differentially expressed genes in K12 ΔhsdSMR. Log and stationary phase gene 
expression changes in K12 ΔhsdSMR from biological triplicates are listed. Genes marked in red 
are deleted and hence downregulated. Fold change by qRT-PCR and number of intragenic K12 
methylation sites in dysregulated genes are listed. FDR <0.05 and log Fold change >1.5 was 
considered significant. 
 
          Thus, global gene expression profiling of hsdSMR mutants of UTI89, CFT073, and K12 
under two different growth conditions identified only a single prophage (CP4-44 in K12) and a 
single gene (uhpA) potentially upregulated in K12 that was not attributable to insertion of the 
selection cassette used to knock out the hsdSMR operon. The overall result is strikingly strong 
that Type I methylation has no effect on expression of any gene in both UPEC strains. For K12 
substrain MG1655, there appear to be up to two loci affected, but this again is contrary to 
expectations based on other published reports of the effect of restriction methylation on global 
patterns of gene expression in other bacteria. 
 
 3.6       Phenotypic consequences of altered Type I DNA methylation in E. coli 
3.6.1      High throughput phenotypic screen does not identify any differences owing to Type  
             I DNA methylation 
        Phenotype microarray (PM) is a high throughput screen which allows a comprehensive 
analysis of cellular phenotypic profiles. Assigning genotype-phenotype associations, i.e. 
identifying the function of an unknown gene by simultaneously screening almost 2000 
phenotypes, which is the primary function of PM utilised here. Using 96 well PM plates (01-20), 
with different conditions such as Carbon sources (PM plates 1 & 2), Nitrogen sources (PM plates 
3, 6, 7 & 8), Phosphorus and Sulphur sources (PM plate 4), nutrient supplements (PM plate 5), 




possible to rapidly and quantitatively evaluate a diverse set of phenotypes [156, 164]. Cellular 
respiration is used as a proxy for growth and growth curves for a wild type reference are 
compared to mutant test strains. If there is no phenotypic difference, the reference and test curves 
overlap (yellow area under curve). If the test strain outgrows the reference strain, the curve shows 
some green area, and this is interpreted as a gained phenotype/resistance in the test strain. 
Similarly, red area under the curve indicates a lost phenotype/resistance in the test strain. An 
average height difference is calculated for each pair of curves; as recommended by the 
manufacturer (Biolog), an average height difference above 150, seen across multiple 
concentrations of the same compound is considered significant. 
        We performed PM to compare UTI89 wild type with UTI89 ΔhsdSMR and UTI89 SWAP 
UTI89 revertant. The entire panel of 20 PM plates were performed twice for each strain and the 
resulting PM plate data from one of the two runs is shown in Figure 12.A and B, with wells 
consistently different in both runs boxed. Most of the wells in all 20 PM plates show yellow 
curves signifying negligible phenotypic differences between UTI89 bearing or lacking its native 
methylation. The most prominent phenotype is the gain of resistance to Paromomycin by UTI89 
ΔhsdSMR (Figure 12.A. PM 12 and Table 6.A). Paramomycin is an aminoglycoside antibiotic; 
the kanamycin resistance cassette I used to knock out hsdSMR is known to confer cross-resistance 
to paramomycin and therefore is the likely reason for this gained phenotype. As expected, the 
UTI89 methylation revertant does not show any phenotypic differences compared to wild type 
(Figure 12.B and Table 6.B). Finally, K12 ΔhsdSMR which shows transcriptional differences 
compared to wild type K12 in Section 3.5.2, does not show any additional phenotypic differences 
by PM (Figure 12.C). Once again the only difference is acquisition of resistance to Paromomycin 
and Geneticin sulfate (also an aminoglycoside antibiotic with cross-resistance mediated by the 
kanamycin resistance gene) which can be rationalised by the selection cassette present in this 




         Of note, there are some wells that visually have some fraction of red or green area under 
the growth curves; however, discussions with the manufacturer (Biolog) led to the conclusion 
that these apparent differences are within the range of technical variability of the assay and are 
not considered reliable. Therefore, based on the experience of Biolog, as well as the concordance 
with the lack of significant changes in the transcriptional data, I did not validate the growth 
phenotypes for these putatively unreliable differences.     
 
Table 6: Phenotype Microarray results for UTI89 and K12 mutants. Phenotypic differences 
observed by PM plates (PM01-20) for Type I mutants with respect to their corresponding wild 
type strains. Experiment was repeated twice and hits listed were reproducible in both runs, with 









Figure 12: Phenotype Microarray panels for UTI89 and K12 mutants. Phenotype Microarray 
results panel for A) UTI89 vs. UTI89 ΔhsdSMR, B) UTI89 vs. UTI89 SWAP UTI89 and C) K12 
vs. K12 ΔhsdSMR. Experiment was performed twice, with wells showing phenotypic difference 
in both runs boxed in all panels. Average height difference for acquired phenotype in mutant vs. 
reference is a green curve, lost phenotype in mutant vs. reference is a red curve and if both strains 
are identical under given condition, a yellow curve. 
 
3.7       SUMMARY : Elucidating the role of Type I restriction modification system mediated  
          methylation in regulating E. coli virulence and physiology 
           E. coli strains UTI89, CFT073 and K12 substrain MG1655 each harbour distinct Type I 
RMSs with both methylation and restriction functions intact. This epigenetic DNA methylation 
helps distinguish self DNA from non-self DNA, but also has the potential to alter gene 
expression. Deletion or replacement of the Type I methylation system in UTI89 appears to have 
no detectable effect in any assay I have used. This includes specific in vitro assays (growth rate, 
motility, biofilm formation, and HA titre) as well as several potentially more sensitive assays (in 
vivo infection, RNA-seq, and phenotype microarrays). I found a similar result in Type I 
methylation knockouts of CFT073 and MG1655, with the exception of one phage and one gene 
in MG1655 that are upregulated. Overall, the result is that Type I methylation generally has no 
effect on any phenotype in three different E. coli strains, which is a distinctly different conclusion 
from other published studies describing global (hundreds to thousands) gene expression changes 















Identification and Characterization of a novel Ribonucleotide 













         In order to investigate the effect of foreign Type I methylation on UTI89 virulence, strain 
UTI89 hsdSK12 designated as KSM3-61-6 was generated. Chapter 4 characterises several 
interesting phenotypes identified in strain KSM3-61-6 and explains how these were attributed to 
a novel mutation in an E. coli ribonucleotide reductase gene and not Type I RMS mediated 
methylation. 
 
4.1        UTI89 SWAP K12 strain KSM3-61-6 has a functional K12 Type I RMS 
        KSM3-61-6 Type I RMS function was tested using the Restriction Modification Assay 
(Figure 13). Using unmethylated and methylated plasmids p0 (0 K12 sites), p1 (1 K12 site) and 
p2 (2 K12 sites) to transform UTI89 and KSM3-61-6. Only unmethylated plasmids p1 and p2 
showed a significant 3 log drop in efficiency of transformation (EOT) when transformed into 
KSM3-61-6 (Figure 13, right red and green bars). KSM3-61-6 when transformed with methylated 
preparations of the same plasmids, did not show a decrease in EOT (Figure 13, right purple and 
light blue bars). UTI89 transformation efficiency is unaffected by the methylation state of these 
plasmids as they bear K12 methylation motifs which are unrecognizable to wild type UTI89 
(Figure 13, left bars). Thus, replacing UTI89 hsdS with the K12 allele successfully changed the 
Type I RMS and by extension methylation to that of K12. This matches data for the other UTI89 
SWAP K12 strain KSM6-26-1 in Section 3.2.2.  
 
Figure 13: Restriction modification assay for strain KSM3-61-6. Restriction Modification 
assay for KSM3-61-6 with plasmids bearing K12 Type I motif. Efficiency of transformation is 
number of colonies obtained on selective vs. non-selective plates, per unit amount of DNA.  Data 






4.2       UTI89 SWAP K12 strain KSM3-61-6 is defective in kidney colonisation 
       KSM3-61-6 growth was compared to wild type UTI89 in LB at 37°C for 24 hours. KSM3-
61-6 has a significant growth defect compared to wild type during late log phase, between 6 to 
10 hours (Figure 14). This LB growth phenotype is absent for strain KSM6-26-1 as observed in 






Figure 14: Growth curves for KSM3-61-6. Growth curves were generated for UTI89 and KSM3-
61-6 in LB at 37°C. Curves represent the mean and bars represent the standard deviation from three 
biological replicates. Significance with respect to UTI89 was calculated by student’s T-test p<0.05. 
Negative control (NC) contains media only. 
 
       Hemagglutination assay did not reveal any difference between UTI89 and KSM3-61-6 in 
terms of Type I pilus expression. Competitive infection was performed with UTI89 wild type and 
UTI89 SWAP K12 strain KSM3-61-6. These co-infections used UTI89 and KSM3-61-6 derived 
differentially antibiotic resistance marked strains (i.e. UTI89 attHK022::neo with UTI89 hsdSK12 
attHK022::cat and UTI89 attHK022::cat with UTI89 hsdSK12 attHK022::neo). Infection was allowed to 
proceed for 1 and 7 days post infection (dpi) to simulate acute and chronic stages of UTI. Log 
Competitive Indices (CI) for bladders and kidneys at both time points were determined (Figure 
15). Median CI value for kidney infection at 1 dpi (0.62) is significantly different from 0. In other 
words, at 1 day post infection UTI89 wild type outcompetes UTI89 SWAP K12 strain KSM3-
61-6 in the kidney. Since bladder CI at 1 dpi is unaffected, this phenotype reflects a defect for 
KSM3-61-6 in terms of kidney ascension. By 7 dpi, this kidney phenotype is lost. Once again, 





Figure 15: Co-infection with KSM3-61-6. Co-infection with wild type and KSM3-61-6 (UTI89 
SWAP K12) strains at 1 (n=20 mice) and 7 (n=45 mice) days post infection. Female C3H/HeN 
mice were inoculated with equal mixtures of UTI89 and KSM3-61-6 and sacrificed at the time 
point indicated on the x-axis. The log10 of the competitive index between the two bacterial strains 
in bladders (blue dots) and kidneys (red dots) are plotted on the y-axis. Medians for each group 
are indicated by a black horizontal line. Wilcoxon signed rank test with *p <0.05, is considered 
significant.   
 
4.3       RNA-seq reveals differentially expressed genes in strain KSM3-61-6 
        Presence of foreign K12 Type I methylation was scrutinised for its effect on the 
transcriptome of strain KSM3-61-6 using log and stationary phase cultures, as described in 
Section 3.5.1. Stationary phase transcription of KSM3-61-6 did not reveal any differentially 
expressed genes (Table 7). However, log phase transcription of KSM3-61-6 shows 47 genes 
significantly dysregulated with respect to wild type UTI89, with 36 genes downregulated and 11 
genes upregulated (Table 8). Strikingly, 27 genes i.e. about 57% of all differentially expressed 
targets are part of the motility cascade and are all downregulated (Table 8, genes marked in blue). 
This hints towards a systematic reduction of bacterial motility gene expression. Also, amongst 
the top hits identified are genes nrdAB and nrdHIEF which encode the two UTI89 class I 
ribonucleotide reductase (RNR) systems and are both upregulated (Table 8). RNRs are essential 
enzyme systems responsible for conversion of ribonucleotides to deoxyribonucleotides. Since the 
transcriptional changes are observed for UTI89 SWAP K12 strain and not ΔhsdSMR strain, I 
looked for the presence of K12 methylation sites in the genes listed in Table 8. Three genes, fliD, 






Table 7: Stationary phase differentially expressed genes in KSM3-61-6. Gene expression 
changes between wild type UTI89 and KSM3-61-6 at stationary phase from triplicate 
experiments. Gene marked in red has been removed in KSM3-61-6. False discovery rate (FDR) 





Table 8: Log phase differentially expressed genes in KSM3-61-6. Gene expression changes 
between wild type UTI89 and KSM3-61-6 at log phase from triplicate experiments. Genes 
marked in blue are part of the motility regulon and gene marked in red has been removed in 
KSM3-61-6. Upregulated genes have their fold change marked in green, downregulated in black. 
False discovery rate (FDR) <0.05 and log Fold change >1.5 is considered significant. 
 
         The gene expression changes observed for UTI89 SWAP K12 strain KSM3-61-6 are in 
contrast to data for KSM6-26-1 (Section 3.5.1), where no changes were observed. Since, both 
strains should be identical genotypically i.e UTI89 hsdSK12, we validated transcript levels for 4 
genes nrdA, flhC, fliA and fliC by qRT-PCR (Figure 16). flhC, fliA and fliC are Class I, II and III 
genes in the flagellar cascade, respectively. flhC being the a master regulator of the entire regulon, 
fliA a flagellar specific sigma factor σ28 required for late gene expression and fliC encodes the 
main structural component, flagellin [165]. Of the three motility associated genes only fliA 
appears significantly downregulated in KSM3-61-6 by RNA-seq (Table 8). nrdA encodes the 
alpha sub unit of the class Ia RNR system.      
           qRT-PCR validates RNAseq results for both UTI89 SWAP K12 strains; wherein fliA and 
nrdA are down and upregulated respectively for KSM3-61-6 (Figure 16 and Table 8) and 
unaffected in KSM6-26-1 (Figure 16 and Section 3.5.1). Also, the vast majority of E. coli Class 
II and III motility genes are downregulated in KSM3-61-6 either by RNA-seq or qRT-PCR (fliC) 
(Figure 16 and Table 8). But not the master regulator flhC, a possible mechanistic target in 
KSM3-61-6. FliC expression is mediated by very efficient translation from a few transcripts [29], 
which potentially explains why there is a reduction in KSM6-26-1 fliC mRNA but no reduction 







Figure 16: qRT-PCR for differentially expressed genes in KSM3-61-6. Fold change 
calculated by qRT-PCR using ΔΔCt method and rRNA gene rrsA as internal control, for targets 
identified by RNA-seq. Experiment repeated thrice for UTI89, KSM3-61-6 and KSM6-26-1, but 
only once for UTI89 SWAP UTI89. Transcript abundance is considered significantly different 
for *p<0.05 by student’s T-test, compared to corresponding wild type. 
 
        Based on the gene expression profile of KSM3-61-6, it appears that this strain should 
demonstrate diminished motility. Soft agar motility assay demonstrated an approximately 25 % 
reduced motility for KSM3-61-6 compared to wild type UTI89 (Figure 17). This also potentially 
explains the in vivo defect in kidney colonisation observed for this strain at 1 dpi (Figure 15). It 
is expected that lack of motility causes a transient bladder and especially kidney colonisation 
defect around 1 to 3 dpi, which gradually diminishes and infection titres return to wild type levels 
at later time points [29, 31]. The subtle extent of the kidney colonisation defect observed in Figure 
15 may stem from the fact that KSM3-61-6 has reduced motility as observed in Figure 17, but 
isn’t completely non motile like the ΔfliC mutant in this paper [29].  Thus, the motility defect 
identified by RNA-seq in strain KSM3-61-6 is a genuine phenotype, which extends in vivo and 





Figure 17: Motility of strain KSM3-61-6. Soft agar motility assay for comparing wild type and 
KSM3-61-6 motility. Experiment was performed thrice, with mean and standard deviation 
plotted. Student’s T-test is used to determine significant difference at *p<0.05. 
 
4.4       Phenotype Microarray identifies additional phenotypic differences for KSM3-61-6 
       Phenotype Microarray (PM) was performed on UTI89 SWAP K12 strain KSM3-61-6 and 
revealed differences with respect to wild type UTI89 (Figure 18). A systematic negative 
difference was observed in PM plate 5 containing nutrient supplements and also PM plates 11 to 
20 representing a wide range of chemical inhibitors (Figure 18). These differences primarily 
constitute marginal single dose differences which never achieved the Quality score cut-off of 150 
and hence are considered as background. Instead, attention was focused on phenotypes which 
demonstrated a large (QS>150) multi dose effect, listed in Table 9. There are 16 conditions under 
which KSM3-61-6 differs from UTI89. Majority of these represent nucleic acid analogues, DNA 
damage inducers and inhibitors of enzymes involved with DNA processing. One of the top hits, 
Azathioprine a purine analogue was selected for independent validation because it represents a 







Figure 18: Phenotype Microarray panel for KSM3-61-6. Phenotype Microarray results panel 
for UTI89 vs. KSM3-61-6 (UTI89 SWAP K12). Experiment was performed twice, with wells 
showing phenotypic differences in both runs marked with boxes. Average height difference (or 
quality score) for yellow curves is low signifying no difference, positive for green curves 
signifying an acquired phenotype in mutant vs. reference strain and negative for red curves 
representing a lost phenotype in mutant vs. reference strain. 
 
 
Table 9: Phenotype Microarray results for KSM3-61-6. List of phenotypic differences 
observed in PM plates (PM01-20) for KSM3-61-6 with respect to UTI89 wild type. Experiment 
was repeated twice and hits listed were reproducible in both runs, with their Average height 
difference as an arbitrary quality score (QS). Phenotype is considered significant if it displays a 





         Azathioprine at a concentration of 1mM caused a reduction in UTI89 growth versus 
DMSO diluent control (Figure 19, blue solid and dash lines). The UTI89 SWAP K12 strain 
KSM6-26-1 behaves exactly like wild type, (Figure 19, green solid and dash lines). However, in 
agreement with Phenotype Microarray (Table 9), UTI89 SWAP K12 strain KSM3-61-6 shows a 
dramatic statistically significant Azathioprine induced reduction in growth (Figure 19, red solid 
line). Even in the presence of DMSO this strain shows a significant defect during late log phase 
(6 to 16 hours), reminiscent of its LB growth defect as observed in Figure 14. 
 
Figure 19: Azathioprine sensitivity of UTI89 SWAP K12 mutants. Growth curves for UTI89, 
KSM3-61-6 and KSM6-26-1 in the presence of 1mM Azathioprine (AZ, solid lines) or diluent 
(DMSO, dash lines). Negative control (NC) contains media only. Curves represent mean values 





4.5        Secondary mutation independent of methylation is responsible for KSM3-61-6  
             phenotypes 
       Even though strains KSM6-26-1 and KSM3-61-6 are genotypically identical i.e. UTI89 
hsdSK12, they behave differently in terms of growth kinetics, motility, kidney colonisation, gene 
expression and sensitivity to several chemical inhibitors (Sections 4.2 to 4.4). Whole genome 
sequencing (WGS) of KSM6-26-1 revealed no unexpected mutations, which allows confident 
assignment of the role of Type I DNA methylation. However, WGS of strain KSM3-61-6 
revealed two nonsynonymous mutations acquired by this strain in the process of cloning (Table 
10). Tetranucleotide insertion in ybaL results in a premature stop codon and consequently a 
protein which is 165 amino acids shorter. A single G to T SNP in gene nrdA results in a K584N 





Table 10: Mutations present in KSM3-61-6. Mutations revealed by whole genome sequencing 
(WGS) of strain KSM3-61-6 with respect to wild type UTI89. Position, type and consequence of 
nonsynonymous mutations are listed. Excludes known manipulation of hsdS locus and each 
mutation independently confirmed by Sanger sequencing. 
 
       Based on sequence homology, ybaL is a putative cation-proton antiport system with no 
information available on the effects of ybaL deletion on E. coli physiology. nrdA is a class Ia 
RNR gene, which is essential in E. coli and has been the subject of previous mutational analysis; 
K584N however is a novel nrdA mutation. To correctly assign the altered phenotype of strain 
KSM3-61-6, the above ybaL and nrdA mutations were independently generated in UTI89 wild 
type. Two phenotypes, namely motility (Figure 17) and Azathioprine sensitivity (Figure 19) were 
selected to further narrow down the gene responsible for the phenotypic differences between the 
two UTI89 SWAP K12 strains. ybaL mutant does not show the motility defect (Figure 20) nor 
Azathioprine sensitivity (Figure 21) of strain KSM3-61-6. Mutation in this gene closely mimics 
wild type UTI89 in both assays. However, nrdA K584N mutation results in decreased motility 
(Figure 20) and Azathioprine sensitivity (Figure 21, solid green line), which very closely 





Figure 20: Motility of UTI89 ybaL and nrdA mutants. Motility of different UTI89 mutants 
assessed by soft agar motility assay. Experiment for UTI89, KSM3-61-6 and KSM6-26-1 
performed thrice and data represents mean and standard deviation. Experiment for UTI89 ybaL 
and nrdA-K584N mutants performed only once. Significance for data with biological replicates 




Figure 21: Azathioprine sensitivity of UTI89 ybaL and nrdA mutants. Growth curves for 
UTI89, KSM3-61-6, ΔybaL and nrdA-K584N in the presence of 1mM Azathioprine (AZ, solid 
lines) or diluent (DMSO, dash lines). Negative control (NC) contains media only. Curves 
represent mean values from three independent experiments for UTI and KSM3-61-6, and one 
experiment for ΔybaL and nrdA-K584N UTI89 single mutants. Significance calculated using 





4.6     SUMMARY: Identification and Characterization of a novel Ribonucleotide reductase    
          gene mutant 
         Ribonucleotide reductase (RNR) systems are responsible for the de novo synthesis of 
deoxyribonucleotides from their ribonucleotide precursors. RNR systems play an important role 
in regulating DNA replication and repair, with a single system capable of generating all four 
deoxyribonucleotides (dATP, dCTP, dTTP and dGTP) [166]. RNR systems are subject to 
complex allosteric regulation, wherein a balanced cellular dNTP pool is constantly maintained 
by sampling the dNTP pool and accordingly synthesizing the appropriate dNTP as well as 
alternating between active and inactive quaternary structures when required [167, 168]. Any 
imbalance can be lethal as it can result in aberrant mutation rates [169, 170]. Owing to their 
essential role in a central cellular metabolic process, namely DNA synthesis and their ubiquitous 
nature in all living organisms, RNR systems are attractive drug targets. Chemotherapy drugs 
targeting RNR systems as antiproliferatives already exist and efforts are underway to develop 
high throughput screening strategies for RNR inhibitors, an otherwise lab-intensive process, so 
as to identify novel therapeutics including antibiotics [171]. 
         nrdAB represents the primary E. coli RNR system, functional under aerobic conditions and 
unlike the other RNR systems present in the genome (nrdHIEF and nrdDG), it is essential [172]. 
WGS of a Type I methylation mutant identified a mutation within nrdA, namely K584N. Amino 
acid K584 does not encompass the catalytic or any of the allosteric sites [172] and based on 
literature it is a novel mutation. Phenotypically, this mutation shows reduced growth at late log 
and log to stationary phase transition, which is when wild type nrdA expression is maximal [173]. 
nrdA-K584N demonstrates sensitivity to nucleotide analogues, DNA damage inducers and most 
strikingly, RNR inhibitor Guanazole by phenotype microarray; Table 9 Section 4.4. Increased 
expression of nrdAB and nrdHIEF as well as sensitivity to known RNR inhibitors suggests that 
K584N is a hypomorph, confirmation of which requires complementation to validate and direct 




phenotypically linking a RNR system and motility [174]. E. coli nrdAB is known to be regulated 
by a complex regulatory network which includes DnaA, Ici, Fnr, Fur, Fis, NrdR and H-NS, 
several of which are global transcription regulators [175]. Several of these are independently 
known to regulate motility either by directly binding to the promoters of motility genes, 
regulating secondary messengers or by unknown mechanisms [174, 176-178]. K584N motility 
phenotype first requires to be validated by complementation, after which it represents a useful 
mutant to try and identify the genes involved in this regulatory crosstalk, either by a candidate 
based approach or an unbiased mutagenesis screen. 
          Leveraging the strengths of next generation sequencing, classical microbiological assays 
and appropriate controls; it was possible to identify and distinguish phenotypes associated with 
a novel mutation in RNR nrdA, which was independent of Type I DNA methylation. This 
previously unknown lysine to asparagine mutation in nrdA, represents a potentially useful tool 
for improving our understanding of the regulation and functioning of these essential enzyme 
systems. UTI89 nrdA-K584N was discovered as a spontaneous mutant in the course of 
elucidating the role of Type I methylation in E. coli virulence, it is not the primary focus of this 



















       Methylation of DNA is a well-known epigenetic mechanism with the ability to impart to 
the genome an additional layer of functionally relevant information. Moreover, this epigenetic 
signature of the genome is amenable to rapid, heritable alterations in response to external stimuli. 
First studied in the context of mammalian development and disease [171, 172], the relevance of 
DNA methylation in several bacterial physiological processes quickly emerged [94]. The 
phenomena of DNA methylation in bacteria was first identified in the context of host defence 
over half a century ago [51]. Methyltransferases associated with bacterial Restriction 
Modification Systems (RMSs) methylate DNA in specific sequence contexts to help differentiate 
self from non-self DNA, protecting against harmful phages and stabilising the genome by 
preventing unregulated horizontal gene transfer. Subsequently, highly conserved DNA 
methyltransferases have been identified independent of the classical RMS endonucleases and 
termed as orphan methyltransferases [91]. These orphan methyltransferases caught the attention 
of researchers as their conservation [76] and in certain cases essentiality [91, 110, 111] implied 
that an alternative function must exist. Orphan methyltransferases such as dam, ccrM and dcm 
have been the subject of intense scrutiny and dam methylation does in fact play an important role 
in bacterial virulence [73, 95, 99, 101-105, 107-112, 114, 179, 180]. dam and ccrM even regulate 
basic cellular processes such as DNA replication, cell division, mismatch repair and controlling 
transposons [94].  
       RMS associated methyltransferases have not been studied as extensively, because their 
primary function is believed to be host defence. However, by virtue of methylating DNA to 
identify host genomic material, these methyltransferases can function via mechanisms similar to 
those utilised by orphan methyltransferases. Publications exist elucidating the role of 
phasevariable RMSs, mainly Type III capable of reversible ON/OFF switching of 




capable of rapidly and reversibly replacing one methylation mark with another [62, 63]. In both 
these cases these RMSs confer upon the host genome the ability to rapidly change phenotypic 
traits to allow better colonisation of a niche or immune evasion, contributing to virulence. 
Publications mentioning such functions for classical RMSs, which lack the ability to reversibly 
change the host methylome are rare [58, 88]. This paucity of information regarding the potential 
role of methylation mediated by classical, fully functional RMSs in virulence is either because 
such systems in fact do not deviate from their primary roles or have not been subjected to proper 
systematic scrutiny. 
        Urinary tract infections (UTIs) are one of the most common infections, both in the 
community as well as nosocomial settings [2]. Although usually self-limiting and treatable by  
antibiotic therapy, the high incidence and rate of recurrence means that UTIs are a significant 
cause of morbidity and public healthcare expenditure [36]. Uropathogenic E. coli (UPEC), which 
is the primary causative agent for UTIs, undergoes a complex life cycle involving intracellular 
and extracellular stages and is adept at evading host immunity and treatment. The repeated and 
prolonged use of antibiotics for UTIs carries an additional risk of causing the emergence of 
antibiotic resistance [1]. Attempts to characterise a universal set of virulence factors specific to 
UPEC have not succeeded. In fact, UPEC strains often encode diverse types and numbers of 
virulence factors, making characterisation and targeting of urinary tract specific virulence factors 
difficult [27]. However UPEC virulence factors such as Type I pili, P pili and Antigen 43 do 
show epigenetic regulatory mechanisms, either due to an invertible promoter element or dam 
methylation [99, 100, 181]. It thus stands to reason that epigenetics, especially DNA methylation, 
plays an important role in regulating UPEC virulence. In addition to the few currently known, 
locus specific effects mediated by orphan methyltransferase dam, whose underlying molecular 
mechanisms have been elucidated [99, 151]. The overall objective of this study is to 
systematically elucidate the functions of the identified methyltransferases irrespective of the type 





5.1      UTI89 encodes a novel Type I methylation motif mediated by a functional RMS 
        Based on sequence homology to known methyltransferases, UTI89 is predicted to possess 
four distinct methylated motifs [79, 138]. However, in order to find which methyltransferases are 
functional, we utilised Single Molecule Real Time (SMRT) sequencing. SMRT sequencing 
identified three motifs methylated to varying extents in the UTI89 genome. Two of these 5’-
GATC-3’ and 5’-CCWGG-3’ belong to known E. coli orphan methyltransferases dam and dcm 
respectively. Although majority of dam methylation sites (96.9%) were methylated, only 1.8% 
of dcm sites could be detected as methylated. This low proportion of methylation is probably 
owing to the weak and diffuse signal detected for 5-methylcytosine (5mC) in SMRT sequencing 
[157] and also because majority of dcm sites are methylated during stationary phase only [74]. 
However, the UTI89 genome did display a novel bipartite methylated sequence 5’-
CCA(N7)CTTC-3’ (methylated N6-methyladenine resides on both strands are underlined). This 
methylation sequence consists of two specific parts, separated by a degenerate sequence of fixed 
length, which is characteristic of Type I RMSs. Indeed, the UTI89 genome does possess a 
previously uncharacterised Type I RMS hsd (host specificity determinant) gene cluster. This 
RMS consists of three genes hsdS (Specificity determining DNA binding component), hsdM 
(Methyltransferase) and hsdR (Endonuclease). The hsd gene cluster is located on a hypervariable 
region of the E. coli chromosome called the immigration control region, which is also present in 
other E. coli strains such as lab adapted commensal strain K12 substrain MG1655 and 
pyelonephritis causing strain CFT073 [54, 138]. The K12 Type I RMS called EcoKI is the first 
one discovered, in the 1960s and has served as the model for all other Type I RMSs. This K12 
RMS has a known specificity (5’-AAC (N6) GTGC -3’) [51], while the CFT073 Type I RMS is 
predicated to methylate (5’-GAAG (N7) TGG -3’) [138].  
       A considerable amount of data exists regarding the roles of dam and dcm in regulating 




decided to systematically investigate the effect of epigenetic DNA methylation mediated by the 
putative Type I RMS. RMS associated methyltransferases are found in conjunction with a partner 
endonuclease, however due to acquired mutations such as truncations or premature stop codons 
these endonuclease genes could be silenced. Therefore a perceived RMS could actually just be 
an orphan methyltransferase whose endonuclease component is in the process of evolutionary 
removal. However, studies pertaining to RMS associated methyltransferases do not always check 
both methylation and restriction functions. To identify the genes responsible for unique UTI89 
Type I methylation and demonstrate the functional status of the responsible RMS, we utilised an 
adapted plasmid transformation based Restriction Modification (RM) Assay [182]. The RM 
assay was first validated using the previously well characterised K12 Type I RMS. Using UTI89 
wild type and Type I RMS deletion mutant, the novel bipartite methylated motif 5’-
CCA(N7)CTTC-3’was successfully assigned to hsdSMR. Moreover, not only was this Type I 
RMS capable of methylating the target site in plasmid DNA, but also distinguishing methylated 
and unmethylated copies of the site and selectively restricting unmethylated plasmids only. 
Similarly, the CFT073 Type I RMS was also tested by the RM assay. CFT073 Type I RMS also 
has both restriction as well as modification functions intact and recognises the sequence 5’-
GAAG(N7)TGG-3’ as predicted. Thus, each of the three E. coli strains encode one fully 
functional Type I RMS, each with a distinct methylation specificity.  
       Type I RMS methylation specificities are difficult to determine by classical methods owing 
to the fact that they cleave DNA at variable distances from their recognition site. However, based 
on a mixture of sequence based predictions as well as biochemical confirmation, there are 
approximately 1047 putative bacterial Type I RMS specificities [138]. Type I RMSs belonging 
to the same family show a high degree of homology within hsdMR, differences mainly exist in 
the hsdS gene which determines DNA specificity. Type I RMS specificity diversification 
frequently occurs by exchanging either the entire or partial hsdS gene by intra family homologous 
recombination [51, 58]. Also, most RMSs are encoded on mobile genetic elements and although 




modular nature of Type I and III RMSs and the fact that the endonuclease component does not 
encode the target recognition domain (TRD) for DNA binding, loss or alterations in the TRD 
does not put the host at immediate risk for endonucleolytic attack. Therefore, to simulate the 
acquisition of a foreign Type I methylation specificity in UTI89, the native Type I RMS genes 
were replaced with those from K12 and CFT073. K12 is a gut derived commensal isolate, but its 
RMS belongs to the same Type IA family and hence merely the chromosomal hsdSUTI89 allele 
was replaced with hsdSK12. CFT073 is another UPEC strain, but its Type I RMS belongs to a 
different family and hence it necessitated replacing the entire native hsdSMRUTI89 locus with 
hsdSMRCFT073. To validate whether these altered RMSs actually function, the RM assay was used. 
As expected, the UTI89 SWAP K12 strain KSM6-26-1 expressed a fully functional K12 Type I 
RMS in the UTI89 genomic context. Also, UTI89 SWAP CFT073 strain KSM6-80-15 expressed 
a fully functional CFT073 Type I RMS in UTI89. This is one of the first studies to chromosomally 
swap Type I RMS mediated methylation patterns so as to evaluate the consequences of foreign 
methylation on host phenotype. 
 
5.2      Altered UTI89 Type I methylation does not affect virulence 
        Based on literature, DNA methylation can alter gene expression by direct mechanisms such 
as influencing the binding affinity of regulatory proteins to the promoters of genes [90, 99, 106] 
and also by unknown indirect mechanism via methylated sites not present at or near the affected 
genes [72, 86]. Also, evidence exists for both orphan as well as RMS associated 
methyltransferases exerting an effect on gene expression. We thus hypothesised that removal of 
754 native UTI89 Type I methylation sites as well as the introduction of 668 (K12) or 784 
(CFT073) foreign methylation sites should manifest phenotypically in UTI89. Phenotypes such 
as biofilm formation, motility, Type I pilus expression and growth kinetics are important 
determinants of UTI89 virulence [152] and can be assayed in vitro under precise conditions. Type 




bladder as well as the subsequent formation of biofilm-like intracellular bacterial communities 
[8, 9, 183]. Biofilm formation acts as a surrogate for the ability to form IBCs. Motility is required 
transiently for both UPEC adhesion to target cells and ascension to the kidneys [29, 30]. Using 
these versatile in vitro proxies for virulence, UTI89 Type I methylation deletion and swap 
mutants were evaluated for differences. Surprisingly, UTI89 mutants did not differ from wild 
type or the revertant in any of the in vitro phenotypes tested. Based on a limited array of UPEC 
specific virulence assays, it appears that contrary to expectations Type I RMS methylation did 
not alter UTI89 phenotype. 
       Although informative, in vitro assays can check only specific parameters and by no means 
represent an exhaustive scrutiny of possible phenotypes nor replicate complex host environments. 
Competitive infections comparing both UTI89 lacking native Type I methylation and bearing 
K12 Type I methylation, showed no difference from wild type. Lack of a virulence phenotype 
cannot be due to the locus and type of inserted selection marker, as this was controlled for. This 
result is in agreement with in vitro data and although unexpected is convincing. 
 
5.3      Type I methylation does not affect global gene expression patterns or phenotypes in  
            multiple E. coli strains  
        Although DNA methylation can potentially alter expression patterns so as to influence 
virulence, data with respect to UTI89 and its Type I methylation mutants convincingly proves 
otherwise. Therefore in order to strengthen the alternative hypothesis that methylation mediated 
by a fully functional classical Type I RMS such as the UTI89 RMS does not perturb global gene 
expression, we employed two approaches. Firstly, we decided to systematically screen using 
broad high throughput approaches for any changes mediated by Type I methylation using RNA-
seq and Phenotype Microarray. Secondly, we extended the hypothesis to include two other Type 
I RMSs similar to the one in UTI89, one in uropathogen CFT073 and another in lab strain K12. 




functional and methylate less than 760 sites each in their respective genomes (754, 595 and 427 
for UTI89, K12 and CFT073 Type I RMSs respectively). SMRT sequencing data shows that 99% 
of the UTI89 Type I methylation sites are methylated, as would be expected for a RMS with a 
functional restriction component. However, consistently unmethylated sites such as those 
protected from methylation by the binding of regulatory proteins could exist for all three E. coli 
strains. For example, unmethylated GATC sites are found in the promoter of the dnaA gene due 
to binding by the SeqA repressor protein [94]. 
        Strand specific RNAseq was performed to investigate the transcriptional patterns in 
stationary and exponential phases. Comparisons were made using the entire panel of UTI89 Type 
I methylation mutants including a deletion mutant, UTI89 bearing K12 methylation, UTI89 
bearing CFT073 methylation mutant and a revertant as control. Comparisons were also made 
between K12 and CFT073 with their respective Type I RMS deletion mutants. We thus hoped to 
be thorough enough to be able to detect any possible effect of Type I RMS methylation on gene 
expression. None of the UTI89 Type I methylation mutants showed any changes in transcript 
levels relative to wild type in exponential or stationary phase. Similarly, lack of CFT073 Type I 
methylation did not alter log or stationary phase gene expression either. Stationary phase 
transcriptomes for K12 Type I RMS deletion mutant remained unaffected, except for the subtle 
borderline upregulation of uhpA, encoding a two component sugar transport system. However, 
during log phase K12 showed upregulation of four genes, all four belonging to the same 
prophage.  
        K12 cryptic prophage CP4-44 gene upregulation was validated by qRT-PCR and represents 
a single small locus specific effect. Interestingly, four K12 methylation sites were identified in 
the coding sequence of the CP4-44 phage genes identified as upregulated. This raises the 
possibility of several direct mechanisms for RMS mediated regulation, including alleviation of 
restriction pressure exerted due to the presence of multiple Type I sites or direct methylation 




phage expression is due to methylation or restriction. This can be tested by comparing CP4-44 
upregulation in K12 ΔhsdSMR (methylation and restriction null mutant) versus K12 ΔhsdR 
(restriction null mutant). Coincidently K12 Type I RMS deletion mutant also shows a growth 
defect in LB during log phase. Consistent with our data, Type I RMS mediated methylation does 
not result in global gene expression changes.  
        Although RNA-seq is a frequently used and powerful genomic tool to study subtle changes 
in transcription, it provides information only under the specific conditions tested. Most studies 
either check a particular growth phase or under a specific, relevant in vivo condition. In selecting 
exponential phase cultures we consciously selected an actively replicating bacterial population. 
Similarly, bacterial cultures passaged for two successive 24 hour periods were selected to 
replicate the stationary phase inoculum used in the murine model for UTI. However, we 
acknowledge that this still represents a limited set of conditions and to conclusively prove that 
Type I RMS methylation bears no consequence on the host, we need to cast the widest net 
possible. To this end, we decided to employ a high throughput phenotypic screen called 
Phenotype Microarray by Biolog Inc. Phenotype Microarray (PM) allows the simultaneous 
analysis in a convenient 96-well format of almost 2000 distinct phenotypes [156].  
        In the absence of any prior information about a particular protein, PM can provide useful 
clues as to the relevant biological function of the protein. In this case, we use PM with the intent 
of elucidating any previously neglected phenotypes for Type I RMS methylation. UTI89 and its 
revertant were included as a negative control and indeed not a single phenotypic difference was 
observed. But, UTI89 and K12 Type I RMS deletion mutants also did not show a single 
phenotypic difference across the entire PM panel, confirming our hypothesis and the rest of the 
data. K12 lacking native Type I methylation which showed reduced growth in LB (Section 3.3.3) 






5.4      Conclusions 
        To summarise, we utilised an array of in vitro and in vivo UPEC specific methods to test our 
initial hypothesis that DNA methylation mediated by Type I RMS can modulate the virulence of 
this important human pathogen. DNA methylation in the context of dam methylation does in fact 
prove this theory, based on prior publications. However, our exhaustive search with UTI89 
strains with altered Type I methylation revealed no effect. Although disappointing, this supported 
the alternative hypothesis that Type I RMS mediated methylation does not have any 
consequences on E. coli physiological processes at all. To prove such a theory, we had to 
rationally employ non-specific high throughput methods such as RNA-seq and Phenotype 
Microarray, so as to comprehensively screen for the presence of any effects due to Type I 
methylation. To lend further credence to this theory, we decided to extend our scrutiny to other 
pathogenic (CFT073) as well as non-pathogenic (K12) E. coli Type I RMSs. It is important to 
note that all three RMSs are fully functional with 427 to 754 sites per corresponding genome, 
however they differ in their methylation specificity, genomic context and the clinical 
manifestations of their host bacterium. Results from PM, a technique which can simultaneously 
screen a diverse set of nutritional and resistance phenotypes, supported this theory. Barring 
cryptic phage transcription in K12 during log phase, no other differences in gene expression were 
observed. These represent small gene expression changes (only 4 genes) at the same genomic 
locus and the biological consequences of which remain to be seen. Based on our thorough 
systematic approach using an extensive set of simple specific as well as high throughput 
molecular assays, we can convincingly say that Type I RMS mediated methylation does not have 
any consequences on UPEC model organism UTI89. This observation holds true to a large extent 
for Type I RMS mediated methylation in other E. coli as well. 
         On the basis of current literature and our study pertaining to the effects of DNA methylation 
on bacterial cellular processes, and specifically the effects of orphan dam methylation versus 




the ability to alter bacterial transcription and hence phenotype. This is not a eukaryotic specific 
mechanism [92]. 2. The vast majority of information pertaining to methylation affecting global 
gene expression is in the context of orphan methyltransferases. Orphan methyltransferases are 
highly conserved and sometimes even essential genes, with no role in host defence [75]. RMSs 
on the other hand, not only show high prevalence among bacterial and archaeal species, but are 
also highly diversified in their methylation specificities [53, 138]. Amongst Type II 
methyltransferases, orphans outnumber RMS associated genes [76]. 3. RMS associated 
methyltransferases can also affect gene expression and virulence, for example Type III 
phasevarions and complex Type I phasevariable systems of S. pneumoniae. However, these 
systems harbour the unique ability to rapidly and reversibly alter methylation, from a simple 
binary ON/OFF system to a complex six-phase switching of methylation patterns, respectively. 
Instances of classical RMSs similarly regulating virulence are extremely rare, such as E. coli 
O104:H4 strain harbouring a phage encoded classical RMS [88]. However, this system was very 
recently acquired via phage transduction and since RMS site avoidance correlates with the 
lifespan of that particular system [52], the long term evolutionary consequences of this classical 
RMS methylation are unknown. 4. The primary molecular mechanism involved in methylation 
mediated gene regulation is the differential binding of regulatory proteins to methylated versus 
unmethylated sites in the promoters of target genes. Based on this information, studies have 
looked at the localisation of methylation target sites in gene regulatory elements and the presence 
of consistently unmethylated target sites, potentially indicative of regulatory protein binding. A 
recent study involving 230 different prokaryotic genomes, revealed that methylation target sites 
in regulatory regions and unmethylated target sites are a frequent feature of orphan Type II 
methyltransferases and not Type II RMSs [76]. 5. Global gene expression changes involving 
large numbers of genes correlates with the number of methylation sites in the genome. For 
example, Type II (palindromic) and III (short asymmetric) sequences occur more frequently than 
Type I (bipartite) sequences in bacterial genomes. Correspondingly, gene expression changes due 




Type III (for example phasevarions [123]) methyltransferases are more diverse and include 
several genes belonging to diverse operons located across the genome. Type I methylation 
mediated effects are fewer in number and locus specific ([58] and this study). 
        Due to the paucity of information especially regarding Type I RMSs, the above points are 
merely observations and by no means conclusive biological rules. Our study aims to address this 
lack of information regarding any additional roles for Type I RMSs using Uropathogenic E. coli 
as a model. Also, in order to simulate the sudden acquisition of a foreign methylation, for example 
via phage transduction, we included UTI89 strains expressing K12 and CFT073 Type I 
methylation patterns. As most studies classify methyltransferases as orphan or RMS associated 
on the basis of gene content which may not be accurate, we chose to functionally test the existence 
of both restriction and modification functions of the Type I RMSs in question. The rational and 
thorough approach of this study sheds some light on the question of whether epigenetic DNA 
modification mediated by Type I RMSs regulates Uropathogenic E. coli virulence, besides its 











Table 11: List of Strains 
Strain Genotype/Relevant characteristic Source/Reference 
UTI89 Clinical isolate [150] 
K12 substrain MG1655 Gut derived lab strain [184] 
CFT073 Clinical isolate [34] 
KSM2-102-4 UTI89 hsdSMR::neo This study 
KSM2-102-7 K12 hsdSMR::neo This study 
KSM7-15-1 CFT073 hsdSMR::neo This study 
KSM6-21-4 UTI89 hsdS::neo-PrhaB-relE This study 
KSM6-26-1 UTI89 hsdSK12 This study 
KSM3-95-4 UTI89 hsdSUTI89 This study 
KSM6-74-1 UTI89 hsdSMR::neo-PrhaB-relE This study 
KSM6-80-15 UTI89 hsdSMRCFT073 This study 
KSM3-39-2 UTI89 attHK022::neo This study 
KSM3-39-1 UTI89 attHK022::cat This study 
KSM3-39-6 UTI89 hsdSMR::FRT attHK022::neo This study 
KSM3-39-3 UTI89 hsdSMR::FRT attHK022::cat This study 
KSM6-29-3 UTI89 hsdSK12 attHK022::neo This study 
KSM6-29-1 UTI89 hsdSK12 attHK022::cat This study 
KSM5-24-7 UTI89 fliC::neo This study 
KSM3-52-1 UTI89 hsdS::neo-PrhaB-relE This study 
KSM3-61-6 UTI89 hsdSK12 This study 
KSM5-72-4 UTI89 hsdSK12 attHK022::neo This study 
KSM5-72-5 UTI89 hsdSK12 attHK022::cat This study 
KSM7-10-1 UTI89 ybaL::neo This study 
KSM7-12-1 UTI89 yfaL::neo-PrhaB-relE This study 
KSM7-13-2 UTI89 nrdA-K584N This study 
 
Table 12: List of Plasmids 
Plasmid Genotype/Relevant characteristic Source/Reference 
pKM208 Red recombinase [185] 
pKD3 cat cassette [147] 
pKD4 neo cassette [147] 
pSLC217 neo-PrhaB-relE casette [148] 
pACYC184 Cloning vector, No Type I sites New England Biolabs 
pKSM3-42-1 1 copy K12 Type I site 5’-AAC (N)6 GTGC -3’ This study 
pKSM3-45-1 2 copies K12 Type I site 5’-AAC (N)6 GTGC -3’ This study 
pKSM3-16-1 1 copy UTI89 Type I site 5’-GAAG (N)7 TGG -3’ This study 
pKSM3-17-1 2 copies UTI89 Type I site 5’-GAAG (N)7 TGG -3’ This study 
pKSM4-95-4 1 copy CFT073 Type I site 5’-GAG (N)7 GTCA -3’ This study 
















3 5’ TCTGCTTCGAACGGTTGTGC UTI89 hsdS test  
4 5’ CGCCGAAGAGACGGAAATTG 
5 5’CCGCATCGCGCTAAATACCTGGATATATCATCAGTAAATACAGGGAA
AGTCCAGCTAAAAATAGAATAAAATGGG 
Amplification of K12 hsdS with 









9 5’ TCTGCTTCGAACGGTTGTGC UTI89 hsdSMR test 
10 5’ GTCATTGCCCGGAAAGGTAC 
11 5’GCGTAAAAATAATAAATAGCGCACCAGAAAGGTGCGCCAGAAAATA
ATGATTAGTTTATCGCCGCGTCAGTGAGTG 
Amplification of CFT073 
















17 5’ TTAGCGATGCGGGTGTGTTG K12 hsdSMR test 










21 5’ GTTATTTGCCGGGGAGACTTCTGCTTC CFT073 hsdSMR test 
22 5’ CGGTTCCTGTAACTTCTGTTTATCTGTC 
23 5’TCAGAATCAGTGCGCAAAGAGAAACTAATCCCAGCAATAACAGGCT
GTATGTGTAGGCTGGAGCTGCTTC 
UTI89 attHK022 insertion with 
neo and cat cassette 
24 5’CGAGCGGCGGATATGTTCGCGGTCGGCATTTTTCGGCGTCATGACTA
AAACATATGAATATCCTCCTTAG 
25 5’ TAAACCACGCGCCAGAGGAT UTI89 attHK022 test 
26 5’ ACGAAATCCCCCTGGTGACA 
27 5’TTAACCCTGCAGCAGAGACAGAACCTGCTGCGGTACCTGGTTGGCTT
TTGGTGTAGGCTGGAGCTGCTTC 




29 5’ AATTTGGCGTTGCCGTCAGT UTI89 fliC test 
30 5’ AGCGGGAATAAGGGGCAGAG 
31 5’CGCGTCTTATCAGGCCTACATATCCGCGCCTATTATCCGGCAACCACC
GTGTGTAGGCTGGAGCTGCTTC 




33 5’ CTCAATGCCTGATGCGACG UTI89 ybaL test 
34 5’ CTTCTGTTTTCCGATCCGTGC 
35 5’TATCCCGAGGCGCTGTTATTTTCATCAATCATCACACCATTGTTTTGG
TCGCTTGCAGTGGGCTTACATG 




37 5’ ACGGCAGCGCCAACAACCTGACGCA 
 
UTI89 yfaL test & amplification 
of nrdA-K584N with flanking 
UTI89 yfaL homology 
38 5‘ ATGGCACTTATGTGCTATCCG 
39 5’ATTGCAGCGGCCGCGAAGGCCTACATGGATTTATTTATTCTGCGAAG
TG 





40 5’ AGCTATGCGGCCGCATAAATCCTGGTGTCCCTGTTGATACC 
41 5’ATTGCAGCGGCCGCGAAGACGTTCATGGCCGGACGCATCGTGGCCG
GCATCA 
pACYC184 UTI89 2nd Type I 
site insertion 
42 5’ AGCTATGCGGCCGCCGTAGAGGATCCACAGGACGGGTGTGG 
43 5’ATTGCAGCGGCCGCAACGGTACCGTGCATTTATTTATTCTGCGAAGT
G 
pACYC184 K12 1st Type I site 
insertion 
44 5’ AGCTATGCGGCCGCATAAATCCTGGTGTCCCTGTTGATACC 
45 5’ATTGCAGCGGCCGCAACGGTACCGTGCCCGGACGCATCGTGGCCGG
CATCA 





pACYC184 CFT073 1st Type I 
site insertion 
48 5’ AGCTATGCGGCCGCATAAATCCTGGTGTCCCTGTTGATACC 
49 5’ATTGCACTCGAGGAGACGCGTAGTCAACTTCGGGCTCATGAGCGCT
TGTTTC 
pACYC184 CFT073 2nd Type I 
site insertion 
50 5’ AGCTATGCGGCCGCCGTAGAGGATCCACAGGACGGGTGTGG 
51 5’ CGGTCTGGTTATAGGTACATTGAGC 
 
Sequencing pACYC184 1st 
Type I site insertion 
52 5’ AGAGATTACGCGCAGACCAAAACG 
 
Sequencing pACYC184 2nd 
Type I site insertion 
53 5’ CTCTTGCCATCGGATGTGCCCA UTI89/K12 rrsA qPCR 
54 5’ CCAGTGTGGCTGGTCATCCTCTC 
55 5’ GGTGATCAAAGCCTACCGTTTA UTI89 flhC qPCR 
56 5’ CAACAAACCGCACCAATGTC 
57 5’ TGAAGTGGCACAGGCAATAG UTI89 fliA qPCR 
58 5’ TCGGCAATATCGATCCCTAAAC 
59 5’ CCTTCATGCTGATGTGGGTAA UTI89 fliC qPCR 
60 5’ GCTTCCACCGATGGTGATATT 
61 5’ CTATGAGCTGCTGTGGGAAA UTI89 nrdA qPCR 
62 5’ GACGGATCGTAGTTGGTGTTAG 




64 5’ AACCAGCCATCCCACATAAC 
65 5’ GTGGGTACAGCCTTCTGTTATC K12 flu qPCR 
66 5’ GTCCAGTGATGTGCCATTCT 
67 5’ GAATTCCGGGTGCTGTATCT K12 yeeS qPCR 
68 5’ ACAGGGCGCGTTTAATCA 
69 5’ ACGCGGACAAACAACTATCC K12 prlF qPCR 
70 5’ CTCCCAGTCGGCACATAAATAC 
71 5’ GTTGCCGAAGTCGAGACATTA K12 yhaV qPCR 
72 5’ GACCGTGATATGCTCCTCAATC 
73 5’ GCCGGACGTCCCAATAAA K12 emrD qPCR 
74 5’ CAGACATTCATCACGCCAAAC 
75 5’ GGAAGGACGCACACTCTTT K12 yhjH qPCR 
76 5’ CTGAACATCACGCCACTCTT 
77 5’ TTTCAGTCTTACGCGCTCTATC 
 
CFT073 malK qPCR 
78 5’ ACTCGCTGGTTAATCACTTCTT 
 
79 5’ ACCGGCGACAAGAACAAT 
 
CFT073 lamB qPCR 
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Burkholderia pseudomallei sequencing identifies genomic
clades with distinct recombination, accessory,
and epigenetic profiles
Tannistha Nandi,1 Matthew T.G. Holden,2,13 Xavier Didelot,3 Kurosh Mehershahi,4
Justin A. Boddey,5,14 Ifor Beacham,5 Ian Peak,5 John Harting,6 Primo Baybayan,6
Yan Guo,6 Susana Wang,6 Lee Chee How,6 Bernice Sim,1 Angela Essex-Lopresti,7
Mitali Sarkar-Tyson,7 Michelle Nelson,7 Sophie Smither,7 Catherine Ong,8 Lay Tin Aw,8
Chua Hui Hoon,1 Stephen Michell,9 David J. Studholme,9 Richard Titball,9,10
Swaine L. Chen,1,4 Julian Parkhill,2 and Patrick Tan1,11,12
1Genome Institute of Singapore, Singapore, 138672, Republic of Singapore; 2The Wellcome Trust Sanger Institute, Cambridge, CB10
1SA, United Kingdom; 3Department of Infectious Disease Epidemiology, Imperial College London, W2 1PG, United Kingdom;
4Department of Medicine, National University of Singapore, Singapore, 119074 Republic of Singapore; 5Institute for Glycomics, Griffith
University (Gold Coast Campus), Southport, Queensland, QLD 4222, Australia; 6Pacific Biosciences, Menlo Park, California 94025, USA;
7Defence Science and Technology Laboratory, Porton Down, Salisbury, SP4 0JQ, United Kingdom; 8Defense Medical and Environmental
Research Institute, DSO National Laboratories, Singapore, 117510, Republic of Singapore; 9Biosciences, University of Exeter, Exeter, EX4
4QD, United Kingdom; 10Faculty of Infectious and Tropical Diseases, Department of Pathogen Molecular Biology, London School
of Hygiene and Tropical Medicine, WC1E 7HT, United Kingdom; 11Duke-NUS Graduate Medical School Singapore, Singapore, 169857,
Republic of Singapore; 12Cancer Science Institute of Singapore, National University of Singapore, 117599, Republic of Singapore
Burkholderia pseudomallei (Bp) is the causative agent of the infectious disease melioidosis. To investigate population diversity,
recombination, and horizontal gene transfer in closely related Bp isolates, we performed whole-genome sequencing (WGS)
on 106 clinical, animal, and environmental strains from a restricted Asian locale. Whole-genome phylogenies resolved
multiple genomic clades of Bp, largely congruent with multilocus sequence typing (MLST). We discovered widespread
recombination in the Bp core genome, involving hundreds of regions associated with multiple haplotypes. Highly
recombinant regions exhibited functional enrichments that may contribute to virulence. We observed clade-specific
patterns of recombination and accessory gene exchange, and provide evidence that this is likely due to ongoing re-
combination between clade members. Reciprocally, interclade exchanges were rarely observed, suggesting mechanisms
restricting gene flow between clades. Interrogation of accessory elements revealed that each clade harbored a distinct
complement of restriction-modification (RM) systems, predicted to cause clade-specific patterns of DNA methylation.
Using methylome sequencing, we confirmed that representative strains from separate clades indeed exhibit distinct
methylation profiles. Finally, using an E. coli system, we demonstrate that Bp RM systems can inhibit uptake of non-self
DNA. Our data suggest that RM systems borne on mobile elements, besides preventing foreign DNA invasion, may also
contribute to limiting exchanges of genetic material between individuals of the same species. Genomic clades may thus
represent functional units of genetic isolation in Bp, modulating intraspecies genetic diversity.
[Supplemental material is available for this article.]
Burkholderia pseudomallei (Bp) is the causative agent of melioi-
dosis, a serious infectious disease of humans and animals and
a leading cause of community-acquired sepsis and pneumonia in
endemic regions (Currie et al. 2010). Initially thought to be
confined to Southeast Asia and Northern Australia, the preva-
lence of Bp appears to be spreading (Wiersinga et al. 2012), and
Bp has been designated a biothreat select agent in the United
States. Bp can persist in extreme environmental conditions and
can infect several plant and animal hosts, including birds, dol-
phins, and humans (Wuthiekanun et al. 1995; Howard and Inglis
2003; Sprague and Neubauer 2004; Larsen et al. 2013). Treatment
of clinical melioidosis is challenging because the bacterium is
inherently resistant to many antibiotics, and Bp infections can
persist in humans for more than a decade (Hayden et al. 2012;
Wiersinga et al. 2012).
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The Bp genome comprises one of the largest and most com-
plex bacterial genomes sequenced to date. Consisting of two large
circular replicons (chromosomes) with a combined 7.2-Mb ge-
nome size (Holden et al. 2004), it contains a rich arsenal of genes
related to virulence (e.g., Type III and Type VI secretion systems,
polysaccharide biosynthesis clusters), metabolic pathways, and
environmental adaptation (Wiersinga et al. 2012). Besides con-
served regions, accessory genes on mobile elements and genomic
islands may also contribute to phenotypic and clinical differences
in microbial behavior (Currie et al. 2000; Sim et al. 2008). Analysis
of the Bp genome has revealed previously unknown toxins and
mechanisms of antibiotic resistance (Chantratita et al. 2011; Cruz-
Migoni et al. 2011).
Most large-scale studies of Bp genetic diversity to date have
analyzed strains using multilocus sequence typing (MLST). These
studies have suggested a high degree of genetic variability between
Bp strains and related Burkholderia species (Cheng et al. 2008), and
have shown that Bp strains belonging to different sequence types
(STs) can often coexist in the same locale and sometimes even
within the same sample (Pitt et al. 2007;Wuthiekanun et al. 2009).
However, due to the limited number of genes analyzed by MLST,
these studies cannot comment on the global proportion of genetic
material shared between strains of different STs nor on the relative
contribution of recombination, mutation, and horizontal gene
transfer on intraspecies genetic diversity. Moreover, although
previous studies have appliedwhole-genome sequencing (WGS) to
study global patterns of Bp genetic heterogeneity and evolution,
earlier BpWGS reports have been confined to a limited number of
isolates (10–12) derived from diverse geographical regions (Nandi
et al. 2010), where geophysical barriers likely limit the propensity
of the analyzed strains to exchange genetic material. To achieve
a comprehensive understanding of genetic variation among
closely related Bp strains, WGS analysis of much larger strain
panels, ideally performed on strains isolated from a common re-
gion and belonging to the same (or closely related) ST groups, is
required.
In this study, we attempted to fill this important knowledge
gap by performingWGS on 106 Bp strains drawn from a restricted
Asian locale (Singapore and Malaysia). The WGS data, exceeding
previous BpWGS studies by 10-fold, enabled us to identify specific
genomic clades of Bp, molecular features of Bp recombination at
the whole-genome level, and accessory genome features contrib-
uting to recombination and horizontal gene transfer. We found
a consistent pattern of genetic separation correlating with MLST,
recombination haplotypes, shared accessory genes, and restriction
modification (RM) systems. We provide evidence that restriction
modification, beyond its role as defense against foreign DNA in-
vasion,mayhave also partitioned the Bp species by restricting gene
flow, resulting in the other observed correlations. Because RM
systems are widely dispersed through the bacterial kingdom, it is
possible that similar principles may apply to other bacterial spe-




We analyzed 106 Bp strains, including 97 strains from Singapore
and Malaysia (87/10) and nine strains from Thailand (Supple-
mental Table S1). The Singaporean and Malaysian strains were
isolated from various clinical, animal, and environmental sources
over a 10 yr period (1996–2005) (see Methods). MLSTclassified the
strains into 22 sequence types (ST). Supporting their close phylo-
genetic relationships, 20 STs belonged to clonal complex CC48
(Supplemental Fig. S1A,B). The majority of strains were of ST51
(43 strains) and ST423 (16 strains).
Due to the high GC-bias of the Bp genome, we initially found
that conventional Illumina sequencing protocols resulted in un-
even genome coverage and suboptimal assemblies (median N50:
2907 bp) (Supplemental Table S2). We overcame this problem by
applying a PCR amplification-free strategy (Kozarewa et al. 2009),
resulting in markedly improved genome coverage and assemblies
(median depth 1003; median N50: 102,577 bp). In total, we pre-
dicted 84,846 high quality SNPs in the WGS panel compared to
the K96243 reference (Chr I: 43,829 and Chr II: 41,017). We vali-
dated the technical accuracy of the WGS data by Sanger sequenc-
ing of 50 randomly selected SNPs. Of the predicted SNPs, all
50 were confirmed by Sanger sequencing.
Whole-genome phylogenetic analysis resolves genomic clades
We excluded SNPs associated with regions of recombination as
previously described (Croucher et al. 2011), resulting in a set of
10,314 SNPs representing mutations inherited by vertical descent
along different lineages (‘‘lineage SNPs’’ [L-SNPs]). Maximum
likelihood phylogenies using the L-SNPs identified three major
clades (‘‘genomic clades’’) containing all the Singapore and
Malaysian strains, clustering apart from Thailand strains (Fig. 1A).
Strains of the same ST grouped together within the same genomic
clade, indicating strong similarities between phylogenies based on
WGS and MLST. However, compared to MLST, the WGS phyloge-
nies provided increased resolving power. For example, although
MLST indicated a high degree of relatedness between ST50 and
ST414 strains, WGS revealed that ST50 is more related to ST46
(Genomic Clade C), with ST414 being a more distant group (Fig.
1A). WGS also subdivided the ST51 strains into two distinct sub-
clades—ST51a (39 strains) and ST51b (four strains) (Fig. 1B)—
distinguished by ;342 distinct L-SNPs (Supplemental Table S3).
Notably, all three clades comprised a heterogeneous intermingling
of strains from different isolation sources (e.g., clinical, animal,
and environmental), arguing against the existence of a genetically
distinct Bp subpopulation preferentially associated with human
disease. The three clades also contained strains isolated during
similar time periods (1996–2005), suggesting that genetically dis-
tinct Bp strains fromdifferent clades can coexist in the same region
over many years.
L-SNPs occurred at a ;1.2-fold higher frequency on Chr II
compared to Chr I (6.1 3 103 SNPs per site for Chr I versus 7.5 3
103 for Chr II, P = 3.083 1014, x2 = 57.68, x2 test) (Supplemental
Table S4a), suggesting a preferential accumulation of genetic mu-
tations on Chr II during evolution. The majority of L-SNPs corre-
sponded to C/G! T/A transitions (Fig. 1C; for Clade ST51a), in the
context of CG dinucleotides (P = 33 1010, binomial test, Fig. 1D),
likely reflecting the tendency of methylated cytosines to form
thymines (Kahramanoglou et al. 2012). For both chromosomes,
L-SNPs preferentially localized to intergenic regions (Chr I: P < 2.23
1016, x2 = 101.42; Chr II: P = 4.1963 1014, x2 = 57.04, x2 test), and
one-third of L-SNPs occurring within genes were nonsynonymous
(Supplemental Table S4b). The dN/dS ratio (proportion of rate of
nonsynonymous substitutions per site to rate of synonymous sub-
stitutions per site) for the major STs (e.g., ST51a, ST84) ranged be-
tween 0.17 and 0.64 per genome. Similar resultswere obtainedwhen




Figure 1. Whole-genome phylogeny and sequence variation of Bp strains. (A) Global phylogeny of Bp strains. Themaximum likelihood treewas constructed
using SNPs not associated with recombination events (see Results). Tip labels are colored according to the geographic locations of isolation ([red] Singapore;
[green]Malaysia; [blue] Thailand; [black] unknown; [pink] imported toUK). Insetbars at right indicate theMLST scheme ([blue] ST51; [cyan] ST422; [red] ST423;
[dark green] ST84; [pink] ST289; [light green] ST46). Three major genomic clades are identified: Clade A (ST51, ST422, ST414, ST169, nST4); Clade B (ST423,
ST84, ST289, nST5); and Clade C (ST46, ST50). (B) Intra-ST subgroups resolved by WGS. ST51 strains cluster into two groups: ST51a and ST51b. Genomic
locations of 342 L-SNPs (including both intra- and intergenic SNPs) distinguishing ST51a and ST51b are shown. The top and bottom panels with four rows show
SNPs exclusively present in the twogroups ST51a+ST51b and ST51aST51b+, respectively. (C )Mutation spectra of ST51a: relative rates of six possiblemutation
categories. Themost commonmutations are C/G! T/A transitions. (D) Fraction of the three classes of cytosine mutations occurring at CG dinucleotides in the
Bp genome compared with the expected fraction based on the average of 100 simulated genomes of the same size and composition (gray).
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with the Bp ‘‘core’’ genome (regions common to all Bp strains,
estimated size 5.64 Mb) (Supplemental Table S5).
Widespread recombination among Bp isolates
Bp strains that are genetically distinct may interact within envi-
ronmental reservoirs such as soil or water (Chantratita et al. 2008;
Mayo et al. 2011) or in co-infected animals and human hosts (Pitt
et al. 2007), thereby providing opportunities for recombination.
Hence, it is vital to understand pathways and processes that facil-
itate or constrain gene flow between strains. To identify genomic
characteristics of Bp recombination, we proceeded to analyze SNPs
associated with recombination (R-SNPs). From 74,532 R-SNPs, we
identified 2373 recombination events across the three genomic
clades, with recombination tract lengths ranging from 3 bp to 71
kb (median ;5 kb). We computed recombination/mutation (r/m)
values, corresponding to the ratio of rates at which substitutions
are introduced by recombination and mutation, across the entire
population. The overall per site r/m ratiowas 7.2. Based upon these
data, we estimate that at least 78% of the BpK96243 reference ge-
nome (;5.67 Mb) has undergone recombination, a level compa-
rable to S. pneumoniae, a highly recombinogenic species (74K/85K
R-SNPs for Bp; 50K/57K R-SNPs for S. pneumoniae) (Croucher et al.
2011). Similar to L-SNPs, higher recombination levels were
observed for Chr II than Chr I (P < 2.2 3 1016, Mann-Whitney
U test),
Besides estimating whole-population metrics, we also com-
puted clade-specific recombination and mutation rates for the
three major Bp genomic clades, using a previously described
Bayesian approach (ClonalFrame) (Didelot and Falush 2007). To
minimize mapping artifacts, we excludedmobile genetic elements
(e.g., phages, transposons, and genomic islands) and based our
analysis on a reduced core genome of 5.6Mb (seeMethods). For all
three clades, the ratio of mutation rate (theta) to recombination
rate (rho) was close to one, suggesting that recombination and
mutation both happen at approximately the same rates. Re-
combination was also found to introduce more substitutions than
mutation (r/m = 4.5 in Clade A, r/m = 8.5 in Clade B, and r/m = 6 in
Clade C) with the highest impact observed in Clade B (Supple-
mental Table S6). These values are in general agreement with the
values obtained from the total population.
The high levels of recombination in the Bp clades motivated
us to also analyze potential sources of recombination imports. We
used previously establishedmethods to assess intra- and interclade
recombination flux (Didelot et al. 2009, 2011). Briefly, recombined
fragments were compared with homologous sequences from other
Bp genomes across the three clades, and a ‘‘match’’ was found if the
sequence was identical or contained a single nucleotide difference.
If amatchwas found tomembers of a single clade, the origin of the
recombination event was attributed to this clade (matches to
strains from multiple clades were categorized as ambiguous). If no
matches were found, the origin was categorized as unknown. To
estimate their relative impact on genomic diversification, the flux
of genomic content between clades was summarized as the pro-
portion of each genome originating from different origins. Of
2481, 821, and 334 recombination events detected within geno-
mic Clades A, B, and C, respectively, we could assign sources
(‘‘matches’’) for ;60% of recombination events (1112 matches to
single clades and 1059 matches to multiple clades). On average,
;5% of each genome from a given clade was found to have
originated from another clade and approximately another 7%
from a source not present in our data set (Supplemental Table S7).
Several of the interclade recombination events were found on re-
cent branches of the clonal genealogy, suggesting that the isolation
is not complete between the clades.
Genome-wide median recombination frequencies (RFs) were
computed to identify genomic regions exhibiting elevated recom-
bination rates and multiple recombination events (Fig. 2A). We
identified 1630 protein-coding genes (Chr I: 897 genes; Chr II: 733)
associated with regions of high recombination (RF > RFmedian +
3MAD, median absolute deviation). Genes experiencing high re-
combination frequencieswere significantly enriched in intracellular
trafficking and secretion pathways (corrected P = 0.0006, binomial
test), whereas genes involved in protein translation were under-
represented (corrected P = 0.012, binomial test) (Supplemental
Table S8). Examples of genomic regions exhibiting elevated recom-
bination included a Type III secretion cluster (TTSS3; BPSS1520–
BPSS1537) previously linked tomammalian virulence (Stevens et al.
2002), and a Type IVB pilus cluster (TFP8, Chr II: BPSS2185–
BPSS2198) (Fig. 2B). Type IV pili (TFP), including those of the sub-
type IVB, encode surface-associated protein complexes involved
in multiple cellular processes (Craig et al. 2004). To evaluate if TFP8
mightmodulate Bp virulence, we generated an isogenic Bp deletion
strain lacking;12.9 kb of the TFP8 locus and assessed the virulence
of the TFP8 mutant in a BALB/c mouse intranasal infection assay.
The TFP8 deletionmutant exhibited significantly reduced virulence
compared to parental Bp K96243 wild-type controls (P = 0.026,
Mantel-Haenszel log-rank test, Fig. 2C). These results support a role
for Type IVB pili in Bp murine virulence, and more generally that
a subset of recombination hotspots in Bp may influence mamma-
lian virulence.
Genome-wide recombination haplotype map of Bp
Extended genomic stretches with high recombination rates often
displayed specific combinations of local independent recombina-
tion events in individual strains, resulting in the creation of dis-
tinct haplotypes. Using the TFP8 gene cluster as an example, some
strains displayed recombination events R2, R7, and R8 (Haplotype
1 [H1]), whereas other strains displayed events R3, R7, and R8
(Haplotype 2 [H2]). In total, we identified five haplotypes (H1–H5)
in the TFP8 gene cluster (Supplemental Table S9). We found that
these five TFP8 haplotypes were tightly associated with specific
clades; for example, haplotype H1 was associated with ST51
strains, whereas haplotype H4 (corresponding to recombination
event R4) was associated with ST84 strains (Fig. 2D). To evaluate
this association at the whole-genome level, we generated a whole-
genome haplotype map of Bp, identifying 85 genomic regions
exhibiting multiple (five or more) haplotypes (Supplemental
Table S10). Similar to TFP8, the vast majority of haplotypes oc-
curred in a genomic-clade specific pattern (Supplemental Fig. S2).
Many of the multi-haplotype genomic regions were involved
in specialized functions such as iron and cofactor metabolism,
detoxification, and virulence (Supplemental Table S10). Almost
half (48%) of the multiple-haplotype genomic regions exhib-
ited at least one haplotype with an excess of nonsynonymous
to synonymous SNPs, consistent with these regions having
altered phenotypic properties. For instance, one haplotype over-
represented in nonsynonymous SNPs occurred in the virulence-
associated TFP1 locus (BPSL0782-BPSL0783), within the pilA gene
in ST51a strains. Notably, pilA plays a role in virulence yet its
role in adherence andmicrocolony formation varies considerably
in different Bp strains (Essex-Lopresti et al. 2005; Boddey et al.




contribute to differences in Bp pathogenicity or survival in dif-
ferent strains.
Bp accessory genome elements exhibit clade restriction
The availability of WGS data for a large Bp panel also provided the
opportunity to quantitatively assess the Bp accessory genome.
Using the Velvet and NUCmer algorithms, we generated de novo
sequence assemblies of genomic sequences not found in the
K96243 reference genome.On average,;183 kb of novel accessory
regions (NAE) were identified for each Bp strain (minimum region
length 1 kb). We found that the Bp genome is ‘‘open,’’ with at least
2897 newnon-K96243 genes associated with the accessory regions
(Fig. 3A). The Bp pan genome (Bp core + Bp accessory) is thus at
least 8802 genes, which is 23 the size of the Bp core genome.
Accessory genes were characterized by a lower percentage GC
content (median value: ;59% 6 5.6) than the core genome
(;68%), consistent with their horizontally acquired nature. Ac-
cessory genes were also significantly enriched in pathways related
to defense mechanisms (corrected P < 0.0005 relative to Bp core
genes) (Fig. 3B).
Using pairwise similarity metrics, we evaluated the extent to
which accessory elements found in one Bp strain might be shared
with other strains. Similar to the recombination haplotypes,
strains belonging to the same genomic clade had a tendency to
share many of the same accessory elements (Fig. 3C). For example,
strains in genomicClade A shared a 15-kb gene cluster ofmetabolic
genes, including biotin carboxylase, NAD-dependent malic en-
zymes, mandelate racemase, and 5-enolpyruvylshikimate-3-phos-
phate synthase (Priestman et al. 2005; Tang et al. 2005; Li et al.
2009). Similarly, strains from genomic Clade B (ST423/ST84/
ST289) shared accessory genes such as filamentous hemaggluti-
nin, fhaC, which plays a crucial role in mediating adherence to
eukaryotic cells (Relman et al. 1989).
Figure 2. Recombination landscape of Bp. (A) Recombination hotspots in Bp. Circles: (outside) genome coordinates; (middle) compositionally biased
regions identified by Alien hunter (Vernikos and Parkhill 2006) (green) and Bp core genome (violet); (innermost) regions of elevated recombination (height
of red bars). Note that recombination levels are higher on Chr II than Chr I. Location of the TFP8 and TTSS3 clusters are indicated. (B) Local recombination
events in the Type III secretion system and Type IVB pilus cluster. (Top) Genomic coordinates and location of protein-coding genes; (dark blue) predicted
recombination events (R1 to Rn, n = number of recombination events) observed in Bp strains belonging to genomic clades (ST group 46, 51, 84, 289, 422,
and 423). The recombination boundaries are indicated by the dark blue circles and the boundaries that fall beyond the depicted locus are shown as open
ended. (C ) Relative virulence of TFP8 deletion mutant. Graphs show survival curves of BALB/c mice following intranasal challenge with varying dosages of
Bp (left: K96243 wild-type; right: TFP8 deletion mutant, units are colony forming units, CFU). See Methods for infection assay details. The TFP8 deletion
mutant is significantly less virulent compared to Bp K96243 parental controls (P = 0.026, Mantel-Haenszel log rank test). (D) Distinct haplotypes at the
TFP8 genomic locus. Each row represents an individual Bp strain arranged according to genomic clade/ST (shown on left with color bars indicating ST51
[blue]; ST422 [cyan]; ST423 [red]; ST84 [dark green]; and ST46 [light green]). Across each row (strain), SNP positions are ordered by genomic coordinate
(top numbers, Bp Chr II, genomic locus 2,935,860–2,976,718), and color-coded according to nucleotide identity (A! green; T! blue; C! orange; and
G! red). The right y-axis ‘‘Haplotypes’’ refers to the specific linear combination of SNPs exhibited by individual strains. In some cases, haplotypes can be
composed of a specific combination of smaller recombination regions (R). For example, Haplotype H1 is composed of recombination regions R2, R7, and
R8. Haplotype alignments were generated using Clustal X (Larkin et al. 2007).
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Evidence of ongoing recombination and gene exchange
within clades
The analyses described above revealed a strong correlation be-
tween Bp clades, core genome recombination haplotypes, and
complements of accessory elements. We hypothesized that these
correlations could be explained by two alternative models—‘‘on-
going recombination’’ or ‘‘vertical descent’’ (Fig. 4A). In the first
model, active recombination is ongoing in Bp, but preferentially
restricted to exchange of DNA within a clade. To test for ongoing
recombination, we computed within-clade nucleotide divergence
levels inDNA sequences predicted to have undergone recombination
and compared these to divergence levels within regions of non-
recombined DNA in strains exhibiting the recombination event. If
recombination were ongoing among strains within a clade, then
this would serve to homogenize the recombining sequences across
strains, whereas nonrecombining regions would accumulate mu-
tations independently in different strains (Fig. 4A, ‘‘Ongoing Re-
combination’’). Thus, the within-clade nucleotide divergence of
recombined regions would be predicted to be lower relative to
nonrecombined regions. In the alternative model, recombination
is not commonly taking place. Here, recombined regions would
have entered a clade in its founder, and then would be found
throughout the clade due mostly to strict vertical descent (Fig. 4A,
‘‘Vertical Descent’’). In this case, recombined regions would be
predicted to accumulate mutations at the same rate as non-
recombined regions.
For each recombined region in a clade, we calculated the av-
erage sequence divergence level in that region, using strains
exhibiting the recombination event (see Supplemental Fig. S3 and
Supplemental Text for a detailed description of this analysis). To
obtain a conservative set of nonrecombined sequences for com-
parison, we then took only those sections of the Bp genome pre-
dicted not to have undergone any recombination in any of the Bp
strains; and for the same strains we calculated the sequence di-
vergence levels in these nonrecombined sequences.We found that
recombined regions in the core genome had uniformly lower se-
quence divergence than nonrecombined regions (Fig. 4B), sug-
gesting that recombination is active and ongoing within clades.
Figure 3. Accessory genome landscape of Bp. (A) Accumulation curves for Bp novel accessory genes (blue). Vertical bars represent standard deviation
values based upon 100 randomized input orders of different Bp STs. The total number of accessory genes is indicated by the red dotted line. (B) Functional
enrichment of Bp accessory genes. COG functional categories are indicated on the y-axis, and the percentage of genes in each COG category is shown on
the x-axis. Dark blue columns represent novel accessory genes, and light blue columns indicate all Bp core genes with COG annotations. COG categories
exhibiting a significant enrichment among the Bp accessory genes are highlighted by asterisks ([*] P < 0.0005, binomial test; after Bonferroni correction).
The COG category ‘‘DNA replication, recombination and repair’’ was excluded as it was represented mainly by mobility genes, particularly transposases
and integrases. (C ) Distribution of accessory elements across Bp clades. The heatmap represents an all-pairwise strain comparison showing the degree of
accessory element overlap between pairs of strains. Strains are arranged on the x- and y-axis according to their genomic clades and sequence types (ST51
[blue]; ST289 [pink]; ST422 [cyan]; ST423 [red]; ST84 [dark green]; and ST46 [light green]). The color scale bar at the bottom indicates the degree of
accessory element sharing (more blue equates to increased sharing). The right-hand chart depicts the different types of restriction-modification (RM)
systems associated with different clades. In each column, the RM systems are color-coded based on their encoded protein-coding sequences. In the first




Figure 4. Distinguishing between ongoing recombination and vertical descent and in Bp. (A) Alternative models for clade-specific recombination haplotypes.
(Left) In the ‘‘Ongoing Recombination’’ model, an imported fragment sweeps through the population via recombination, resulting in homogenization of the
recombining fragment across strains. The recombining fragment should show lower levels of sequence diversity compared to nonimported regions. (Right) In the
‘‘Vertical Descent’’ model, an ancestral strain acquires a genomic fragment (yellow) from an external strain and subsequently transmits that fragment to all daughter
strains in a clonal fashion. In this model, the imported fragment should accumulate new point mutations (green bars) at a similar rate to nonimported regions. (B)
Within-clade sequence diversity of recombined regions compared to nonrecombined regions. Scatter plots comparing within-clade sequence diversity values of
individual recombined regions (x-axis) to nonrecombined regions (y-axis) for the same strains in a given clade. Sequencediversity decreases in the direction of the red
arrows (to right and upward). (*) Data points highlighted by the red bar correspond to recombined regions exhibiting 100% sequence identity. To visualize these
points in amanner that capturesboth their density andextremely low sequencediversity, thesewereplottedwithin the x-axis rangeof 6.9–7.6onanegative log scale.
Sequence diversity is defined as the number of SNPs per kb. (C ) Sequence features of nonrecombined regions (NR), recombined regions (R), and accessory elements
(AE). (Top) BpK96243genomic tracks ofChr I andChr II. Row1:Genomic locations of recombined regions (red). Row2:Genomic locations of 16knownBpgenomic
islands (gray). (Bottom) Sequence feature comparisonofgenes innonrecombined (white;NR), recombined (red; R), andaccessoryelements (gray;AE): (i)GCcontent
(Puigbo et al. 2008); (ii) effective codon number (Puigbo et al. 2008); and (iii) sequence complexity (Pietrokovski et al. 1990). Each hourglass plot spans the 25th to
75th percentile (interquartile range [IQR]) of all genes in that category,with the bottleneck at themedian.Horizontal tickmarks showdata rangeswithin 1.53 IQRof
the 25th and 75th percentiles. Open circles represent outliers outside this range. Thewidth of the bottleneck (i.e., the length of the V-shaped notch) depicts the 95%
confidence interval for themedian. (D)Within-clade sequencediversity of accessory elements compared tononaccessory elements. Accessory elements are defined as
regionsnotpresent in theBpK96243 reference strain (seeMethods). Scatter plots compare average sequencediversity values for individual accessoryelements (x-axis)
to corresponding nonaccessory elements (y-axis) for the same strain pairs in a given clade. Sequence diversity is defined as the number of SNPs per kb.
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Extending this analysis to the gene level, we found that re-
combination has opposite effects on within- and between-clade
divergence; genes in recombined regions had higher between-
clade diversity comparedwith genes in nonrecombined regions, as
expected, but much lower within-clade diversity (Supplemental
Fig. S4). To rule out the possibility that the lower sequence di-
vergence in recombined regions might be due to recombined re-
gions possessing different sequence features or gene functions
than nonrecombined regions (despite both regions being part of
the same core genome), we also compared GC content, effective
codonnumber, sequence complexity, andCOG functions between
the recombined regions, nonrecombined regions, and accessory
elements. The latter was included because accessory elements are
known to be distinct in gene function and sequence characteristics
from the core genome (Kung et al. 2010). We found recombined
and nonrecombined regions to be highly similar and distinct from
accessory elements (Fig. 4C). For example, nucleotide frequencies
between recombined and nonrecombined regions were similar
(Chr I: x2 = 0.0012, P-value = 1; Chr II: x2 = 2 3 104, P-value = 1,
x2 test) (Supplemental Table S11), and COG analysis of all genes
associated with recombination regions failed to reveal any signif-
icantly enriched biological pathways compared to the whole ge-
nome (Supplemental Table S12), indicating that general baseline
recombination in Bp is not functionally selected.
Besides recombination in the core genome, the correlation
between Bp clades and complements of accessory elements sug-
gested a further test for whether recombination is ongoing in Bp.
Similar to the logic for the core recombined sequences above, ac-
cessory elements that are pervasive throughout a given clade could
be undergoing active, ongoing exchange (which would homoge-
nize their sequence within the clade) or be inherited through
vertical descent (and thus accumulate mutations similar to adja-
cent nonrecombining regions) (Fig. 4A). Both these possibilities
are consistent with clade-specific complements of accessory ele-
ments (Fig. 3C). We found that within each clade, accessory ele-
ments also showed lower sequence divergence levels compared to
nonaccessory elements in the same strains (Fig. 4D). Thus, these
results suggest that in both the core and accessory genome, there is
a strong signal for ongoing, active recombinationwithin Bp clades.
Identification of clade-specific RM systems
The clade-specific pattern of haplotypes and accessory elements in
Bp, coupled with evidence of ongoing gene flow within strains of
the same clade, suggests that reciprocal barriers to gene exchange
may exist between strains belonging to different clades. We hy-
pothesized that these barriers might be due, at least in part, to the
use of distinct restriction-modification (RM) systems in each clade.
RM systems comprise different combinations of endonuclease,
methylase, and DNA specificity domains that use specific meth-
ylation patterns to label endogenous ‘‘self’’ genomicDNA, whereas
unmodified exogenous DNA is recognized as ‘‘non-self’’ and sub-
sequently cleaved and destroyed (Ershova et al. 2012; Makarova
et al. 2013). Studies have proposed that RM systems can act as
barriers to horizontal gene transfer (Waldron and Lindsay 2006;
Hoskisson and Smith 2007; Dwivedi et al. 2013). However, a role
for RM systems in restricting intraspecies recombination is less well
described (Waldron and Lindsay 2006).
By interrogating genes in the Bp accessory genome and mo-
bile genetic elements, we identified four different Bp RM systems
(I, II, III, and IV) (Roberts et al. 2007). Notably, specific sets of RM
systems were found in association with genomic clades bearing
distinct haplotypes and accessory genome features. For example,
although clearly related by lineage (Fig. 1), clades ST51 and ST422
exhibit different recombination patterns and sets of accessory ele-
ments: We found that ST51 strains contained RM Type IIGC genes,
whereas ST422 strains harbored both RMType IIGC and RMType IC
systems. Similarly, strains from genomic Clade B (ST423/ST84/
ST289) were largely dominated by RM Type IC and Type IBC sys-
tems,with type III RMgenes additionallypresent in ST84 strains (Fig.
3C). The presence of these clade and ST-specific RM systems, which
are predicted to result in clade-specific patterns of DNAmethylation,
may provide a molecular barrier to interclade gene sharing.
Methylome sequencing reveals clade-specific epigenetic
profiles
To provide direct experimental data that Bp strains from different
clades have distinct methylation profiles, we subjected one repre-
sentative strain from Clade A (Bp35) and one strain from Clade B
(Bp33) to whole-genome methylome analysis using SMRT se-
quencing technology (Murray et al. 2012). Because SMRT se-
quencing has the ability to measure DNA polymerase activity in
real time, base modifications such as methylation can be detected
as a change in the kinetics of base pair incorporation (Flusberg et al.
2010; Schadt et al. 2010).
SMRTsequencing followed by de novo assembly for Bp33 and
Bp35 was performed to obtain two circular contigs of 4.0 and 3.1
Mb (average GC content is 68%) with 2403 and 1473 post-filter
base coverage, 213 and 223 preassembled read coverage, re-
spectively (Chin et al. 2013). We identified a 12.4-kb plasmid in
Bp35 called pBp35 that to our knowledge represents the first
plasmid described for Bp (Supplemental Fig. S5; Supplemental
Data: plasmid sequence and annotation in GenBank format). We
analyzed the local sequence contexts for all the methylated bases
in both the strains and identified sequence motifs associated with
these methylated bases. Both Bp strains showed methylation
throughout their entire genomes. In total, six unique methylated
motifs were identified in the two Bp strains (Table 1). Of these, one
motif (59-CACAG-39) was shared by the two strains, whereas the
other five were strain- or clade-specific. For example, the type II
motif (59-GTAWAC-39) is unique to Bp35 (Clade A representative),
whereas the type I motif (59-GTCATN5TGG-39) is present only in
Bp33 (Clade B representative).
We proceeded to match the different motifs to specific RM
systems found in the two genomes. Reassuringly, the shared CACAG
motifwas found to be associatedwith a conservedType III RMsystem
found in both strains. However, Bp 35 exhibited three strain-specific
methylated motifs, and these could be associated with Type I and II
systems found specifically in the Bp35 clade. Similarly, Bp 33
exhibited two strain-specific methylated motifs, and these could be
associated with Type I RM systems found specifically in the Bp33
clade. For both strains, the fraction of strain-specific methylated
motifs was close to 100%, consistent with their predicted methyla-
tion and restriction functions operating at high efficiency (Table 1).
The demonstration that strains belonging to different Bp clades in-
deed have distinct methylation patterns is consistent with our hy-
pothesis that clade-specific RM activity may represent a barrier to Bp
interclade recombination and accessory element transfer.
Bp RM systems impede foreign DNA uptake in E. coli
To functionally test if clade-specific RM systems of Bp can impede




system associated with Genomic Clade A (Bp33) in E. coli ( Janscak
et al. 1999; Kasarjian et al. 2003). We engineered one plasmid to
carry the Type I ‘‘restriction’’ endonuclease (R+), and a second
separate plasmid to carry the ‘‘specificity’’ and ‘‘methylase’’ pro-
teins (M+) (Fig. 5A). M+R+ and M+R E. coli strains were then sec-
ondarily transformed with reporter plasmids carrying zero, one,
and two copies of the RM recognition site predicted from SMRT
sequencing (59-GTCATN5TGG-39; see Table 1), and efficiencies of
transformation (EOT) were calculated (Fig. 5B). We found that
when transformed into M+R+ strains, unmethylated reporter
plasmids carrying one or two recognition sites exhibited a > 100-
fold decrease in EOT compared to reporter plasmids with no rec-
ognition sites (P < 0.01; Student’s t-test) (Fig. 5C). Importantly, the
Type I restriction endonuclease is required for this decrease, as no
EOT differences were observed when the plasmids (zero, one, and
two sites) were transformed into M+R strains which only express
the methylase (Fig. 5C). This result indicates that the restriction
endonuclease of the Clade A-specific Type I RM system is indeed
active and capable of impeding the uptake of non-self DNA har-
boring an unmethylated Type I recognition site.
Next, we isolated plasmids with methylated recognition sites
by passaging them through M+R E.coli strains and transformed
them into M+R+ strains. In contrast to the results using un-
methylated plasmids, all three plasmids (zero, one, or two recog-
nition sites) exhibited no significant EOT differences (Fig. 5D).
This result indicates that, at least for one Bp clade-specific RM
system, methylation of the recognition sites by RM methylases is
sufficient to facilitate uptake of non-self DNA, even in the presence
of its cognate restriction endonuclease.
Discussion
In this study, we performed WGS on a panel of Bp strains drawn
from a restricted geographic locale to explore the contribution of
genemutation, recombination, and horizontal gene transfer to the
molecular diversity of closely related Bp isolates. We found that Bp
strains can be partitioned into distinct genomic clades and that
a major proportion of the Bp core genome variation is strongly
influenced by both mutation and recombination. Bp diversity is
further enhanced by an accessory genome component that is at
least double the Bp core genome. Moreover, using diverse ap-
proaches, including (1) sequence diversity comparisons in both
recombination and accessory regions supporting active gene
flow within but not across clades; (2) genome-wide methylome
sequencing demonstrating clade-specific epigenetic profiles asso-
ciated with distinct RM-systems; and (3) experimental demon-
stration in an E. coli system that Bp RM systems are functionally
active and sufficient to mediate the methylation and restriction of
non-self DNA, our results point toward a model in which Bp RM
systems may function as a barrier to gene exchange between dif-
ferent Bp clades.
Phylogenetic analysis of the Bp clades revealed that they
comprised mixtures of Bp isolates from animal, clinical, and en-
vironmental sources, arguing against the existence of a genetically
distinct population of Bp capable of infecting humans. Supporting
this model, in a separate analysis, we were unable to confidently
identify a consistent set of signature genetic changes in strains
associated with human disease (T Nandi and P Tan, unpubl.). The
genetic similarity between clinical, animal, and environmental Bp
strains raises the possibility that additional genetic changesmay not
be required for an environmental Bp strain to successfully cause
human disease. This model is consistent with previous proposals
that Bp is an ‘‘accidental pathogen,’’ inwhich adaptations incurred
by Bp to survive in its natural reservoir (soil and potentially single-
celled organisms located therein, e.g., amoebae) must have in-
directly contributed to its ability to colonize a mammalian host
(Casadevall and Pirofski 2007; Nandi et al. 2010). This ‘‘accidental
virulence’’ hypothesis is further supported by epidemiological data
in which patients with clinical melioidosis often possess pre-in-
fection morbidities such as diabetes, which may contribute to
a weakened host immune response (Currie et al. 2010).
Our data revealed several genome-wide features of the Bp re-
combination landscape. We found that recombination in Bp is
pervasive, approaching levels previously reported for S. pneumonia
(Croucher et al. 2011), and frequently involved defined sets of
haplotypes. Importantly, analysis of genes in regions associated
with high recombination suggests that haplotypes and re-
combination hotspots in Bp are not randomly distributed, but
biased toward genomic regions associated with niche adaption,
survival, and virulence. This included a TTSS cluster involved in




















m6A 3086 3082 99.87 — — This study
Type II 59-GTAWAC-39
39-CATWTG-59
m6A 1152 1141 99.05 — — This study
59-CAGN6CTG-39
39-GTCN6GAC-59
m6A 5214 5197 99.67 — — This study




m6A 86 86 100 — — This study
59-GTCATN5TGG-39
39-CAGTAN5ACC-59
m6A 211 210 99.53 — — This study
Type III 59-CACAG-39 m6A 5214 5197 99.67 BceJI BURCENBC7_AP5195 REBASE
aThe methylated position within the motif is highlighted in bold. Pairs of reverse-complementary motifs belonging to the same recognition sequence
were grouped together.
bThe total number includes motifs occurring on both the ‘‘+’’ and ‘‘’’ strands.
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intracellular survival of Bp and virulence (Stevens et al. 2002) and
a type IVB pilus cluster (TFP8) that we have validated in this study
as required for maximal virulence in murine infection assays. It is
thus possible that the other regions of high recombination iden-
tified in this study may contain additional genes involved in Bp
adaptation, survival, and virulence.
Previous studies have shown that strains of different STs can
be frequently co-isolated in the wild (Wuthiekanun et al. 2009).
However, it is not known if such co-isolated strains are able to
engage in an unrestricted exchange and transfer of genetic mate-
rial. We found that strains associated with different Bp genomic
clades tended to exhibit distinct sets of recombination haplotypes
Figure 5. Restriction of non-self DNA by clade-specific Bp RM systems. (A) Molecular cloning of a Type I RM system specific to Bp genomic Clade A. The
RM system comprises three genes: (R) ‘‘restriction,’’ (M) ‘‘methylase,’’ (S) ‘‘specificity.’’ Genes S (yellow) and M (blue) were cloned in plasmid pSLC-279
with kanamycin resistance (KmR) to give the M+ plasmid. Gene R (red) was cloned in plasmid pSLC-280 with ampicillin resistance (ApR) to give the R+
plasmid. Resistance genes are depicted in cyan. Green arrows represent the T5 promoter used to induce expression of the cloned genes. Plasmids are not
drawn to scale. (B) Efficiency of transformation (EOT) assay. Reporter plasmids p0, p1, and p2 harbor zero, one, and two copies of the predicted Type I
recognition site (59-GTCATN5TGG-39; indicated by green triangles). Plasmid p0 should not show any EOT changes because it does not contain Type I
recognition sequences. Unmethylated plasmids p1 and p2, when transformed intoM+R+ strains, should be recognized via their Type I sites and cleaved by
the Type I restriction enzyme (registered as a drop in number of transformants). However, when transformed into M+R strains that express the meth-
yltransferase alone, no EOT differences should be observed. In contrast, methylated p1 and p2 plasmids (obtained by passage through M+R strains;
methylated sites indicated by red stars and superscript m), when transformed into M+R+ strains, should be recognized as ‘‘self’’ DNA by the Type I system
and resist cleavage, resulting in minimal EOT changes. (C ) EOT assay results using unmethylated plasmids. Host strains are MG1655 (MR, no RM
system, cyan); SLC-623 (M+R+, complete RM system, red); and SLC-621 (M+R, methyltransferase only, green). Reporter plasmids are pACYC184 (p0,
control plasmid); pSLC-277 (p1, 1 recognition site); and pSLC-278 (p2, 2 recognition sites). Significant differences in EOT are observed between
control plasmid p0 and plasmids p1 and p2 when transformed into M+R+ strains (P < 0.01) but not in host E. coli or M+R strains. EOT in this study is the
normalized number of CmR transformants obtained per unit amount of plasmid DNA. (D) EOT assay usingmethylated plasmids. Reporter plasmids were
passaged through M+R strains prior to transformation, which is predicted to cause recognition site methylation. No significant EOT differences are
observed across the strains. All experiments were performed in triplicate, and data are presented as mean and standard deviations. Data are presented




and accessory elements. These findings suggest that Bp clade/ST
subgroupsmay represent a functional and potentially limiting unit
of within-species genetic diversity. However, it is important to note
that although our findings suggest a general scenario of recom-
bination events being largely clade-specific, exceptions do exist.
One example of a possible recombination across separate clades
involved a heme/porphyrin locus (BPSS1245–BPSS1247), where
a haplotype present in strain P171/04 from ST84 (but not other
ST84 strains) was highly similar to the haplotypes of ST51 strains
(Supplemental Fig. S6). One explanation for these exceptions is
that although barriers to interclade gene exchange do exist, they
may be incomplete or perhaps only recently established.
Two broad models of Bp evolution could explain this clade-
restriction pattern. First, clade restriction might result from effec-
tive physical or niche separation, in which strains from different
clades are adapted or restricted to distinct niches in the environ-
ment, and therefore do not share DNA. However, as mentioned
above, strains of different STs can be co-isolated; and while this
does not rule out the presence of microscale niche differences be-
tween strains, such ‘‘micro-niches’’ remain to be experimentally
proven. Alternatively, the discovery of clade-specific RM systems
provides an epigenetic explanation for Bp clade restriction. In this
model, acquisition of a diversity of RM systems to combat invading
DNAmay thus have occurred as a primary event, and the resulting
epigenetic differences may in turn have established barriers to
intraclade DNA exchange. A synthesis of these two models is also
possible, where early subspeciation is initially driven by epigenetic
barriers and followed subsequently by traditional niche selection.
Consistent with this model, we observed that among ST84 strains,
the two Malaysian Bp strains, EY2 and EY5, clustered separately
from the remaining seven Singapore strains, being separated by
13 L-SNPs mapping to 12 protein-coding genes. This scenario
could be explained by initial RM-driven epigenetic isolation of the
ST84 clade, followed by geographical separation between the Sin-
gapore and Malaysian ST84 strains. The presence of localized
concentrations of nonsynonymous changes suggests the possible
existence of specific selective pressures driving further divergence,
and it is also possible that the driver for speciation in Bp is cur-
rently shifting from divergence due to genetic/epigenetic separa-
tion to divergence due to selection in different niches. As such, our
results provide a potential snapshot of early incipient speciation in
a microorganism associated with diverse genomes and habitats.
Methods
Ethics statement
This research was approved by the GIS Institutional Review Board.
Animal studies were performed in accordance with the UK Scien-
tific Procedures Act (Animals) (1986) and UK Codes of Practice for
the Housing and Care of Animals Used in Scientific Procedures
(1989).
Bacterial strains, plasmids, and primers
Strains used were obtained from DMERI, DSO National Labora-
tories. These include (1) 56 clinical isolates from melioidosis pa-
tients between 1996 and 2004; (2) 34 animal isolates from various
species (e.g., monkeys, pigs, birds, and dogs) diagnosed with
melioidosis between 1996 and 2005; and (3) 16 soil isolates from
1996 to 2000 (Supplemental Table S1). The isolates were sampled
from a diversity of locations and not a single site (AL Tin, pers.
comm.). For E. coli experiments, plasmids bearing predicted
recognition sequences for the Clade A-specific Type I RM system
(59-GTCATN5TGG-39) were generated by PCR-mediated insertion
(see Supplemental Methods). Gene sequences encoding the Bp33
Type I restriction modification system proteins (‘‘specificity,’’
‘‘methylase,’’ and ‘‘restriction endonuclease’’) were cloned into
expression vectors driven by a T5 inducible promoter (DNA2.0,
Singapore). All plasmids were propagated in E. coli K12 strain
MG1655. Bacterial strains, plasmids, and primers are listed in
Supplemental Table S13.
Genomic DNA extraction and multiplex sequencing
Live bacteria were grown in a BioSafety Level 3 facility in DSO
National Laboratories. Genomic DNA was extracted using the
Qiagen Genomic Tip 500/G kit (Qiagen). Unique index-tagged li-
braries for each sample were created, and up to 33 separate libraries
were sequenced per lane on an Illumina HiSeq instrument with
100 base paired-end reads. Libraries were constructed using an
amplification-free method (Kozarewa et al. 2009). Raw Illumina
data were split to generate paired-end reads, and assembled using
a de novo genome-assembly program, Velvet v0.7.03 (Zerbino and
Birney 2008), to generate a multicontig draft genome for each Bp
isolate.
Gene annotation, SNP, and phylogenetic analysis
Paired-end reads were mapped against the chromosomes of
B. pseudomallei K96243 (accession numbers BX571965 and
BX571965) (Holden et al. 2004). Bp genes were predicted using
FGENESB (http://www.softberry.com). Gene orthologs were de-
termined using OrthoMCL (Chen et al. 2006). RM systems were
inferred based on the specificity sequences of homologs in REBASE
(Roberts et al. 2007) and categorized into subtypes—IC, IBC, IIG,
IIGC, IIP, and IIB—on the basis of their genetic organization,mode
of action, recognition sites, and cleavage loci (Roberts et al. 2003).
SNPs predicted to have arisen by homologous recombination were
identified using Gubbins and excluded from phylogenetic re-
construction (Croucher et al. 2011). Indels were identified using
Dindel (Albers et al. 2011). Maximum likelihood phylogenies were
constructed using RAxML v0.7.4 (Stamatakis et al. 2005). SNPs
ancestral and derived alleles (polarization) were determined
according to the outgroup reference strain sequence.
Recombination analysis
The general time-reversible model with gamma correction was
used for among-site rate variation for 10 initial random trees. To
measure clade-specific recombination rates, ClonalFrame (Didelot
and Falush 2007) was applied separately to each Bp clade. To re-
duce mapping artifacts, we focused on the 5.6-Mb portion of the
core genome that excludes mobile genetic elements and other
potentially biased regions such as surface polysaccharides, secre-
tion systems, and tandem repeats. Recombination events were
extracted from ClonalFrame as genomic fragments, where the
probability of recombination for a given branch of the tree was
consistently > 50% and reached 95% in at least one location. Po-
tential origins of recombination imports were investigated as
previously described (Didelot et al. 2009, 2011; Sheppard et al.
2013). To determine haplotypes, SNP alleles at the recombination
loci were concatenated to give a single haplotype string for each
strain. The aligned strings were then subjected to hierarchical
clustering as implemented in R package ‘‘hclust.’’ The resulting
dendrogramwas used to assign strains to distinct haplotype groups
using the ‘‘cutree’’ function in R. Within-clade sequence diversity
comparisons between recombined and nonrecombined regions
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were performed as described in Supplemental Figure S3 and the
Supplemental Text. Potential differences in sequence composition
between recombined and nonrecombined regions were assessed
using Artemis release 13.0 (Carver et al. 2012) or the K2 algorithm
in CLC Main workbench 6.5 (http://www.clcbio.com) (Wootton
and Federhen 1993).
Bp mutagenesis and mouse virulence studies
Isogenic Bp mutants carrying a 12.9-kb deletion TFP8 were gener-
ated in a two-step process as previously described (see Supplemental
Methods; Essex-Lopresti et al. 2005; Boddey et al. 2006). Virulence
of wild-type andmutant Bp strains was assessed using an intranasal
BALB/c mouse model (Essex-Lopresti et al. 2005). Briefly, groups of
six age-matchedBALB/c femalemicewere anesthetized and infected
intranasally with 10-fold dilutions (101–106) of either wild-type Bp
K96243 or TFP8 deletion strains grown overnight at 37°C with
shaking. Mice were recovered, and survival was recorded for up to
51 d. Analysis was performed using the Mantel-Haenszel log rank
test inGraphPad Prism 4 or by Regressionwith LifeData inMiniTAB
v13.0, using a significance threshold of P = 0.05.
Accessory genome analysis
Nucmer (Kurtz et al. 2004)was used to generate alignments ofVelvet
contigs against the reference strain Bp K96243 to identify novel
accessory regions (NAE). NAE values for individual Bp strains were
defined as blocks with aminimal 1000-bp length that was absent in
BpK96243 (medianNAEper strain = 183,482 bp). Sequence diversity
comparisons between accessory and nonaccessory regions utilized
accessory regions > 1000 bp and performed using MUMmer 3.20
under DNAdiff default settings (Kurtz et al. 2004).
SMRT sequencing and data analysis
Twenty micrograms of gDNA was processed to create SMRTbell
sequencing templates > 10 kb (average insert size 17 kb) and
sequenced using a PacBio RS II System in which polymerase-
MagBead-bound templates were loaded at an on-plate concentra-
tion of 150 pM. Templates were subsequently sequenced using
DNA Sequencing Kit 2.0, with data collection of 180 mins
(Pacific Biosciences). Genomes were assembled using HGAP (Chin
et al. 2013) with default parameters in SMRTAnalysis Suite version
2.1 (Pacific Biosciences). Additional manual assembly of contigs
was carried out in cases of unique overlapping sequence. Con-
sensus sequence polishing was done using the Quiver algorithm in
Genomic Consensus version 0.7.0. Base modification analysis was
performed by mapping SMRT sequencing reads to the respective
assemblies using the BLASR mapper (Chaisson and Tesler 2012)
and SMRT Analysis Suite version 2.1 using standard mapping
protocols. Clustering of sequence motifs was performed using
Motif Finder (https://github.com/PacificBiosciences/DevNet/wiki/
Motiffinder). See Supplemental Methods for further details.
Restriction-modification assay
Plasmids containing methylated and unmethylated Type I re-
striction sites were transformed into E. coli strains engineered to
express all three proteins of the Type I RM system or only the
specificity andmethylase units. Efficiency of transformation (EOT)
values were computed by comparing bacterial titers (colony
forming units per mL, cfu/mL) on antibiotic selection plates di-
vided by the corresponding titers from LB plates. EOT values were
log transformed and plotted for analysis of RM system restriction
activity. EOT values from triplicate experiments were compared
using a two-tailed Student’s t-test. See Supplemental Methods for
further details.
Statistical analysis
All statistical analyses were performed using R-2.15.1 (Ihaka and
Gentleman 1996).
Data access
The data from this study have been submitted to the European
Nucleotide Archive (ENA; http://www.ebi.ac.uk/ena) under acces-
sion number ERP000251. Methylation data have been submitted
to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.
nlm.nih.gov/geo/) under accession number GSE55168.
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ABSTRACT
Creation of defined genetic mutations is a power-
ful method for dissecting mechanisms of bacterial
disease; however, many genetic tools are only devel-
oped for laboratory strains. We have designed a mod-
ular and general negative selection strategy based
on inducible toxins that provides high selection strin-
gency in clinical Escherichia coli and Salmonella iso-
lates. No strain- or species-specific optimization is
needed, yet this system achieves better selection
stringency than all previously reported negative se-
lection systems usable in unmodified E. coli strains.
The high stringency enables use of negative instead
of positive selection in phage-mediated generalized
transduction and also allows transfer of alleles be-
tween arbitrary strains of E. coli without requiring
phage. The modular design should also allow further
extension to other bacteria. This negative selection
system thus overcomes disadvantages of existing
systems, enabling definitive genetic experiments in
both lab and clinical isolates of E. coli and other En-
terobacteriaceae.
INTRODUCTION
Elucidation of the molecular basis for a given phenotype in
bacteria (such as the ability to cause an infection) is heav-
ily reliant on the ability to create defined genetic mutations.
Numerous systems exist for manipulation of bacterial chro-
mosomes; in general, the most powerful of these use selec-
tion to isolate the desired mutant. Positive selection mark-
ers based on antibiotic resistance genes are thus a mainstay
of the genetic toolbox in nearly every genetically tractable
bacterium.
However, cloning strategies relying solely on positive se-
lection markers (which enable isolation of bacteria carrying
the marker) result in ‘marked’ strains, where the marker it-
self or a residual scar remains in the genome, potentially
causing unanticipated effects. Creation of definitive genetic
constructs (e.g. a single point mutation in a gene of interest)
is therefore greatly facilitated by negative selection mark-
ers (which allow selection of bacteria without the marker).
Having negative selection enables a two-step strategy of (i)
positive selection-mediated deletion/replacement of a gene
of interest by a selection cassette followed by (ii) negative
selection-mediated, seamless replacement of the same cas-
sette by a mutated allele (Figure 1A). Comparison with an-
other strain in which the selection cassette is similarly re-
placed with a wild-type allele thus allows rigorous assign-
ment of phenotypic differences to the engineered point mu-
tation.
Negative selection markers are in general less efficient
than positive selection markers, even for well-studied bac-
teria such as Escherichia coli (1–8). Particularly for disease-
causing clinical isolates, negative selection systems that re-
quire host genotype modification (e.g. ccdB, tolC, thyA,
rpsl and thymidine kinases (4–8)) are impractical, as
the required host modifications often involve conserved
metabolic functions that may impact virulence (9), thereby
confounding the analysis or requiring an additional step to
restore the original genotype. Among negative selection sys-
tems that are usable in unmodified host strains (and are
therefore candidates for direct use in clinical isolates), ad-
ditional drawbacks include low selection stringency (as for
sacB (2)) and the need for strain-specific optimization of se-
lection conditions (as for the tetA and tetA–sacB systems
(1,3)).
To overcome these disadvantages in unmodified hosts, we
designed a general and modular negative selection system
based on inducible toxins. We optimized selection condi-
tions in one clinical strain of E. coli, UTI89, then verified
that this design was usable without further modification or
optimization in lab and other clinical isolates of E. coli as
well as in Salmonella enterica, enabling convenient two-step
creation of markerless and scarless chromosomal point mu-
tations. The negative selection module achieved high selec-
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Figure 1. Design and characterization of a negative selection module. (A) Schematic of a two-step cloning strategy for allelic replacement using positive
and negative selection. Step 1. A PCR product (depicted with a thick black baseline) containing a positive–negative selection cassette (kan-PrhaB-relE
here) flanked by sequence (shaded gray) homologous to the targeted gene is subjected to double crossover recombination (indicated by crossing lines) to
replace the gene. Selection for this replacement is done using the positive selection marker (kanamycin here). Step 2. Another PCR product (thick black
baseline) containing the same or a different allele (indicated by *) of the target gene, also flanked by sequence homologous to the targeted locus is subjected
to double crossover recombination to reintegrate the original locus. The resulting genome carries no residual markers or DNA scar. Selection for this
reintegration is done using the negative selection marker (plating on rhamnose in this case). (B) Schematic diagram of template plasmid pSLC-217. The
negative selection module (PrhaB driving relE) is shaded in black. The positive selection module (neo, mediating kanamycin resistance) is shaded gray.
Transcriptional terminators are indicated by open boxes. Universal priming sites P1 and P2 are shown as arrows. Other features (FRT sites, AmpR gene)
are indicated by open box arrows.
tion stringency in all tested strains, exceeding all other re-
ported negative selection systems usable in unmodified lab
isolates ofE. coli by up to 60-fold, and approaching theoret-
ical predictions of maximum stringency based on mutation
rates. The high negative selection stringency enabled its use
in traditional phage-mediated generalized transduction, in
which an additional benefit is the generation of unmarked
transductants using a wild-type donor. Furthermore, we
were able to use the negative selection system to perform
a modified phage-free ‘transduction’ (which we term gener-
alized allelic exchange) using transformed whole genomic
DNA between two uropathogenic isolates of E. coli, an
otherwise difficult problem due to the lack of transducing
phages for clinical strains (10). Therefore, this negative se-
lection system is a convenient and powerful addition to the
genetic toolbox for all E. coli strains that, in combination
with traditional antibiotic markers, enables the creation of
arbitrary unmarked mutations in all tested strains of E. coli
and other Enterobacteriaceae and allows for definitive ge-
netic experiments even in clinical strains. It further enables
new applications for generalized allelic exchange between
different strains.
MATERIALS AND METHODS
Media and culture conditions
LB andM9 agar were used as complex and minimal media,
respectively. For plasmid maintenance and selection of pos-
itive selection antibiotic markers, media was supplemented
with antibiotics (Sigma, Singapore) at the following con-
centrations: ampicillin (100g/ml), kanamycin (50g/ml),
chloramphenicol (20 g/ml) and tetracycline (10 g/ml).
M9 agar was supplemented with 0.2% glucose to repress
toxin gene expression or with 5% sucrose (for cat-sacB se-
lection), 0.2% rhamnose (for all PrhaB-driven toxins) or 0.2%
arabinose (for ParaB-driven toxins). Maintenance of plas-
mids carrying the toxin genes was carried out in LB sup-
plemented with 2% glucose.
Bacterial strains and plasmids
Relevant characteristics of bacterial strains and plasmids
used in this study are listed in Supplementary Table S1. The
template plasmids pKD3 and pKD4 were obtained from
AddGene and were modified in accordance with the Ad-
dGene Material Transfer Agreement for non-commercial
purposes.
tetA negative selection
Overnight cultures of UTI89 carrying tetA on plasmids or
integrated into the chromosome were diluted 1:100 into
fresh media and grown to an optical density at 600nm
(OD600) of 1. Serial 10-fold dilutions were plated to quan-
tify the number of surviving bacteria (CFU) on selective
and non-selective (LB) plates. Selective plates were supple-
mented with tetracycline (for positive selection) or 2–4 mM
NiCl2 (for negative selection).
Plasmid construction
All plasmids used in this study are listed in Supplementary
Table S1. To facilitate cloning, we first inserted several re-
striction sites (AatII, SmaI and SacII) into the AfeI site of
pKD4, generating pSLC-243. Toxic genes were amplified
from E.coli MG1655 (relE, chpBK, mqsR, higB, yafQ and
yhaV),Pseudomonas aeruginose (tse2 (11)) orE. coliUTI89
(phage  holin (12)) genomic DNA by PCR then cloned us-
ing NdeI and BamHI sites (in pAH120) or NdeI and NheI
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(in pAH150 (13)) to place them under the control of the
rhaB or araB promoter, respectively. Each promoter-toxin
module, including the flanking tL3 and rgnB transcription
terminators from pAH120 or pAH150, was cloned by blunt
ligation into the SmaI site of pSLC-243 to generate template
plasmids (pSLC-17 containing kan-PrhaB-relE is shown in
Figure 1B). All plasmids were propagated in E. coli strain
BW23473 (pir+, low copy number) or BW23474 (pir116,
high copy number). The sequences of all negative selection
cassettes are available upon request.
Recombineering
All genomic manipulations were carried out using previ-
ously described Red recombinase recombineering protocols
optimized for lab or clinical isolates of E. coli (14), with mi-
nor modifications. The positive–negative selection cassette
was amplified by PCRusing the P1 andP2 universal primers
for pKD4. Primers used for cloning are listed in Supplemen-
tary Table S8. Primers used for fimH constructs were as pre-
viously described (15). Each primer was synthesized with an
extra 50 bp of sequence at the 5′ end that was homologous to
the targeted genomic locus. Red recombinase was expressed
from the pKM208 (in E. coli) or pKD46 (in S. enterica
Serovar Typhimurium 14028S) helper plasmids. Overnight
cultures (LB-ampicillin, 30◦C with agitation) of the target
strain were diluted 1:100 into fresh media, grown at 30◦C
with agitation to OD600 = 0.2–0.3, and induced with 1 mM
Isopropyl -D-1-thiogalactopyranoside (IPTG) (pKM208)
or 0.2% arabinose (pKD46) for 30–45 min. The induced
cells were then heat shocked for 15 min at 42◦C, followed by
swirling in an ice water bath for 15min. Cells were harvested
by centrifugation (5000 rpm for 10 min), washed two times
with cold (4◦C) water, re-suspended in 1/100 of the original
culture volume of cold 10% glycerol, and frozen in 50 l
aliquots as competent cells. To perform double crossover
homologous recombination, 1 g of a PCR product was
transformed by electroporation into thawed competent cells
using 1mm electroporation cuvettes in a GenePulser XCEL
set to an output voltage of 1500 V with 25 F capacitance
and 400  resistance (Bio-Rad, Singapore). Cells were then
recovered in LB at 37◦C with shaking for 2 h followed by
static incubation (no shaking) for 2 h, plated on selective
plates, and incubated overnight (for kanamycin selection)
or for 24–48 h (for rhamnose selection) at 37◦C.
Diagnostic PCR and Sanger sequencing
Colony PCR reactions were used to check for
insertion/replacement of the selection cassette. The
first primer pair was used to specifically detect the locus of
desired homologous recombination and the second primer
pair was to detect the presence or absence of the specific
toxin gene at the desired locus. Primers used are listed in
Supplementary Table S8. Primers for fimH constructs were
uti8 + 4913333 and uti8 − 4915222 as described previously
(15). The strains were confirmed using Sanger sequencing
of the diagnostic PCR products with the same primers used
for amplification (1st Base, Singapore).
Immunoblot
Bacteria from 1 ml of culture at OD600 = 1.0 was harvested
by centrifugation (14 000 rpm, 1 min). The bacterial pel-
let was resuspended in 300 l of 4× sodium dodecyl sul-
fate (SDS) loading buffer (50% glycerol, 0.5% SDS, 0.25
M Tris, mercaptoethanol and bromophenol blue). Ten mi-
croliters of this sample was analyzed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
(15% polyacrylamide gel). Proteins were transferred to a ni-
trocellulose membrane using a Trans-Blot R© SD Semi-Dry
transfer cell (Bio-Rad, Singapore). Blots were probed with
anti-GroEL antibody (Sigma, Singapore) at a 1:6000 dilu-
tion in Tris-Borate-EDTA (TBE) with 5% skimmed milk to
assess loading quantities. Blots were probed with custom
anti-OmpC monoclonal antibodies (Abmart Inc., Shang-
hai, China). Antibody 4H15 (1:1000 dilution) recognizes
both the wild type and mutant OmpC protein (mutated
in loop 5 residues) while 4K3 (1:1000) was raised against
the OmpC loop 5 residues and thus does not detect the
mutant OmpC protein. Secondary antibodies used were
ECLTM anti-rabbit IgG Horseradish peroxidase (HRP)-
linked whole antibody (1:10 000) for anti-GroEL antibody
and ECLTM anti-mouse IgG HRP-linked whole antibody
(1:10 000). Blots were visualized using Amersham HRP
substrate in a Chemidoc machine (Bio-Rad, Singapore).
Whole genome sequencing
Genomic DNA from strain SLC-561 (UTI89 fimH::FRT;
mlaA::mlaAUTI89) was prepared from 1mL of an OD600 of
1 culture using theWizard R© Genomic DNAExtraction Kit
(Promega) and prepared for Illumina sequencing using the
TruSeq DNA library preparation kit (Illumina) according
to the manufacturer’s recommendations. This library was
sequenced on a HiSeq 2000 (2 × 76 bp reads), yielding 5
680 917 read pairs (∼170× coverage). After quality filtering,
fastq files were analyzed with cortex var (version 1.0.5.20)
from the Cortex package (16) using a joint analysis with
UTI89 (NCBI accession number NC 007946) as the refer-
ence genome; the resulting VCF files indicated the known
deletion at the fimH locus but no other variants (insertions,
deletions, or single nucleotide polymorphisms) that passed
quality filters. The sample was further tested for large (>100
bp) structural variations relative to the UTI89 reference
genome using the SVRE program (Sukumaran and Chen,
unpublished data) ; no large structural variations besides
the fimH deletion were found that differed from wt UTI89.
Hemagglutination titers
These were performed as previously described (15). Briefly,
1 ml of an OD600 = 1.0 suspension of bacterial cells in PBS
was gently pelleted (4000 × g, 2 min) and resuspended in
100 l phosphate buffered saline (PBS). Twenty-five micro-
liters of this was serially diluted in a row of a 96-well V-
bottom plate (Corning #3897) where each well contained
25 l of PBS (with or without mannose) (dilution range 1:2
to 1:4096). Twenty-five microliters of guinea pig red blood
cells in PBS were added to each well. The plate was gen-
tly agitated and incubated overnight at 4◦C. The HA titer
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reported was the greatest dilution of cells that resulted in
visible clumping of erythrocytes.
SDS–EDTA sensitivity
Overnight cultures were diluted 1:100 into fresh media and
grown to OD600 = 1. Serial 10-fold dilutions were plated on
differentmedia to quantify the number of surviving bacteria
(CFU). Selective plates were supplemented with 0.5% SDS
and between 0.75–2.25mMethylenediaminetetraacetic acid
(EDTA) and non-selective plates were supplemented with
0.5% SDS, with or without kanamycin.
Selection stringency
Overnight grown cultures were diluted 1:100 into fresh me-
dia and grown to OD600 = 1. Serial 10-fold dilutions were
carried out and plated on non-restrictive (plain LB for all
strains; also including antibiotic plates for antibiotic resis-
tant strains) media to quantify the number of surviving bac-
teria (CFU) in the original suspension. 1010 cells (10 ml cul-
ture ofOD600 = 1, centrifuged and re-suspendedwith 200l
PBS) were spread on appropriate restrictive plates to check
for negative selection (on M9-rhamnose or M9-arabinose
for strains carrying the negative selection cassette) and pos-
itive selection (LB-kanamycin for strains not carrying the
kanamycin positive selection marker) stringency. Selection
stringency was determined by dividing the calculated CFU
of the original inoculum on restrictive plates by the average
number of CFU that grew on non-restrictive plates.
Luria–Delbruck fluctuation test
Strainswere grownovernight on a non-restrictive plates (LB
for MG1655 and LB-kanamycin for SLC-568) and one sin-
gle colony was resuspended in 50 l of PBS. Twenty mi-
croliters of this suspension was diluted 200× and aliquoted
into the central 60 wells of each of 2× 96-well plates per
strain. Each well received 20 l of the diluted suspension
(approximately 102 or 104 CFU/well) and 180 l of non-
restrictive media (LB for MG1655 and M9 with 0.2% glu-
cose for SLC-568). The plates were then incubated at 37◦C
with shaking (220 rpm) for 6 h (MG1655, starter cultures
with 104 CFU/well) or 18 h (SLC-568, starter cultures with
102 CFU/well). (As a control, we also carried out 8-h incu-
bations with SLC-568; the resulting data was similar to that
from experiments using an18-h incubation). Ten wells from
each plate were used to calculate total CFU per well by se-
rial dilutions. The remaining 50 wells from each of the two
plates were pelleted (100 total) and resuspended in 200l of
selectivemedium (LB-kanamycin forMG1655 andM9with
0.2% rhamnose for SLC-568). The plates were then incu-
bated overnight at 37◦C with shaking (220rpm) after which
the cells were again pelleted and resuspended in 10 l of re-
strictive medium and spotted on restrictive agar plates. The
agar plates were incubated at 37◦C for 24–48 h. The num-
ber of wells which gave rise to colonies growing on restric-
tive agar plates was counted and the mutation rate of the
strains was determined using the following formula (17);
Mutation rate =
− ln (no. of negative samples/total no. of samples)
total no. of cell divisions
Generalized transduction
Transduction using P1vir was performed in MG1655 us-
ing standard protocols (18). A transducing lysate gener-
ated from wild type MG1655 was used to infect SLC-568
(MG1655 hsdS::kan-PrhaB-tse2) followed by plating onM9-
rhamnose as described above in the ‘Recombineering’ sec-
tion.
Generalized allelic exchange
Isolated genomicDNA fromE. coliCFT073 was sheared to
an average length of 10 kb fragments by sonication (Bran-
son Digital Sonifier Disruptor 450) (2 × 5 s pulses at 10%
power on ice). Ten micrograms of sheared DNA was trans-
formed into competent SLC-557 (UTI89 ompC::kan-PrhaB-
relE) expressing red recombinase. Cells were recovered in
LB at 37◦C with shaking for 2 h followed by static incuba-
tion (no shaking) for 2 h then plated onM9-rhamnose agar
plates, and screened via PCR and sequencing for allelic ex-
change at ompC locus using P21 and P22 primer set.
BLAST analysis of type II toxins
Type II toxin genes present in MG1655 were taken from
(19) and from the NCBI RefSeq annotation of theMG1655
genome (NC 000913). Finished E. coli genome sequences
were downloaded from NCBI RefSeq (Supplementary Fig-
ure S2). Each non-K12 genome was used as the database
to search for each toxin gene using the blastn (using the
toxin gene sequences) and tblastn (using the toxin pro-
tein sequences) programs (BLAST 2.2.28+) with default
parameters. Examination of the blastn and tblastn results
showed that a cutoff of a blastn alignment over 80% of
the toxin gene length captured all genes with simultane-
ously >88% DNA identity and >84% protein identity over
at least 80% of the toxin gene (or protein) sequence. This
80% blastn alignment cutoff also included four additional
gene/genome combinations which had potential frameshift
mutations (yafQ and yafO in SMS 3 5; cbtA in O55 H7
RM12579 and P12b) but for which the entire gene sequence
was otherwise present. We thus used 80% alignment over
the toxin gene length by blastn as the cutoff to call toxins as
present or absent in a given genome.
RESULTS
Existing negative selection systems are not practical for a
clinical isolate of E. coli
We first tested those existing negative selection systems that
do not require host genotype modification for their ability
to function in single copy in the chromosome of an unmod-
ified clinical uropathogenic isolate of E. coli, UTI89. Only
two systems, tetA (1) and sacB (20), could potentially be
used in UTI89. Selection against Tet resistance by fusaric
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acid is known to require optimization in different strains of
E. coli and may not be usable in others (21); we were unable
to demonstrate negative selectionmediated by the tetA gene
found on pBR322 in UTI89 after optimization of fusaric
acid and salt concentrations (data not shown). It has also
been reported that Ni2+ salts can be used to select against
TetR strains and that the selectivity can in some cases exceed
1 in 106 cells (1), but the selection power and optimal Ni2+
concentration varied between different E. coli strains, typ-
ically requiring above 6mM NiCl2. We found that, indeed,
growth of UTI89/pBR322 (TetR) relative to UTI89 was in-
hibited by 4 orders of magnitude at an optimal concentra-
tion of 3 mM NiCl2. However, pBR322 has an estimated
copy number of 20/cell. In order to use this system for chro-
mosomal manipulation, it must work at a copy number of
1/cell. We found that the sensitivity of TetR UTI89 to NiCl2
decreased with copy number, to the point that noNiCl2 sen-
sitivity was found with UTI89::tet (containing a single copy
chromosomal tetA gene) relative to UTI89 (Supplementary
Figure S1), as was also seen with DH10B (a lab adapted
strain of E. coli) (1).
Gram negative bacteria carrying the B. subtilis sacB gene
accumulate toxic metabolites when grown in the presence of
sucrose. The sacB gene is widely used for negative selection
(20,22,23), but it suffers from relatively high false positive
rates for chromosomal manipulations due to spontaneous
suppressor mutations that inactivate sacB (24). This has the
overall effect of reducing its stringency to<2.3× 10−5 (20).
However, in UTI89, a single chromosomal copy of cat-sacB
mediated negative selection with a relatively weak selection
stringency of 3.40 × 10−2. Recently, a system combining
both the tetA and sacB genes has been reported with im-
proved stringency (3) but is very sensitive to selection con-
ditions and therefore requires strain-specific optimization.
Therefore, a negative selection system immediately usable
in clinical strains of E. coli is lacking.
Design of a modular negative selection cassette based on in-
ducible toxins
We sought to design a new negative selection system that
would both provide high stringency and not require strain-
specific optimization. Negative selection using the mazF
toxin gene has been demonstrated in single strains of Bacil-
lus subtilis (25) andClostridium acetobutylicum (26), though
no data on stringency was reported. These reports sug-
gested that isolated toxins from toxin–antitoxin (TA) sys-
tems could be generally useful as negative selectionmarkers,
even when used in heterologous species (mazF is an E. coli
gene, yet seems to function in Gram positives). We there-
fore asked whether a general system providing tightly con-
trolled induction of a toxin gene could be used in E. coli
and other Enterobacteriaceae. The E. coli MG1655 (a lab-
adapted fecal isolate) chromosome is known to carry nu-
merous TA systems (19); we focused on Type II TA sys-
tems (in which both toxin and antitoxin are proteins) be-
cause they are more easily identified and therefore likely to
be more completely annotated. To develop a system for use
in clinical isolates (in particular, UTI89), we reasoned that
the TA system we used should be absent from the UTI89
genome. Using BLAST analysis, we identified 12 candidate
toxins present in MG1655 but not in the UTI89 genome
(Supplementary Table S2). Further analysis using 55 non-
K12 full genome sequences available at NCBI RefSeq high-
lighted 7 MG1655 toxins (rnlA, ypjF, ykfI, ydaS, yjhX, relE
and mqsR) that were not found in more than half of non-
K12 genomes (Supplementary Figure S2 and Supplemen-
tary Table S2).
We created a negative selection cassette consisting of the
relE toxin (chosen for its small size, to minimize the PCR
length in subsequent steps and its potential for inactivation
by mutation) driven by the rhaB promoter (chosen for its
‘tight’ control; it is induced by growth on rhamnose and re-
pressed by growth on glucose). To further ensure deliberate
control of expression, we included the tL3 and rgnB termi-
nators flanking the PrhaB-relE to guard against read-through
transcription from other promoters; and we retained the
native rhaB ribosome binding site. For use in making un-
marked chromosomal mutations, we combined this nega-
tive selection cassette with a kanamycin resistance gene, a
traditional positively selectable antibiotic marker. We built
the construct as a derivative of the well-designed cloning
system described by Datsenko and Wanner (14) based on
Lambda Red recombinase and antibiotic selection using
the pKD4 template plasmid. We refer to the derived tem-
plate plasmid as pSLC-217 and to the combined positive–
negative selection cassette as kan-PrhaB-relE (Figure 1B).
Efficient, scarless and markerless manipulation of the UTI89
chromosome
To validate our system, we first used the kan-PrhaB-relE cas-
sette to perform a two-step allelic replacement of the ompC
gene at its native locus in UTI89. We used a Red recom-
binase protocol optimized for clinical isolates of E. coli
(22) to replace the native ompC gene by homologous re-
combination with a linear PCR product (containing kan-
PrhaB-relE flanked by homology arms targeting the ompC
locus), using positive selection on kanamycin (Figure 1A,
step 1).We then used PCRproducts for the wild typeUTI89
ompC and a mutated ompC (carrying mutations in extra-
cellular loop L5) allele in a subsequent Red recombinase-
mediated double-crossover replacement of the integrated
positive–negative selection cassette, using negative selection
on rhamnose (Figure 1A, step 2). Clones were screened us-
ing PCR for the entire ompC locus as well as for specific
insertion of the relE toxin gene at the ompC locus (Sup-
plementary Figure S3A). Positive clones identified by PCR
were verified by testing for loss of kanamycin resistance, re-
stored ability to grow on rhamnose (Supplementary Fig-
ure S3B), and Sanger sequencing of the entire ompC locus.
The efficiency for isolating the correct recombinant dur-
ing the counterselection step was 87–100% as calculated
by testing 30 colonies from each counterselection step by
PCR, growth on rhamnose, and loss of the positive selec-
tion marker. To further confirm that the restored ompC lo-
cus was functional, we tested for OmpC protein expression
using immunoblotting.We sawOmpC protein expression in
whole cell extracts for the parental wild type strain as well
as both recombined strains (carrying a wt and L5 mutant
ompC, respectively), but noOmpC band in the intermediate
knockout strain. Furthermore, using an antibody specific to
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the L5 loop of OmpC, we saw detection only in the parental
wild type (wt) and the strain with the restored wt ompC al-
lele but not in the knockout or the strain carrying the L5
mutant allele (Supplementary Figure S3C). Therefore, the
combination of our negative selection cassette with a tradi-
tional positive selectable marker has enabled us to create a
functional, scarless mutation directly in the ompC locus of
UTI89.
Creation of markerless mutations at arbitrary loci in UTI89
We verified that the kan-PrhaB-relE positive–negative selec-
tion cassette could be used to manipulate arbitrary genes
in UTI89 by performing gene deletion and complementa-
tion at three other loci (Supplementary Table S3). We used
the two-step integration/knockout followed by replacement
of the integrated dual selection cassette, using negative se-
lection on rhamnose to create isogenic mutant strains or
unmarked mutations with defined deletion junctions (Sup-
plementary Tables S1 and S3). We successfully deleted and
reintegrated the mlaA and hsdS genes, verifying each by
both diagnostic PCR and Sanger sequencing of the lo-
cus. Functional confirmation of mlaA knockout and rein-
tegrated constructs was also done using an SDS–EDTA
sensitivity assay (Supplementary Table S4). We also made
unmarked versions of previously reported strains carry-
ing point mutations in the fimH gene (15), eliminating the
downstream linked kanamycin gene previously required for
the second step of cloning. All clones were confirmed to
contain the predicted mutations by diagnostic PCR and se-
quencing of the new junctions created by recombination.
Furthermore, all of the unmarked fimH mutants were ver-
ified to have similar type 1 pilus function to their marked
counterparts based on hemagglutination of guinea pig red
blood cells (Supplementary Table S5).
No off-target mutations are created
Expression of Red recombinase can induce a 10-fold in-
crease in spontaneous mutations (22). As the goal is to
perform well-defined chromosomal manipulations, the two
rounds of Red recombinase mediated recombination are a
potentially large problem for off-target, unintended muta-
tions. To mitigate this, we followed the recommendations
of Campellone and Murphy to minimize Red recombinase
induction to 30–45 min prior to generation of competent
cells in both recombination steps (22). To further address
whether off-target mutations were being generated, how-
ever, we performed whole genome sequencing on a strain
that had undergone a chromosomal knockout then rein-
tegration of the mlaA gene. Using Cortex (which detects
SNPs and small indels) (16), we found no mutations com-
pared with the parental strain (prior to the initial knockout
of mlaA). We also used a new sensitive structural variation
caller (which detects larger inversions, duplications, inser-
tions, deletions and other more complex rearrangements;
manuscript in preparation) and again found no differences
in genomic rearrangements compared with the parental
strain. While we only examined one strain, the complete ab-
sence of any detectable off-target mutations in over 5 Mbp
of sequence in this strain indicates that unintended muta-
tions are not generally being created at a high rate during
these engineering steps.
Generalization of negative selection for other host strains by
module replacement
The positive–negative selection cassette we createdwas built
from several well known genetic elements (promoters, ter-
minators, RBS sequences and antibiotic markers). In the in-
terest of generality, potentially enabling use in other E. coli
strains as well as non-E. coli bacteria, we first verified that
we could simply replace the promoter and antibiotic marker
without having to perform any optimization of sequences or
selection conditions. We created ParaB-relE, where the neg-
ative selection would be carried out with growth on ara-
binose. We also switched the parental template plasmid to
pKD3, encoding a chloramphenicol positive selection cas-
sette (Supplementary Table S3). Indeed, switching between
PrhaB and ParaB or chloramphenicol and kanamycin had
little effect on the efficiency of the negative selection step
(based on limited testing of 7–8 colonies by PCR and loss
of the positive selectionmarker) when used in a similar two-
step allelic replacement at the ompC locus of UTI89 us-
ing the previously defined selection conditions we used for
UTI89 (although the antibiotic and sugar were altered as
necessary).
Given that several toxins encoded by MG1655 besides
relE were also potential candidates for use in UTI89, but
that may be variably present in other E. coli strains, we
next tested whether we could also simply replace the toxin
gene in a modular fashion. We tested several other toxins
(mqsR, higB, yhaV, yafQ and chpBK) with PrhaB, using the
same cloning sites we used for relE to make identical fu-
sions of the start codon of each toxin gene with the pro-
moter and ribosome binding site of our template plasmid.
We further reasoned that alternative toxins, such as those
from phage or antibacterial secretion systems, might func-
tion effectively both inE. coli (thus enabling use inMG1655
and other lab strains) as well as in other bacteria. We there-
fore also included the holin gene (324 bp) from phage  (12)
in UTI89 and the tse2 type 6 secretion system toxin (477 bp)
fromPseudomonas aeruginosa (11). These positive–negative
selection cassette variants were again tested using the same
two-step knockout/replacement protocol without modifi-
cation of transformation or growth conditions. We found
that, except for variants containing higB and yafQ (see be-
low), all variants were usable for creating markerless muta-
tions in UTI89.
Finally, we tested our system in different bacterial
strains. We replaced the ompC gene in CFT073 (another
uropathogenic E. coli clinical isolate (27)), EDL933 (an
enterohemorrhagic E. coli isolate (28)), TOP2515 (a cys-
titis isolate that has never been reported to be manipu-
lated on its chromosome (29)), and S. enterica serovar Ty-
phimurium 14028S (30) with the ompC allele from UTI89
(Supplementary Table S3). In addition, we replaced the
hsdS gene in E. coli MG1655 with the hsdS gene from
UTI89 (Supplementary Table S3) using the P. aeruginosa
tse2 gene as the negative selection system toxin. All replace-
ments were successful as verified by PCR, growth pheno-
types, and Sanger sequencing. Furthermore, for all variant
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cassettes and all strains tested, we used the same amplifi-
cation primers, transformation conditions, and negative se-
lection conditions (M9 with 0.2% rhamnose) that we had
originally used for UTI89. Thus, our positive–negative se-
lection cassette is indeed general and needs no optimization
when used in different clinical isolates of E. coli and other
Enteric bacteria.
Inducible toxins mediate high negative selection stringency
We noted in these manipulations that, in general, very
few background/false positive colonies grew on rhamnose
plates (Supplementary Figure S3B). Furthermore, two tox-
ins, higB and phage  holin, could suppress growth on
rhamnose when present on a high copy plasmid but not
when present in single copy on the chromosome (Supple-
mentary Figure S4). These data suggested that different tox-
ins vary in selection stringency, which might be useful for
creating negative selection cassettes in organisms lacking
tightly regulated promoters. We first tested selection strin-
gency by calculating the fraction of viable colony form-
ing units (CFUs) that were able to grow under restrictive
conditions (smaller numbers indicate higher stringency).
This test measures the frequency of colonies growing un-
der restrictive conditions (as opposed to the actual muta-
tion rate – see below), is naturally related to the background
colonies one would observe during a typical cloning proce-
dure, and has been used previously in rapid screens of mu-
tability (31–33). We therefore refer to these values as ‘strin-
gency frequencies’. We plated bacteria carrying a positive–
negative selection cassette in single copy in the chromosome
onto each of LB, LB-antibiotic and M9-rhamnose or M9-
arabinose plates. On non-restrictive plates, we quantified
bacteria by plating serial dilutions of the original culture,
while on restrictive plates, we concentrated 1010 CFU from
10 ml of OD600 = 1 culture and plated them all. For refer-
ence, the parental strains and the strains with the replaced
alleles (both sensitive to kanamycin or chloramphenicol)
were also plated to the same plates to test the stringency
of positive selection on antibiotics (Figure 2A). We found
that positive selection markers mediated very strong selec-
tion (stringency frequencies of 10−9–10−10) in UTI89 (Fig-
ure 2A). Among negative selection markers, different tox-
ins, when driven by the PrhaB promoter, did indeed vary in
their strength of selection, but the toxins that were usable
for negative selection in single copy on the UTI89 chromo-
some had stringency frequencies of 10−7–10−8 (Figure 2A
and Supplementary Table S6). Because the insertion site
of a negative selection cassette may affect its relative copy
number due to the timing of DNA replication, and copy
number influences expression levels and thereby potentially
stringency, we repeated these tests with the kan-PrhaB-relE
selection cassette integrated into different loci in UTI89.
In general, stringency did not vary much across different
loci within UTI89 (Figure 2B, Supplementary Figure S5A),
across different E. coli strains, or in Salmonella (Figure 2C,
Supplementary Figure S5B). Notably, the tse2 toxin (11)
from the Pseudomonas Type VI secretion system had the
highest stringency frequency (1.96× 10−8) at the hsdS locus
in MG1655 (Figure 2C). In comparison, the highest strin-
gency for any negative selection system reported to date for
unmodified E. coli strains (MG1655 or its close relatives,
all lab-adapted) is 6 × 10−7 (presumably also a stringency
frequency) using a combined tetA–sacB cassette (3).
We verified that CFU quantification on rhamnose plates
was accurate by comparing CFU calculated by serial dilu-
tions plated to both plain LB and M9-rhamnose; no dif-
ferences were seen for any of the wild-type strains (Sup-
plementary Table S7). Furthermore, we also tested a con-
trol in which the kanamycin gene and PrhaB were integrated
into the chromosome without an accompanying toxin gene
(SLC-658); this also showed no toxicity from growth on
rhamnose compared with plain LB (Supplementary Table
S7).
To further validate the high stringency of our system,
we explored several additional lines of reasoning for the
strain carrying the tse2 toxin in MG1655 (SLC-568). First,
we repeated our initial stringency frequency test by plating
a higher number (1011 CFU; total culture volume 100 ml,
OD600 = 1) of cells onto M9-rhamnose plates; we found a
similar stringency frequency (1.11 × 10−8; Supplementary
Figure S6), representing growth of at least several hundred
colonies in each of three replicates of this experiment.
Second, we estimated the theoretical maximum possi-
ble stringency (i.e. lowest mutation rate) based on chro-
mosomal replication error rates for MG1655, assuming
that only mutations within the negative selection cas-
sette itself could confer breakthrough growth. The range
of mutation rates for MG1655 has been reported to be
between 1 × 10−3 and 3.3 × 10−3 /genome/generation
(34,35); this translates into 2.2 × 10−10 to 7.1 × 10−10
mutations/nucleotide/generation. The PrhaB-tse2 cassette is
811 bp; therefore the expected mutation rate is 1.8 × 10−7
to 5.8 × 10−7 mutations/cassette/generation. Not all mu-
tations would inactivate the toxin or disrupt its expression;
this fraction is difficult to quantify, but we take as lim-
its the expected fraction of coding mutations that would
be expected to be nonsense (5%) (36) and the fraction of
lacImutations that are dominant (40%) (37) (this range en-
compasses the estimated fraction (20%) of missense muta-
tions (∼70% of all de novomutations) that are strongly dele-
terious (overall 14% of all de novo mutations)) (36). This
gives an expected inactivation rate between 0.9 × 10−8 and
2.3×10−7/cassette/generation. In addition the toxin could
be inactivated by a spontaneous large deletion, which oc-
curs at a rate of between 1.79 × 10−9 and 2.5 × 10−7 per
generation inE. coli (38–40). These calculatedmutation rate
values are now rates at which colonies growing on rhamnose
could be generated, and should be considered distinct from
the stringency frequencies measured and discussed above.
Measurement of experimental rates of mutation (as op-
posed to stringency frequencies) is more involved; the rel-
evant issues have been previously elucidated by Luria and
Delbruck (17). We carried out a Luria–Delbruck fluctua-
tion test to directly measure experimental rates of muta-
tion to breakthrough growth on rhamnose. Using two dif-
ferent starting small culture sizes (see ‘Materials andMeth-
ods’ section), we calculated a mutation rate toward growth
on rhamnose of 1.42 × 10−8, within the theoretical range
based on per-nucleotidemutation rates calculated above. As
a control, we also performed a Luria–Delbruck fluctuation
test for mutations conferring resistance to kanamycin. The
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Figure 2. Selection stringency tests. (A) Selection stringency tests for different toxins. Data shows the selection stringency, which is calculated as: CFU/ml
on restrictive agar divided by CFU/ml on non-restrictive agar. First set of bars represents the positive selection stringency for wild type (UTI89) strains
tested in each experiment. The middle set of bars represents the negative selection stringency for each strain carrying the dual selection cassette integrated
into the ompC locus in UTI89. The last set of bars represents positive selection stringency for the strains in which the selection cassette has been replaced
with the wild type ompC allele in a subsequent negative selection step. (B) Stringency does not vary with chromosomal locus. Data shows the positive
selection stringency for wild-type strains (on the left) followed by the negative selection stringency for strains carrying the kan-PrhaB-relE cassette at
different loci in UTI89 (on the right). (C) The positive–negative selection cassette is usable in different strains of E. coli and in Salmonella. Toxins and
strains are as indicated. For graphs in (A–C), data represents the average of the log-transformed values of selection stringencies with error bars indicating
standard deviation of the log-transformed stringency values calculated from three independent biological replicates.
fluctuation test gave a mutation rate to resistance (1.11 ×
10−10) that was lower than our rate for mutation of our neg-
ative selection cassette, in keeping with the better stringency
frequency of kanamycin (2.30 × 10−10) as measured above.
As a final verification of the reproducibility of the high
stringency of our negative selection cassettes, we performed
the same cloning to create a separate but isogenic strain to
SLC-568 (designated SLC-657) and assayed its frequency of
breakthrough growth on rhamnose (by plating 1010 CFU),
again arriving at 2.38 × 10−8 (Supplementary Figure S6).
We therefore conclude that the negative selection stringency
(mutation frequencies) of the tse2 system in MG1655 is in-
deed better than previously published negative selection sys-
tems and that its mutation rate is very close to the theoret-
ical minimum mutation rate expected for a system of this
size.
Negative selection by inducible toxins enables unmarked al-
lelic exchange
We then asked whether high negative selection stringency
could be leveraged to enable ‘difficult’ applications such
as generalized transduction, where positive selection mark-
ers are traditionally required (though recently P1 transduc-
tion has been performed using a tetA-sacB negative selec-
tion cassette (3)). We performed generalized transduction
with a phage P1 lysate (generated from unmodified wild-
type MG1655) to complement an hsdS knockout (replaced
with kan-PrhaB-tse2; host strainMG1655 (SLC-568)); selec-
tion on rhamnose resulted in growth of >2000 transduc-
tants (out of ∼109 plated CFU), of which 16/16 (100%)
were positive for restoration of the wild-type hsdS locus
by PCR. In contrast, no colonies were observed when the
P1 phage lysate itself was plated, and 200 colonies were
observed on rhamnose when only SLC-568 (the recipient
strain) cells were plated. The estimated efficiency of >90%
compares favorably with the 56–63% efficiency reported us-
ing tetA-sacB (3), consistent with the higher stringency of
our system. Transduction using negative selection improves
on traditional generalized transduction because the result-
ing transductants contain no residual antibiotic marker or
scar and because unmarked, unmodified strains can be used
as the donor.
However, clinical strains are often difficult to manipulate
using generalized transduction, either due to phage speci-
ficity (10) or low efficiency. We were unable to perform a
restoration of the ompC locus in UTI89 using P1-mediated
generalized transduction from unmodified MG1655, and
we were unable to create a P1 transducing lysate from ei-
ther UTI89 or CFT073. We speculated that we could cir-
cumvent these difficulties by mimicking transduction using
transformation of sheared genomicDNA (Figure 3A). Such
a strategy would remove limitations imposed by the need
to create a transducing lysate from the donor strain that
could successfully infect the recipient strain.We refer to this
phage-free ‘transduction’ as generalized allelic exchange.
Reimplementation of generalized transduction in this way
would not only expand its potential use to strains with-
out transducing phage, but could also potentially lead to a
novel application for strain hybridization we term ‘mass al-
lelic exchange’ (see ’Discussion’ section). We directly trans-
formed sheared genomic DNA from CFT073 by electro-
poration into SLC-557 (UTI89 ompC::kan-PrhaB-relE) ex-
pressing Red recombinase. Selection on rhamnose followed
by PCR screening resulted in identification of the desired
recombinant, where CFT073 genomic DNA had replaced
the ompC locus in UTI89, in 2/55 colonies (3.6%). We se-
quenced the DNA flanking ompC in these two clones and
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Figure 3. Generalized allelic exchange. (A) Schematic of the generalized allelic exchange strategy. A negative selection marker (open rectangle) is inserted
into the recipient strain (UTI89 here) at a defined locus (thick black arc, ompC in this case). Sheared whole genomic DNA from another strain (CFT073
here, red lines) is transformed into UTI89, and growth on restrictive conditions allows selection for replacement of the targeted locus (thick red arc) with
no residual marker or scar. (B) Recombination breakpoints for ompC allelic exchange fromCFT073 to UTI89. A schematic of the gene organization of 6kb
surrounding the ompC gene in UTI89 is shown at the top. The rectangles below depict recombination breakpoints of two clones (SLC-578 and SLC-579) as
determined by Sanger sequencing of the ompC gene and flanking sequence. In each, a central region of CFT073 sequence encompassing the ompC gene is
indicated in gray, while the surrounding UTI89 sequence is indicated by black. (C) Schematic for strain hybridization by mass generalized allelic exchange.
A library of UTI89 with random insertions of the negative selection system (thick black arcs) throughout the chromosome is subjected to the process in
(A) en masse. Growth on restrictive conditions would result in a library of hybrids in which each locus originally carrying the negative selection system
insertion has been replaced by the homologous locus from CFT073 (thick red arcs).
found that the precise recombination breakpoints were dif-
ferent (Figure 3B), as expected from the random shearing
of the CFT073 genomic DNA. Of note, selection stringency
is paramount in this application, as only 0.2% of the input
DNA (the CFT073 genome is ∼5 Mbp, while DNA was
sheared to 10 kb) is ‘on-target’ for replacement of the nega-
tive selectionmodule at the ompC locus. Therefore, our neg-
ative selection system enables phage-free generalized allelic
exchange between different strains of E. coli, substituting
for generalized transduction.
DISCUSSION
There is a surprising lack of stringent and general negative
selection tools, even for cloning strains of E. coli. Indeed,
several recent reports (3,4,41) have highlighted the need for
better negative selection systems in E. coli. In general, pre-
vious systems have suffered from low stringency, a require-
ment for modified hosts, or a need to optimize selection
conditions separately for each host strain. In the context
of understanding the genetic basis of pathogenesis in pri-
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mary clinical isolates, these drawbacks have made negative
selection largely impractical. Particularly for loss of func-
tion studies, high frequency site-specific recombinase sys-
tems such as Cre-lox (42) and Flp-FRT (14) can be lever-
aged tomanipulate chromosomal loci with only a small scar
left behind, largely alleviating the need for negative selec-
tion. However, allelic replacement experiments in clinical
isolates to date have been relatively rare compared with loss
of function experiments; when done, they are limited either
due to laborious construction methods or due to use of a
linked positive selection marker.
General and stringent negative selection systems could
remove these limitations on direct genetic studies of unmod-
ified clinical pathogenic isolates. Recent reports of new neg-
ative selection systems have continued to focus on cloning
strains of E. coli (3,4,41). These reported systems may be
applicable to clinical strains, though the requirement for
or complexity of strain-specific optimization is still unclear.
Our system, due to its modular design, can accommodate
essentially any toxin gene, whether from a toxin–antitoxin
system, phage system, secretion system or potentially other
as yet unknown genetic modules. We have demonstrated
that the majority of tested toxins can be converted with-
out optimization into effective negative selection systems
that vary little in their efficiency and stringency. Further-
more, we have shown that no optimization is needed to use
these systems in multiple clinical strains of E. coli, includ-
ing a previously uncharacterized clinical isolate and a well-
studied lab strain of E. coli, as well as in S. enterica Serovar
Typhimurium. Therefore, we anticipate that little or no op-
timization will be needed for the vast majority of E. coli
strains.
The stringency and generality of our design certainly de-
pends on the availability of tightly regulated promoters in
E. coli and other enteric bacteria. We have shown that both
the rhamnose and arabinose promoters are sufficiently well
controlled in single copy to enable bacterial growth when
not specifically induced and are very stringent in preventing
growth when induced. Based on similar promoter dynam-
ics when present in single copy on the chromosome, we also
expect the widely used lac promoter to be a viable promoter
for driving toxin genes (43,44). Additional promoters na-
tive to E. coli and other Enterobacteria that respond to pH
(45), temperature (46) or oxygenation conditions (47) could
also be used. This intentional modularity of transcriptional
control, enabling use of different promoters, is particularly
valuable for generalization to other bacterial systems.
We noted that, while four of six tested TA system genes
could be immediately used in our strategy, higB was only
viable for negative selection when present on a plasmid in
multiple copies, while yafQ could not be used for negative
selection at all. Interestingly, this implies that the induced
expression level from a single copy is insufficient to pro-
hibit growth. In all cases, the 5′ untranslated sequence and
ribosome binding sequence were identical among our con-
structs. Therefore, we suspect that the observed variation in
toxicity at the same levels of promoter induction could be
due to additional transcriptional (such as pause or termi-
nation sites), translational (such as rare codons or mRNA
stability), or post-translational effects (such as protein fold-
ing or intrinsic toxicity thresholds) unique to individual tox-
ins. Regardless of the mechanism, however, our results im-
ply that toxins differ in their ‘effective toxicity’ when we
controlled copy number and promoter induction; this con-
cept of a threshold for toxicity has been introduced pre-
viously in relation to levels of the antitoxin within a cell
(48). Because the toxins themselves are known to function
in a broad range of bacteria (25,26) as well as eukaryotes
(yeast) (49), toxin genes that are permissive for cell growth
at low transcription levels may enable the use of less op-
timal (less tight) inducible promoters. Furthermore, due to
the large number of toxin-antitoxin systems (and other bac-
terial toxins from phages and secretion systems) present
in public databases from genome sequencing efforts (cat-
aloged, for example, in TADB (50), RASTA (51) and the
PanDaTox (52) databases), it seems likely that effective tox-
icity will vary greatly, especially if codon usage or tran-
scriptional controls within the coding sequences are not re-
moved. Indeed, one could imagine collecting a database of
toxin genes that are characterized based on the threshold
transcriptional or induction level required for toxicity; this
could then be queried to identify reasonable candidates for
use with existing inducible promoters to generate additional
negative selection systems depending on the available ge-
netic tools in a given system.
We have performed numerous chromosomal manipula-
tions in UTI89 and other lab and clinical E. coli strains
using all variants of these negative selection systems. The
construction of definitive strains for genetic tests in clini-
cal isolates is no longer less convenient than in lab strains.
However, we have relied on the widely used Red recom-
binase system from phage . Expression of this system in
E. coli is known to be mutagenic, and we use it in each of
two steps to manipulate the chromosome. While following
published recommendations for limiting the length of re-
combinase expression (22), the possibility still remains that
unselected mutations may be induced that could confound
interpretation of downstream experiments. To definitively
address this possibility, we used full genome sequencing of
one of our allelic replacement strains and found no unex-
pected mutations of any class, including SNPs, small in-
dels, or large scale rearrangements. Furthermore, pheno-
typic testing of a panel of FimHmutants, all constructed by
allelic replacement, showed perfect concordance with previ-
ously published results (in which the strains carried a linked
positive selection marker).
Our system exceeds the reported stringency of selection
(measured using stringency frequencies) of the next best
reported system (tetA–sacB in MG1655, W3110 and/or
DH10B; 6 × 10−7 (3)) by up to 60× in lab strains of E.
coli (kan-PrhaB-tse2 in MG1655; 1.11×10−8 as measured by
plating 1011 CFU); this begins to approach (within 5×) the
selection stringency frequency of positively selectable an-
tibiotic markers in some strains we have tested (kanamycin
in E. coli EDL933; 2.40 × 10−9). The stringency frequency
in clinical strains (kan-PrhaB-relE in UTI89; 3.31 × 10−8) is
17-fold better than the tetA–sacB system as measured in lab
strains, and it remains high without the need for strain- or
species-specific optimization of transformation or growth
conditions. We have further measured mutation rates for
growth on restrictive conditions and find that these also cor-
respond well with expected minimum theoretical rates for
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inactivating mutations as calculated by previously reported
genomic mutation rates in E. coli (34,35). We have used the
more easilymeasured stringency frequencies to compare the
different systems. This is similar to previous screens of mu-
tation rates in E. coli (31–33), though perhaps not fully rig-
orous. We note, however, that our stringency frequencies in-
dicate that kanamycin is more stringent than our negative
selection system (namely, using PrhaB-tse2), and we obtain
the same result when making a more careful measurement
of mutation rate. Furthermore, measurement of mutation
frequencies is able to detect mutator strains as those with
higher mutation frequencies (32,33). Thus our and previ-
ous data both argue that measurement of stringency (mu-
tation) frequencies is reasonable for a relative comparison
of mutation rates, a notion further supported by additional
theoretical analysis of fluctuation tests for mutation rates
(53).
Although mutation rates and frequencies are not directly
comparable, we note here two further observations inspired
by a discussionwith one of the reviewers. First, our expected
minimum mutation rate (0.9 × 10−8) and calculated mu-
tation rate (2.45 × 10−8) are both similar to the mutation
rates towards resistance to phage measured by Luria and
Delbruck themselves (1.1× 10−8–4.1× 10−8) (17). In look-
ing closely at their original data, the culture sizes (0.2–10 ml
with 1 × 108–4×1010 CFU in each) are also similar to ours.
The ‘average’ number of resistant bacteria measured in each
of their cultures, due to the jackpot effect, is higher than the
number of resistant bacteria measured in the majority of
their cultures (50–95% of cultures in each experiment have
fewer resistant bacteria than the average), which forms part
of the motivation for developing the fluctuation test instead
of relying on mutation frequencies. Furthermore, using a
‘simple expectation’ calculation of (# of bacteria) × (mu-
tation rate) as an arbitrary cutoff, Luria and Delbruck ob-
serve an average frequency of mutant CFU above this num-
ber, while we see frequencies of background growth near or
below this number. This again highlights the distinction be-
tween mutation frequencies and rates, arguing that direct
measurements of rates are more reliable. This observation
may also indicate that we have not sampled enough inde-
pendent cultures to capture the high variance in the number
of mutations present per culture; unfortunately, due to the
way we performed the fluctuation tests, we did not collect
data on the number of resistant CFU per culture.
However, as a second point, we do note another inter-
esting set of data that provides an informative comparison
with our work. Recently, Luria–Delbruck fluctuation tests
were performed on E. coli for resistance to rifampicin, in
the context of examining the relationship of cell density
with mutation rate (54); the measured range of mutation
rates to rifampicin resistance spanned ∼2 × 10−9 to 1 ×
10−8. Several earlier studies have examined mutation to ri-
fampicin resistance in E. coli using simple frequency tests;
two large studies of E. coli isolates obtained mutation fre-
quencies of 2.5 × 10−9 to 1 × 10−8 (31) and 5 × 10−9 to
5 × 10−8 (32), and a third study of E. coli and Salmonella
obtained <1 × 10−8 to 5 × 10−8 (33). The mutation rate
and frequency studies differ in the strains and media used,
but overall the results match our data in that the (more sim-
ply measured) mutation frequencies are quantitatively sim-
ilar to the mutation rates measured using the fluctuation
tests. Furthermore, we also note a quantitative similarity
between the stringency frequency (2.30 × 10−10) and mu-
tation rate (1.11 × 10−10) that we measured for kanamycin
resistance. Again, we note only that the quantitative similar-
ity between stringency (mutation) frequencies and mutation
rates that we observe in our data is mirrored in published
data and present in multiple experiments with different se-
lection cassettes; we therefore suggest that this likely indi-
cates our measurements are accurate. However, the concep-
tual separation of rates and frequencies must still be main-
tained. Formost other negative selection cassettes, however,
only stringency frequencies are available, and the following
discussion of stringencies should be considered in the con-
text of the foregoing discussion.
Unlike several commonly used systems including sacB or
tetA, our negative selection cassettes appear to come very
close to the theoretical maximal stringency (based on mu-
tation rate) for genes of their size, which may account for
their superiority over these systems. Although the theoreti-
cal maximal stringency for sacB is between 1.67× 10−8 and
4.25 × 10−7, the reported stringencies (usually using strin-
gency frequency) measured for this system are much lower
(E. coli HS996; 2.3× 10−5 (20)). Similarly, although the the-
oretical maximal stringency for tetA is between 1.33× 10−8
and 3.40 × 10−7, the reported stringencies in different host
strains and at different nickel concentrations vary between
10−4 and 10−6 (1). These systems fall short of expectations
in their behavior by 100- to 1000-fold (assuming the corre-
spondence between mutation frequencies and rates should
also hold for these systems). Why is our system more ro-
bust to selection conditions and changing host strains than
previous systems? We speculate that several aspects of our
design contribute to higher stringency. First, we are using
toxins that have presumably evolved for the purpose of effi-
ciently stopping cell growth; in contrast, tetracycline resis-
tance and the sacB gene were evolved for other purposes,
and their use for negative selection is based on leveraging
other properties they confer on cells. Second, we have in-
cluded several features that enable us to have ‘tight’ con-
trol over toxin induction, including transcriptional termi-
nators and the well characterized rhamnose and arabinose
promoters to reduce basal uninduced expression; and the
use of the native rhaB RBS sequence and minimal media
with a single carbon source to ensure good ‘induced’ ex-
pression. The combination of an inducible toxin, therefore,
for arresting cell growth becomes reliably stringent in dif-
ferent strains and species so long as we can maintain low or
no basal expression. A further potential improvement may
also be gained by using genomic templates for amplification
of the positive–negative selection cassette, thereby eliminat-
ing the possibility of the template plasmids conferring resis-
tance during recombination, despite their reliance on condi-
tional replication origins. In contrast, the variable selection
mediated by tetA or sacBmay be due to their overall expres-
sion levels in and membrane properties of different strains.
We finally note that generality and high stringency is com-
mon for negative selection systems that require special host
genotypes (such as tolC (41), thyA (6) and neo-rpsl (7)); we
have now provided this benefit to unmodified lab and clin-
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ical isolates of E. coli and Salmonella and potentially other
Enterobacteriaceae.
In practice, stringency does seem to vary for our negative
selection system in different experimental settings, but no
more than it does for positive selection markers. For exam-
ple, in the reimplementation of P1 transduction using nega-
tive selection with MG1655 carrying the tse2 toxin, we saw
a higher number of background colonies (200 out of 109
CFU, giving a background frequency of 5 × 10−6). How-
ever, we have observed this result with positive selection
markers as well. Kanamycin stringency frequency is 2.3 ×
10−10, but use of the Datsenko and Wanner protocol with
Red recombinase leads to background colonies (not the de-
sired recombinants and not able to regrow on kanamycin
upon passage) growing on kanamycin plates at a frequency
higher than this. This discrepancy in kanamycin stringency
frequency may be due to the mutagenic effect of Red re-
combinase expression, although we and others (22) see no
evidence for higher mutation when Red recombinase ex-
pression is limited in time. Similarly, we have no good ex-
planation for the higher background rate when performing
P1 transduction compared to simple titering on rhamnose
plates. However, the variation in stringency seems to apply
to both negative and positive selection markers.
The generally high stringency of our negative selection
system is sufficient to enable previously inaccessible large
scale genomic manipulations. We have carried out an ini-
tial proof of concept experiment which shows that the sys-
tem is powerful enough to select for clones of UTI89 that
have been transformed with the correct 10 kb fragment of
the CFT073 genome (0.2% of the total genome) and then
recombined it into the correct ompC locus. Potentially, ad-
ditional development of this technology to reduce back-
ground colonies and improve genomicDNA transfer length
and efficiency, such as by using Hfr strains for conjugation
or transducing lysates, would enable the transfer of entire
swaths of genomic DNA from unrelated strains, subject to
flanking homology. Combined with transposon engineer-
ing, a pool of strains containing randomly inserted nega-
tive selectable markers could then be used to create libraries
of wholesale allelic exchange mutants in a procedure we
term ‘mass allelic exchange’ (Figure 3C). This would finally
enable a practical genetic technology for assigning pheno-
typic consequences to intra-species polymorphisms as well
as close inter-species differences. This enabling of sexual ge-
netics in non-naturally competent bacteria could be espe-
cially powerful for dissecting the differences between strains
of E. coli (or other bacteria) that cause different diseases in
humans, a longstanding and perplexing problem.
One drawback of relE and several of the other toxins used
is that they tend to be bacteriostatic instead of bacterioci-
dal. This necessitates an extra step of colony purification
during standard cloning procedures and must be accounted
for in large-scale allelic exchange experiments. However,
switching to a bacteriocidal toxin should alleviate this draw-
back and increase the efficiency and convenience of this sys-
tem, while possibly simultaneously further broadening the
host range.
In summary, we have designed a modular and general
negative selection system that is both extremely powerful
and highly versatile, potentially enabling generalization to
other bacteria. The high selection stringency enables novel
and improved applications including generalized allelic ex-
change between arbitrary E. coli strains (or even between
different species). This negative selection module should
therefore be particularly useful in the dissection of bacte-
rial virulence as well as regulation, physiology, speciation,
and evolution.With further optimization, libraries of strain
hybrids could be created that would surmount drawbacks
inherent to positive selection based hybrids (55), enabling
sexual genetic strategies to systematically evaluate the thou-
sands of DNA polymorphisms that typically separate unre-
lated clinical isolates of E. coli and other bacteria that are
not naturally competent.
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Complete Genome Sequence of Uropathogenic Escherichia coli Strain
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Escherichia coli represents the primary etiological agent responsible for urinary tract infections, one of the most common infec-
tions in humans. We report here the complete genome sequence of uropathogenic Escherichia coli strain CI5, a clinical pyelone-
phritis isolate used for studying pathogenesis.
Received 24 April 2015 Accepted 29 April 2015 Published 28 May 2015
CitationMehershahi KS, Abraham SN, Chen SL. 2015. Complete genome sequence of uropathogenic Escherichia coli strain CI5. Genome Announc 3(3):e00558-15. doi:10.1128/
genomeA.00558-15.
Copyright © 2015 Mehershahi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.
Address correspondence to Swaine L. Chen, slchen@gis.a-star.edu.sg.
Urinary tract infections (UTIs) are one of the most frequentlyencountered bacterial infections, with uropathogenic Esche-
richia coli (UPEC) responsible for more than 80% of community
acquired infections (1). Although often characterized as self-
limiting and amenable to antibiotic therapy, UTIs often recur,
causing significantmorbidity to individual patients (2). Recurrent
UTIs further lead to potential public health concerns due to high
antibiotic usage (3, 4). Studies of UPEC pathogenesis have re-
vealed that intracellular infection of bladder epithelial cells is a key
feature leading to bacterial survival, antibiotic resistance, and re-
current UTI (5–20). UPEC strain CI5 is a clinical pyelonephritis
isolate (21) that has been used inmany of these studies using both
in vitro cell culture models and in vivo murine infection models
(22, 23). These have examined the role of Toll-like receptor 4
(TLR4) (13), cyclic AMP (cAMP), and Ca2 signaling during
UPEC invasion into bladder epithelial cells and the subsequent
epithelial cell response (12, 16, 24). Additional studies have used
CI5 to understand kidney infection and renal nephropathy during
in vivo infection in mice (25). The genome sequence of CI5 will
thus serve as a useful resource for future studies into the infection
cycle of this important human pathogen.
CI5 genomic DNA was sheared to a size of approximately 10
kbp using a g-Tube (Covaris). An SMRTbell library was prepared
according to the manufacturer’s instructions, loaded with a Mag-
Bead bound library protocol, and sequenced using the P4-C2
chemistry on the PacBio RS II instrument (Pacific Biosciences)
with a 180-minmovie time.De novo assemblywas performedwith
the Hierarchical Genome Assembly Process (HGAP3) in the
SMRT Analysis suite version 2.3 using default parameters (26). In
total, there were 249,158 reads and 822,531,331 nucleotides that
passed filtering, representing an approximate coverage of 80
(based on the final assembly) and a preassemblymean read length
of 8,815 bp.
UPEC CI5 harbors a single chromosome of 4,885,378 bp with
a GC content of 50.8% and a previously unknown plasmid
(pCI5) of 207,265 bp with a GC content of 47.3%. Annotations
of the CI5 genome and plasmid were performed using the NCBI
ProkaryoticGenomeAnnotationPipeline (PGAAP) (27). TheCI5
chromosome and plasmid together contain 4,879 protein coding
sequences, as well as 22 rRNA and 88 tRNA genes. The finished
genome sequence of UPEC CI5 and its newly discovered plasmid
pCI5 will aid in precise genetic manipulation and thereby further
improve the study of UPEC virulence.
Nucleotide accession numbers. The complete sequences of
the uropathogenic E. coliCI5 chromosome and plasmid have been
submitted to GenBank under the accession numbers CP011018
and CP011019, respectively.
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Complete Genome Sequence of Streptococcus agalactiae Serotype III,
Multilocus Sequence Type 283 Strain SG-M1
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Streptococcus agalactiae (group B Streptococcus) is a common commensal strain in the human gastrointestinal tract that can also
cause invasive disease in humans and other animals. We report here the complete genome sequence of S. agalactiae SG-M1, a
serotype III, multilocus sequence type 283 strain, isolated from a Singaporean patient suffering frommeningitis.
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Streptococcus agalactiae (group B Streptococcus, or GBS) is aGram-positive bacterium commonly found as a commensal in
the gastrointestinal and genitourinary tract of up to 40% of hu-
mans (1). S. agalactiae can cause pregnancy-associated infections,
which can lead to invasive neonatal disease (bacteremia, pneumo-
nia, and meningitis) after delivery; invasive disease (bacteremia,
meningitis, and soft tissue infections) in all age groups; and uri-
nary tract infections (2, 3). Furthermore, GBS is an important
veterinary pathogen in several animals, including cows (mastitis)
(4) and fish (meningoencephalitis) (5). GBS has been classified by
serotype (Ia, Ib, II to IX) (6). Strain SG-M1 is a serotype III clinical
isolate of GBS, isolated from a patient in Singapore suffering from
meningitis; this isolate was collected as part of an outbreak inves-
tigation in Singapore associated with the consumption of raw fish
(Barkham et al., unpublished data), in accordance with Singapore
ethics regulations for exemption from IRB review. By multilocus
sequence typing (http://pubmlst.org/sagalactiae), SG-M1 was de-
termined to be a multilocus sequence type 283 strain (ST283);
previously, ST283 strains were isolated from a meningitis patient
in Hong Kong (7) and aquatic animals, the latter representing a
potential zoonotic source (8).
SG-M1 was grown overnight in brain heart infusion broth at
37°C with shaking. The bacteriumwas collected by centrifugation
and lysed in a buffer containing 20 mM Tris-Cl (pH 8.0), 2-mM
sodium EDTA, 1.2%Triton X-100, and 20mg/mL lysozyme from
chicken eggwhite (MPBiomedicals cat. no. 100831) at 37°C for 45
min. Genomic DNA was then extracted using a Qiagen QIAamp
DNA minikit and sheared to a size of approximately 10 kbp using
g-Tube (Covaris). A 10-kb SMRTBell library was prepared for se-
quencing according to theprotocols recommendedbyPacificBiosci-
ences, loaded with a MagBead-bound library protocol, and se-
quenced using P5-C3 chemistry on the PacBio RS II instrument
(Pacific Biosciences) with a 240-minmovie time on two SMRTCells.
De novo assembly was performed with the Hierarchical Genome
Assembly Process (HGAP3) in the SMRT Analysis suite version
2.3 using default parameters (9). In total, there were 62,129 reads
and 740,417,316 nucleotides that passed filtering, representing an
approximate coverage of 260 (based on the final assembly) and
a preassembly mean read length of 11,917 bp.
S. agalactiae SG-M1 harbors a single chromosome of 2,116,810
bp with a GC content of 35.5%; no plasmids were found. Anno-
tations of the CI5 genome and plasmid were performed using the
NCBI Prokaryotic Genome Annotation Pipeline (PGAAP) (10).
SG-M1 contains 2,037 protein coding sequences, as well as 7
rRNAoperons and 81 tRNA genes. The finished genome sequence
of S. agalactiae SG-M1 will aid in further understanding the caus-
ative basis for invasive disease caused by GBS.
Nucleotide sequence accession number. The complete se-
quence of the S. agalactiae strain SG-M1 chromosome has been
submitted to GenBank under the accession number CP012419.
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Abstract: Studies of Uropathogenic Escherichia coli (UPEC) pathogenesis have relied heavily on genetic
manipulation to understand virulence factors. We applied a recently reported positive-negative
selection system to create a series of unmarked, scarless FimH mutants that show identical phenotypes
to previously reported marked FimH mutants; these are now improved versions useful for definitive
assignment of phenotypes to FimH mutations. We also increased the efficiency of this system by
designing new primer sites, which should further improve the efficiency and convenience of using
negative selection in UTI89, other UPEC, and other Enterobacteriaceae.
Keywords: negative selection; UTI89; FimH
1. Introduction
Urinary tract infections (UTIs) are a major problem in women worldwide, with uropathogenic
Escherichia coli (UPEC) causing 74% of community-acquired and 65% of nosocomial infections [1].
Several UPEC strains, including Escherichia coli (E. coli) UTI89, have been shown to form intracellular
bacterial communities (IBCs) in mice and in humans [2–4]; IBCs may be responsible for recurrent UTIs
in mice [5]. Type 1 pili, encoded by the fim operon in nearly all E. coli, is the major virulence factor for
UPEC during UTI [6,7]. FimH is the mannose-binding adhesin found at the tip of type1 pili which
mediates binding to mannosylated proteins on bladder epithelial cells [8–11], facilitating colonization
and invasion of cells in vitro [12,13] and in vivo [6,14] and enabling IBC formation [14–16].
Previous FimH studies have used isogenic strains carrying mutant fimH alleles on plasmids [17]
or on the chromosome [14,16]. Chromosomal strains, in particular, have the advantages of native
copy number and chromosomal context, and therefore native transcriptional regulation. However,
manipulating the chromosome of clinical E. coli isolates such as UTI89 is more challenging than in
lab-adapted strains, for which most cloning systems have been developed. This results in strains that
are either marked [14,16] or carry residual cloning scars [18]. Formally, from a genetic point of view,
creation of unmarked, scarless mutations in genes such as fimH would enable the strongest possible
assignment of phenotype changes to allelic differences.
We have recently published a novel negative selection system to facilitate chromosomal
manipulation in UTI89 [19]. This system consists of a toxic gene (relE) expressed from a tightly
controlled promoter, such as the rhamonse-inducible PrhaB promoter. Under normal growth conditions,
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Pathogens 2016, 5, 9 2 of 6
the PrhaB promoter is not active, no relE is transcribed, and cells grow normally. However, under
rhamnose induction, the production of relE transcript results in the production of the RelE toxin
(an mRNAse), which then stops cell growth. Thus, under restrictive conditions, only cells that do not
contain a functional negative selection cassette are able to grow. This negative selection cassette is
combined with the kanamycin resistance gene to create a dual positive-negative selection cassette,
which was used in a simple two-step procedure to create unmarked, scarless mutations in fimH in
its native chromosomal context. We verified that our new unmarked strains show no in vitro or
in vivo differences from their corresponding marked strains, validating that the previously reported
phenotypes are indeed due to FimH and that the negative selection system generates no artifactual
phenotypes in a large set of independent cloning steps. Furthermore, we discovered that most
undesired mutants during recombineering (which are subsequently screened out during routine strain
verification) using this system were due to recombination at short homology sites in the selection
cassette; we eliminated this with newly designed template priming sites. The strains we have created
here will be useful in the future for the definitive assignment of phenotypes to FimH mutations,
while our modified negative selection protocol will increase the efficiency and convenience of creating
unmarked, scarless mutations in UTI89 and other clinical isolates of E. coli.
2. Results and Discussion
2.1. Creation of an Isogenic Series of Definitive (Unmarked, Scarless) FimH Mutants
We used the kan-PrhaB-relE positive-negative selection cassette [19] to recreate an unmarked,
isogenic series of previously characterized FimH mutants (Figure 1a and Table S1) [14]. These newly
created strains no longer carry a linked antibiotic resistance cassette, and therefore are theoretically
definitive genetic constructs for isolating phenotypes due to the corresponding FimH mutation.
These new unmarked strains therefore also can be utilized in identical assays as the parental UTI89,
including transformation with kanamycin-resistant plasmids or the use of kanamycin in subsequent
chromosomal manipulations.
2.2. Definitive FimH Constructs Have No Artifactual Phenotypes
To validate that the new unmarked fimH mutant strains indeed recapitulate previously reported
phenotypes, we tested them for in vitro type 1 pilus function using guinea pig red blood cell
agglutination. We saw no difference between any of the eight pairs of marked and unmarked strains
(Table S2). We then tested three alleles in an in vivo murine model of urinary tract infection. Marked
versions of the wild-type, A62S, and A27V/V163A FimH alleles previously were shown to have no
defect, a 1.5-log defect, or a 4–5 log defect, respectively, at 24 hpi in the bladder [14]. We saw the
same phenotypes with the new unmarked strains (Figure 1b), and also verified that the reconstructed,
unmarked wild-type FimH strain was not significantly different from the unmodified, parental UTI89.
We also saw no difference among matched strains in kidney infection titers (Figure 1c). Therefore, use
of a combined positive-negative selection cassette in UTI89 is indeed an effective method for creating
definitive genetic constructs. This system is applicable in other Enterobacterial strains, including
other UPEC, E. coli, and Salmonella, and should also be useful for definitive genetic studies in these
organisms as well.
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selection-mediated allele replacements. This increased the efficiency of the negative selection step
to nearly 100% (nearly all colonies growing have the intended recombination event), simplifying
subsequent strain verification, although this eliminates the possibility of using Flp recombinase to
eliminate the positive-negative selection step after the initial gene knockout.
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Figure 2. Elimination of undesired FRT recombinants during recombineering. (a) Genetic organization
of the major recombinant products found during recombineering. The ompC locus and surrounding
genes are shown as an example. Top, genetic organization of the initial ompC knockout strain
(ompC::kan-PrhaB-relE) created by recombineering using positive selection for kanamycin. Bottom
left, genetic organization of the product of undesired recombination between FRT sites during
subsequent allele replacement by recombineering using negative selection (ompC::FRT). Bottom right,
the genetic organization of the desired recombination where a restored wt ompC allele has replaced the
positive-negative selection cassette during recombineering using negative selection (ompC::ompCwt).
The percentage of colonies in each class, based on PCR screening after negative selection, is shown
below each diagram (data taken from 30 recombineering steps using negative selection in 4 loci in
UTI89). Blue vertical bars indicate FRT sites. (b) Redesigned priming sites for template plasmid
pSLC-217 (and other pKD4 derivatives). Red arrows indicate new priming sites which exclude flanking
FRT sites in the resultant amplified positive-negative selection cassette. New primer sequences are
indicated in red as P1 forward and P2 reverse. Black arrows indicate the original priming sites 1 and 2
(for pKD4). Blue vertical bars indicate FRT sites. New primer sequences for pKD3 derivatives are listed
in Table S3.
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3. Experimental Section
3.1. Bacterial Strains and Plasmids
Bacterial strains and plasmids used in this study are listed in Table S1.
3.2. Chromosomal FimH Mutations and Recombineering
SLC-502 (UTI89 fimH::kan-PrhaB-relE) was used for all allelic replacements. Previously reported
marked fimH mutants were used as templates to amplify fimH alleles [14] using primers UTI89+4913234
fimH and UTI89-4914539 fimH (Table S3). Recombineering was performed as previously described [19].
3.3. PCR and Sequencing
Colony PCRs were used to check for insertion/replacement of the selection cassette with
locus-specific primers (Table S3). All mutations were confirmed by using Sanger sequencing (1st base,
Singapore) on PCR products with the same primers used for amplification.
3.4. Hemagglutination Assay
These were performed as previously described [14].
3.5. In Vivo Mouse Infections
All bacterial strains were cultured in type 1 pili-inducing conditions and used to infect seven- to
eight-week-old C3H/HeN female mice (InVivos, Singapore) as previously described [21].
4. Conclusions
Using a large series of scarless, unmarked FimH mutants, we have recapitulated previously
reported FimH phenotypes, validating the assignment of them to FimH mutations. This further
demonstrates that using a combined positive-negative selection cassette is an effective way to generate
definitive genetic constructs in UTI89. We have further improved the efficiency of the negative
selection step by eliminating one class of undesired recombinations. These protocols and cloning
strategies can also be used to generate definitive genetic constructs in other UPEC, E. coli, and
other Enterobacteriaceae.
Supplementary Materials: The following are available online at www.mdpi.com/2076-0817/5/1/9/s1, Table S1:
Strains and plasmids used in this study, Table S2: FimH mutations and HA titers in UTI89, Table S3: Primers used
in this study.
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Abstract: Fluorescent proteins, especially green fluorescent protein (GFP), have been instrumental in
understanding urinary tract infection pathogenesis by uropathogenic Escherichia coli (UPEC). We have
used a recently developed GFP variant, vsfGFP-9, to create new plasmid- and chromosome-based
GFP derivatives of the UPEC strain UTI89. The vsfGFP-9 strains are nearly 10ˆ brighter with no
in vitro growth or in vivo virulence defects compared to previously reported GFP-expressing UTI89
strains. The chromosomal vsfGFP-9 strain is equivalent to the wild type UTI89 during in vivo UTI,
while both plasmid GFP constructs have an equivalent virulence defect compared to non-plasmid
carrying UTI89. These new vsfGFP-9 expressing strains should be useful for further studies of the
pathogenesis of UTI89, and similar strategies can be used to create improved fluorescent derivatives
of other UPEC strains.
Keywords: GFP; uropathogenic Escherichia coli; urinary tract infection
1. Introduction
Fluorescent proteins (FPs) have been instrumental to our understanding of bacterial
pathogenesis [1]. FPs have been used widely in plasmid- or chromosome-based strategies in in vitro
and in vivo studies [1,2]. Plasmid-based GFPs generally have higher copy number and expression,
benefitting brightness at the cost of cell-to-cell variation (due to different copy numbers in different
cells), plasmid instability, and fitness defects due to plasmid carriage or high GFP expression. Fitness
defects in particular then complicate studies of pathogenesis, which more often manifest in vivo.
In contrast, chromosomal GFPs tend to have lower expression and lower brightness, limiting utility
for visualizing small (or individual) bacterial collections while mitigating these other problems with
variability, stability, and fitness.
Urinary tract infections (UTIs) are one of the most common bacterial infections of humans,
accounting for over $2.3 billion in medical expenditures annually in the US [3]. Most UTIs are
caused by strains of E. coli, thus the term uropathogenic E. coli (UPEC). As with other infectious
diseases [1,4], fluorescent proteins have been instrumental for many discoveries of the pathogenic
mechanisms utilized by UPEC, including the development of intracellular bacterial communities
(IBCs) [5,6], quiescent intracellular reservoirs (QIRs) [7], and avoidance of neutrophil killing [6] by the
cystitis strain UTI89 [8]. For these studies, two strains are commonly used, both of which express the
GFPmut3 variant of GFP [1]: UTI89 carrying plasmid pANT4 [9] and UTI89 attHK022::COM-GFP [10].
Both of these strains have been used to monitor formation of intracellular structures during UTI
Pathogens 2016, 5, 3; doi:10.3390/pathogens5010003 www.mdpi.com/journal/pathogens
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by microscopy [7,10,11], but to date UTI89/pANT4 has not been further characterized for other
infection phenotypes.
Since the identification of GFPmut3, new variants of GFP demonstrate various improved
properties [12]. One of these in particular, superfolder GFP (sfGFP) [13], has higher brightness
and faster folding kinetics than the currently used GFPmut3. We have further improved the brightness
of sfGFP by fusing it to a GFP-specific single domain antibody [14] using the vGFP strategy to create a
monomeric fluorophore with 30%–50% increased brightness and pH resistance [15]. We refer to this
improved sfGFP as vsfGFP-9.
We here report the creation of new derivatives of UTI89 carrying vsfGFP-9 on the chromosome
or on a derivative of the pANT4 plasmid that provide nearly 10ˆ increased brightness to the
commonly used UTI89 attHK022::COM-GFP and UTI89/pANT4, respectively. We demonstrate that
these derivatives, despite the markedly higher brightness, have no fitness defects relative to the strains
they are intended to replace. Furthermore, we find that the plasmid-based strains (UTI89/pANT4 and
SLC-638) have an equivalent fitness defect relative to UTI89 as measured by infection load. In contrast,
chromosomal expression of vsfGFP-9 produces brightness approaching that of UTI89/pANT4 without
a defect in IBC formation or infection load. These new, brighter strains should be useful in future
studies of the pathogenic mechanisms of UTI89, and the strategies employed here can be similarly
applied to improve fluorescent derivatives of other UPEC strains.
2. Results and Discussion
2.1. New vsfGFP-9 Expressing Derivatives of UTI89 Are 10ˆ Brighter Than Former GFP Expressing Strains
We generated UTI89 derivatives carrying plasmid (SLC-638) and chromosome (SLC-719)
based vsfGFP-9 constructs intended to improve on UTI89/pANT4 and UTI89 attHK022::COM-GFP,
respectively. As controls, we also created corresponding sfGFP derivatives (plasmid: SLC-634;
chromosomal: SLC-717). The vsfGFP-9 strains had no gross growth defect relative to UTI89 or to
their corresponding GFPmut3 strain (SLC-638 compared with UTI89/pANT4; SLC-719 compared
with UTI89 attHK022::COM-GFP) (Figure 1a). By flow cytometry, we found that the strains carrying
vsfGFP-9 were the brightest; both on the plasmid and on the chromosome, the vsfGFP-9 strains
were nearly 10ˆ brighter than their corresponding GFPmut3 strains and ~1.5ˆ brighter than the
corresponding sfGFP strain (Figure 1b). Based on Western blots for GFP, the increased brightness
was due to both increased expression as well as the enhanced brightness of vsfGFP-9 over sfGFP
and GFPmut3 (Figure 1c). Interestingly, SLC-719 (carrying a chromosomal vsfGFP-9) approached
the brightness of UTI89/pANT4 (carrying a plasmid-based GFPmut3) (Figure 1b, light and dark
green traces).
2.2. New Chromosomal vsfGFP-9 Construct Has No Fitness Defects during UTI Relative to Former GFP
Expressing Strains
Because plasmid carriage as well as high GFP expression can both lead to fitness defects in vivo,
we tested the vsfGFP-9 constructs in an in vivo murine model of UTI. Using competitive infections
against the parental (nonfluorescent and unmodified) UTI89, we generally saw no fitness defect at
6 hpi or 24 hpi for either UTI89 attHK022::COM-GFP or SLC-719 (chromosomal vsfGFP-9) in either the
bladder or the kidney (Figure 2a,b); at 24 hpi in kidneys we saw a slight (<0.5 log) but significant defect
in UTI89 attHK022::COM-GFP. In contrast, we saw a significant defect in competitive infections for both
UTI89/pANT4 and SLC-638 (plasmid vsfGFP-9) relative to UTI89 at 6 hpi and 24 hpi; however, there
was no significant difference in the competitive indices between these plasmid-carrying strains.
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Figure 1. In vitro characterization of vsfGFP-9 derivatives of UTI89. (a) Growth curves in Lysogeny 
broth (LB) medium for the parental wt UTI89/pSLC-306 (empty vector control; dark blue), UTI89 
attHK022::COM-GFP (green), SLC-719 (chromosomal vsfGFP-9; light blue), UTI89/pANT4 (red), and 
SLC-638 (plasmid vsfGFP-9; purple); (b) Flow cytometry analysis of green fluorescent protein (GFP) 
brightness for UTI89/pSLC-306 (red), UTI89 attHK022::COM-GFP (blue), SLC-717 (chromosomal sfGFP; 
brown), SLC-719 (light green), UTI89/pANT4 (dark green), SLC-634 (plasmid sfGFP; pink), and SLC-
638 (purple). M indicates the median GFP fluorescence. (c) Quantification of GFP protein levels in 
UTI89 strains. (top) Immunoblot of samples from panel (b) using α-GFP antibody. α-RNAPβ was 
used as a loading control. 
We next tested these strains for IBC formation. Validating previous reports that used GFPmut3 
expressing strains to study IBCs, we found no significant difference in the number of IBCs formed by 
any of the strains tested relative to wt UTI89 as quantified by LacZ staining (Figure 2c). The 
fluorescent strains also enabled a more convenient quantification of IBCs by direct observation under 
a fluorescent dissecting microscope; again no significant difference was seen between UTI89/pANT4 
and SLC-638, though the number of IBCs for each strain detected was slightly higher than (though 
well correlated with) LacZ staining (Figure 2d). Highlighting the brightness advantage of the new 
strains, among the chromosomal GFP expressing strains, we were only able to detect IBCs by 
fluorescence in SLC-719 but not with UTI89 attHK022::COM-GFP (except weakly in two cases; this was 
due to low fluorescence of this strain over background bladder fluorescence), which is consistent with 
the higher fluorescence of SLC-719 that we measured by FACS. 
Figure 1. In vitro characterization of vsfGFP-9 derivatives of UTI89. (a) Growth curves in Lysogeny
broth (LB) medium for the parental wt UTI89/pSLC-306 (empty vector control; dark blue), UTI89
attHK022::COM-GFP (green), SLC-719 (chromosomal vsfGFP-9; light blue), UTI89/pANT4 (red), and
SLC-638 (plasmid vsfGFP-9; purple); (b) Flow cytometry analysis of green fluorescent protein (GFP)
brightness for UTI89/pSLC-306 (red), UTI89 attHK022::COM-GFP (blue), SLC-717 (chromosomal sfGFP;
brown), SLC-719 (light green), UTI89/pANT4 (dark green), SLC-634 (plasmid sfGFP; pink), and
SLC-638 (purple). M indicates the median GFP fluorescence. (c) Quantification of GFP protein levels in
UTI89 strains. (top) Immunoblot of samples from panel (b) using α-GFP antibody. α-RNAPβ was used
as a loading control.
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Figure 2. In vivo characterization of vsfGFP-9 derivatives of UTI89. Competitive infections between UTI89 attHK022::COM-GFP, SLC-719, UTI89/pANT4, and SLC-638 and 
the parental wt UTI89 were performed. (a) Logarithm of the competitive index against wt UTI89 in the bladder at 6 and 24 hpi. Higher values indicate wt UTI89 outcompetes 
the GFP strain; (b) Log competitive index against wt UTI89 in kidneys at 6 and 24 hpi. Red bars indicate median values. *, p < 0.05 (two-tailed Wilcoxon signed-rank test 
whether log competitive indices are different from 0). (c) Quantification of IBCs at 6 hpi; (d) Comparison of GFP versus LacZ staining to quantify IBCs for plasmid-based 
GFP expressing strains. Data from UTI89 attHK022::COM-GFP (open circles), SLC-719 (red), UTI89/pANT4 (gray), and SLC-638 (green) are shown. R2 coefficient for combined 
data from SLC-719, UTI89/pANT4, and SLC-638 is indicated in the legend. 
Figure 2. In vivo characterization of vsfGFP-9 derivatives of UTI89. Competitive infections between UTI89 attHK022::COM-GFP, SLC-719, UTI89/pANT4, and SLC-638
and the parental wt UTI89 were performed. (a) Logarithm of the competitive index against wt UTI89 in the bladder at 6 and 24 hpi. Higher values indicate wt UTI89
outcompetes the GFP strain; (b) Log competitive index against wt UTI89 in kidneys at 6 and 24 hpi. Red bars indicate median values. *, p < 0.05 (two-tailed Wilcoxon
signed-rank test whether log competitive indices are different from 0). (c) Quantification of IBCs at 6 hpi; (d) Comparison of GFP versus LacZ staining to quantify IBCs
for plasmid-based GFP expressing strains. Data from UTI89 attHK022::COM-GFP (open circles), SLC-719 (red), UTI89/pANT4 (gray), and SLC-638 (green) are shown.
R2 coefficient for combined data from SLC-719, UTI89/pANT4, and SLC-638 is indicated in the legend.
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3. Experimental Section
Strains and growth conditions. UTI89 [8], UTI89 attHK022::COM-GFP [10], and UTI89/pANT4 [9,16]
have been previously described. Lysogeny broth (LB) was used for all growth. Ampicillin was
supplemented as required at 100 µg/mL, and kanamycin at 50µg/mL. For mouse infections, bacteria
were grown under type 1 pili inducing conditions as previously described [17]. Bacterial growth curves
were measured using a Bioscreen C MBR (Bioscreen, Finland) in LB medium at 37 ˝C for 24 h.
Construction of sfGFP and vsfGFP-9 expressing strains. All plasmids used in this study are listed in
Table S1. All primers used for cloning and homologous recombination were purchased from Sigma
(Singapore) and are listed in Table S2. The genes encoding sfGFP and vsfGFP-9 were amplified by PCR
using primer pairs P1-P2 from plasmids pSLC-253 and pSLC-255 respectively. The PCR products were
then digested and cloned into pANT4 (replacing GFPmut3) using XbaI and HindIII restriction sites to
produce pSLC-282 (containing sfGFP) and pSLC-284 (containing vsfGFP-9). Nonfluorescent colonies
from the pSLC-282 cloning contained plasmids without GFP, giving pSLC-306 (empty vector control
for pANT4). pSLC-282 was transformed into UTI89 to give SLC-634; pSLC-284 was transformed into
UTI89 to give SLC-638.
For chromosomal GFP strains, annealed complementary pairs of oligonucleotides (primer P3
and its reverse complement) containing a rrnB_T2 transcriptional terminator [18] upstream of a
modified σ70 promoter [19] were digested with ClaI and XbaI and cloned into plasmids pSLC-253 and
pSLC-255 digested with the same enzymes to generate pSLC-293 (sfGFP) and pSLC-294 (vsfGFP-9).
We integrated sfGFP or vsfGFP-9 between chromosomal coordinates 1044461-62 in UTI89, which is the
attHK022 region, using a two-step positive-negative selection system [20]. Briefly, the kan-PrhaB-relE
cassette was amplified from pSLC-217 [20] using primers P4 and P5 and integrated into the attHK022
region using Red recombinase-mediated recombineering [21] to generate SLC-653. Primer pairs P5 and
P6 were used to amplify fragments containing sfGFP or vsfGFP-9 from plasmids pSLC-293 or pSLC-294;
these PCR products were used to replace the kan-PrhaB-relE cassette by Red recombinase-mediated
recombineering with negative selection on M9 media supplemented with 2% rhamnose, giving SLC-717
(sfGFP) and SLC-719 (vsfGFP-9).
Western blots. Primary antibodies (and dilutions) used were anti-GFP mouse monoclonal antibody
(1:6000; Santa Cruz Biotechnology, Shanghai, China), anti-RNA Polymerase β (1:6000; Santa Cruz
Biotechnology, Shanghai, China). The secondary antibodies were ECL™ Anti-rabbit IgG and ECL™
Anti-mouse IgG, both conjugated with Horseradish peroxidase (HRP) and used at a 1:10,000 dilution.
Mouse infections. Infections were performed as previously described [17]. Data shown is the
result of two separate experiments performed on separate days with four to six mice per strain and
per time point. Six to seven-week old C3H/HeN female mice were obtained from Harlan (Israel).
In co-infections with UTI89 and SLC-719 (chromosomal vsfGFP-9), SLC-719 colonies were differentiated
from UTI89 cells by visualization of green fluorescence under 10ˆmagnification because neither strain
carries an antibiotic resistance cassette. In coinfections with UTI89 and UTI89 attHK022::COM-GFP,
UTI89 attHK022::COM-GFP colonies were quantified by plating on LB supplemented with kanamycin,
and UTI89 colonies were calculated by subtraction of UTI89 attHK022::COM-GFP titers from total
titers quantified on LB plates. In each experiment, two to three of these LB plates were also used to
quantify UTI89 attHK022::COM-GFP titers using green fluorescence under 10ˆ magnification; in all
cases, the fluorescence-based quantification was within 10% of the kanamycin-based quantification.
IBCs were quantified in single infections for UTI89, UTI89 attHK022::COM-GFP, UTI89/pANT4,
SLC-717, SLC-719, and SLC-638. At 6 hpi, infected mice were sacrificed, and harvested bladders were
hemisected, stretched onto silicone pads, and fixed with 3% paraformaldehyde (Sigma) as previously
described [17]. IBCs from GFP-expressing strains were quantified by fluorescence at 10ˆmagnification.
All samples were then subjected to X-Gal staining for independent quantification as previously
reported [11]. Data shown is the result of two separate experiments performed on separate days with
four mice per strain per experiment.
Pathogens 2016, 5, 3 6 of 7
Flow cytometry. Flow cytometry analysis for GFP expression was performed on a S3™ Cell Sorter
(Bio-Rad, Hercules, CA, USA).
4. Conclusions
We have created new plasmid- and chromosome-based GFP expressing derivatives of UTI89.
Through using a new vsfGFP-9 gene as well as optimization of expression, these are nearly 10ˆ brighter
than previously published GFP UTI89 derivatives, and have no in vitro or in vivo defects compared
with previous GFP-expressing strains. These strains should be useful for future studies of UTI89
pathogenesis and for the creation of vsfGFP-9 derivatives of other UPEC and E. coli.
Supplementary Materials: The following are available online at www.mdpi.com/ 2076-0817/5/1/3/s1, Table S1:
Plasmids used in this work, Table S2: Primer sequences used in this study.
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